日本臨牀　72/増刊5　　最新臨床脳卒中学(上)

出版社： 日本臨牀社
発行日： 2014-07-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新臨床脳卒中学（上）─最新の診断と治療─
電子書籍版： 2014-07-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 日本臨牀　72/増刊5 最新臨床脳卒中学（上）

    ―目次―

    特集　最新臨床脳卒中学（上）─最新の診断と治療─

    脳血管障害総説
    1．総　　　論
    2．疫　　　学
    3．病型分類
    4．病態生理
    5．危険因子
    6．診断手順と重症度診断
    7．診断・治療ガイドライン
    8．治療戦略を目指した研究
    9．画像検査・診断
    10．脳卒中に伴う諸症状とその管理
    11．リハビリテーション
    12．最新の治療動向：概論

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

脳血管障害総説

P.12 掲載の参考文献
1) 厚生労働省大臣官房統計情報部 : 平成26年我が国の人口動態-平成24年までの動向-, p17, 2014.
 
2) 厚生労働省大臣官房統計情報部人口動態・保健社会統計課保健統計室 : 平成23年 (2011) 患者調査の概況, p27, 平成24年11月.
 
3) 中医協資料 : 中医協 総3-1 18.11.29, 7対1入院基本料届出状況等について.
 
4) 中医協資料 : 中医協 総1 25.11.20, 入院医療 (その4).
 
5) 日本脳卒中学会ホームページ. [http://www.jsts.gr.jp/]
 
6) 呉健ほか : 内科書 上巻, 改訂第31版 (沖中重雄改訂), 南山堂, 1961.
 
7) 金谷春之ほか : 脳卒中急性期症例に対する安静度の検討-特に患者移送の問題と諸検査付加の影響-. 日本医事新報 No.1991:12-18, 1962.
 
8) 金谷春之ほか : 脳卒中急性期症例に対する安静度の再検討-特に患者移送の問題と移送前後の諸検査成績を中心として-. 日本医事新報 No.2083:27, 1964.
 
9) 金谷春之ほか : 第4回日本臨床神経学会総会抄録 高血圧性脳出血急性期例の安静度の検討. 臨床神経学 3(4):261, 1963.
 
P.18 掲載の参考文献
1) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group : Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581-1587, 1995.
 
2) Hacke W, et al : Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317-1329, 2008.
PubMed
3) Wahlgren N, et al : Thrombolysis with alteplase 3-4. 5 h after acute ischaemic stroke (SITS-ISTR) : an observational study. Lancet 372:1303-1309, 2008.
PubMed
4) Sandercock P, et al ; IST-3 collaborative group : The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]) : a randomised controlled trial. Lancet 379:2352-2363, 2012.
 
5) Parsons M, et al : A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366:1099-1107, 2012.
 
6) Antithrombotic Trialists' Collaboration : Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis in individual participant data from randomised trials. Lancet 373:1849-1860, 2009.
PubMed
7) Uchiyama S : Clopidogrel resistance : identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Ther 29:e100-111, 2011.
PubMed
8) Shinohara Y, et al : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised, non-inferiority trial. Lancet Neurol 9:959-968, 2010.
PubMed
9) Benavente OR, et al ; SPS3 Investigators : Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367:817-825, 2012.
 
10) Wang YW, et al : Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11-19, 2013.
PubMed
11) Uchiyama S, et al : Final results of Cilostazol-Aspirin Therapy Against Recurrent Stroke with Intracranial Artery Stenosis (CATHARSIS). International Stroke Conferenc, Honolulue, 2013.
 
12) Uchiyama S, et al : Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation. J Stroke Cerebrovasc Dis 21:165-173, 2012.
PubMed
13) Miller CS, et al : Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110:453-460, 2012.
PubMed
14) Uchiyama S : Concept of acute cerebrovascular syndrome. In : TIA as Acute Cerebrovascular Syndrome (ed by Uchiyama S, et al), Kargar AG, Basel, 2013.
 
15) Rothwell PM, et al : Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRES study) : a prospective population-based sequential comparison. Lancet 370:1432-1442, 2007.
 
P.25 掲載の参考文献
1) 山浦晶 : 脳動脈瘤の外科 (Standerd and Modified Techniques), 医学書院 1995.
 
2) Molyneux A, et al : International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group : International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised trial. Lancet 360:1267-1274, 2002.
 
3) Molyneux AJ, et al ; International Subarachnoid Aneurysm Trial (ISAT) Collaborative Group : International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms : a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 366:809-817, 2005.
 
4) Molyneux AJ, et al ; ISAT Collaborators : Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT) : long-term follow-up. Lancet Neurol 8:427-433, 2009.
 
5) 吉峰俊樹 (編) : 科学的根拠に基づくくも膜下出血診療ガイドライン第2版, 脳卒中の外科 第36巻 (増刊号), にゅーろん社, 2008.
 
6) Wiebers DO, et al : International Study of Unruptured Intracranial Aneurysms Investigators : Unruptured intracranial aneurysms : natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362:103-110, 2003.
 
7) Yonekura M : Small unruptured aneurysm verification (SUAVe Study, Japan)-interim report. Neurol Med Chir (Tokyo) 44:213-214, 2004.
PubMed
8) UCAS Japan Investigators ; Morita A, et al : The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366:2474-2482, 2012.
 
9) Raymond J, et al ; TEAM collaborative Group : Atrial on unruptured intracranial aneurysms (the TEAM trial) : results, lessons from a failure and the necessity for clinical care trials. Trials 12:64, 2011.
 
10) Chen Z, et al : Experiences and complications in endovascular treatment of paraclinoid aneurysms. J Clin Neurosci 20:1259-1263, 2013.
PubMed
11) Chalouhi N, et al : Stent-assisted coiling of intracranial aneurysms : predictors of complications, recanalization, and outcome in 508 cases. Stroke 44:1348-1353, 2013.
PubMed
12) Becske T, et al : Pipeline for uncoilable or failed aneurysms : results from a multicenter clinical trial. Radiology 7:858-868, 2013.
 
13) North American Symptomatic Carotid Endarterectomy Trial Collaborators : Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325:445-453, 1991.
PubMed
14) MRC European Carotid Surgery Trial : interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 337:1235-1243, 1991.
 
15) Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273:1421-1428, 1995.
PubMed
16) Halliday A, et al ; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group : Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms : randomised controlled trial. Lancet 363:1491-1502, 2004.
 
17) Dumont TM, Rughani AI : National trends in carotid artery revascularization surgery. J Neurosurg 116:1251-1257, 2012.
PubMed
18) Martin EC, et al : Percutaneous Transluminal Angioplasty in Non-Atheroscklerotic Disease. Radiology 135:27-33, 1980.
PubMed
19) Bergeon P, et al : Transluminal angioplasty for recurrent stenosis after carotid endarterectomy. Prognostic factors and indications. Int Angiol 12:256-259, 1993.
PubMed
20) Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS) : a randomised trial. Lancet 357:1729-1737, 2001.
PubMed
21) Mas JL, et al ; EVA-3S Investigators : Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med 355:1660-1671, 2006.
PubMed
22) SPACE Collaborative Group : Ringleb PA, et al : 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients : a randomised non-inferiority trial. Lancet 368:1239-1247, 2006.
 
23) Hopkins LN, et al : The Carotid Revascularization Endarterectomy versus Stenting Trial : credentialing of interventionalists and final results of lead-in phase. J Stroke Cerebrovasc Dis 19:153-162, 2010.
 
24) International Carotid Stenting Study investigators ; Ederle J, et al : Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study) : an interim analysis of a randomised controlled trial. Lancet 375:985-997, 2010.
 
25) Carotid Stenting Trialists' Collaboration : Bonati LH, et al : Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis : a preplanned meta-analysis of individual patient data. Lancet 376:1062-1073, 2010.
PubMed
26) Beckman JA : Management of asymptomatic internal carotid artery stenosis. JAMA 310:1612-1618, 2013.
PubMed
27) Yasargil MG, et al : Microsurgery : Applied to Neurosurgery, Thieme, Stuttgart, 1969.
 
28) Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med 313:1191-1200, 1985.
 
29) JET Study Group : Japanese EC-IC Bypass Trial (JET Study) 中間解析結果 (第二報). 脳卒中の外科 30:434-437, 2002.
 
30) Powers WJ, et al ; COSS Investigators : Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia : the Carotid Occlusion Surgery Study randomized trial. JAMA 306:1983-1992, 2011.
PubMed
P.31 掲載の参考文献
1) Shinohara Y : Regional differences in incidence and management of stroke. Is there any difference between western and Japanese guidelines on antiplatelet therapy? Cerebrovasc Dis 21(Suppl 1):17-60, 2006.
 
2) 脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン2004 (篠原幸人ほか編), p1-234, 協和企画, 2004.
 
3) Shinohara Y, et al : Postpublication external review of the Japanese guidelines for the management of stroke 2004. Stroke 40:1439-1443, 2009.
PubMed
4) 脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン2009 (篠原幸人ほか編), p1-358, 協和企画, 2009.
 
5) Shinohara Y, et al : Japanese Guidelines for the Management of Stroke 2009. J Stroke Cerebrovasc Dis 20 (Suppl 1):S1-S209, 2011.
 
6) Hennerici MG, Shinohara Y : Comparison of stroke guidelines : similarities and differences between Japanese and European recommendations for the management and prevention of acute ischemic and hemorrhagic strokes. Cerebrovasc Dis 35:399-401, 2013.
PubMed
P.36 掲載の参考文献
1) The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group : Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333(24):1581-1587, 1995.
 
2) Yamaguchi T, et al : Japan Alteplase Clinical Trial (J-ACT) Group : Alteplase at 0.6 mg/kg for acute ischemic stroke within 3hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810-1815, 2006.
 
3) 端和夫ほか : 我が国における脳梗塞rt-PA (アルテプラーゼ) 静注療法の普及-日本脳卒中学会脳卒中医療向上・社会保険委員会 適正使用部会の取り組みと成果-. 脳卒中 32:1-11, 2010.
Medical*Online
4) Kwan J, et al : A systemic review of barriers to delivery of thrombolysis for acute stroke. Age Ageing 33:116-121, 2004.
 
5) 中川原譲二ほか : 発症-来院時間からみた地域差-来院方法, 重症度, 病型を含めて. 脳卒中データバンク 2009 (小林祥泰編), p36-37, 中山書店, 2009.
 
6) Miyamatsu N, et al : Effects of public education by television on knowledge of early stroke symptoms among a Japanese population aged 40 to 74 years : a controlled study. Stroke 43:545-549, 2012.
 
7) Miyamatsu N, et al : Public awareness of early symptoms of stroke and information sources about stroke among the general Japanese population : the Acquisition of Stroke Knowledge Study. Cerebrovasc Dis 35:241-249, 2013.
PubMed
8) Morimoto A, et al : Effects of intensive and moderate public education on knowledge of early stroke symptoms among a Japanese population : the Acquisition of Stroke Knowledge Study. Stroke 44:2829-2834, 2013.
PubMed
9) 天野達雄ほか : 中学生に対する脳卒中啓発活動 : Act FAST. 脳卒中の外科 39:204-210, 2011.
Medical*Online
10) 中山博文ほか : 一般市民への啓発活動. 救急・集中治療 24:787-792, 2012.
 
P.43 掲載の参考文献
1) 小林祥泰 : 脳卒中急性期患者データベース構築に関する研究. 21世紀型医療開拓推進研究事業報告書, 2002.
 
2) 小林祥泰 (編) : 脳卒中データバンク, 中山書店, 2003.
 
3) 小林祥泰 (編) : 脳卒中データバンク 2005, 中山書店, 2005.
 
4) 小林祥泰 (編) : 脳卒中データバンク 2009, 中山書店, 2009.
 
5) Kimura K, et al : Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 18:47-56, 2004.
PubMed
6) 北園孝成 : 福岡脳卒中データベース研究 (Fukuoka Stroke Registry ; FSR). 福岡医誌 102:285-292, 2011.
Medical*Online
7) 山口修平, 小林祥泰 : 脳卒中データバンクからみた最近の脳卒中の疫学的動向. 脳卒中, 2014 (印刷中).
 
8) Toyoda K et al : Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 39:1740-1745, 2008.
PubMed
9) Johnsen SP, et al : Preadmission oral anticoagulant treatment and clinical outcome among Patients hospitalized with acute stroke and atrial fibrillation : a nationwide study. Stroke 45:168-175, 2014.
PubMed
10) Yamaguchi T, et al : Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810-1815, 2006.
 
P.50 掲載の参考文献
1) Ueshima H, et al : Cardiovascular disease and risk factors in Asia : a selected review. Circulation 118:2702-2709, 2008.
 
2) Kubo M, et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34:2349-2354, 2003.
 
3) Kita Y, et al : Trend of stroke incidence in a Japanese population : Takashima stroke registry, 1990-2001. Int J Stroke 4:241-249, 2009.
 
4) Go AS, et al : Heart disease and stroke statistics-2013 update : a report from the American Heart Association. Circulation 127:e6-e245, 2013.
PubMed
5) Tunstall-Pedoe H : Monitoring trends in cardiovascular disease and risk factors : the WHO "Monica" project WHO Chron 39:3-5, 1985.
PubMed
6) Fujiyoshi A, et al : Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res 35:947-953, 2012.
PubMed
7) Lewington S, et al : Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.
PubMed
8) Kitamura A, et al : Proportions of stroke subtypes among men and women>or=40 years of age in an urban Japanese city in 1992, 1997, and 2002. Stroke 37:1374-1378, 2006.
 
9) Cui R, et al : High serum total cholesterol levels is a risk factor of ischemic stroke for general Japanese population : the JPHC study. Atherosclerosis 221:565-569, 2012.
PubMed
10) Imamura T, et al : LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 40:382-388, 2009.
 
11) Nagasawa SY, et al : Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group : a pooled analysis of 65594individuals from 10 cohort studies in Japan. J Am Heart Assoc 1 : e001974, 2012.
PubMed
12) Tanabe N, et al : Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events-the JALS-ECC-. Circ J 74:1346-1356, 2010.
PubMed
13) Di Angelantonio E, et al : Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993-2000, 2009.
PubMed
14) Ohira T, et al : Carotid artery wall thickness and risk of stroke subtypes : the atherosclerosis risk in communities study. Stroke 42:397-403, 2011.
PubMed
15) Noda H, et al : Low-density Iipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage : the Ibaraki Prefectural Health Study. Circulation 119:2136-2145, 2009.
 
16) Sturgeon JD, et al : Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke 38:2718-2725, 2007.
 
17) Soyama Y, et al : High-density lipoprotein cholesterol and risk of stroke in Japanese men and women : the Oyabe Study. Stroke 34:863-868, 2003.
PubMed
18) Patel A, et al : Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678-2686, 2004.
 
19) Sakurai M, et al : HbA1c and the risks for all-cause and cardiovascular mortality in the general Japanese population : NIPPON DATA90. Diabetes Care 36:3759-3765, 2013.
PubMed
20) Cui R, et al : Diabetes mellitus and risk of stroke and its subtypes among Japanese : the Japan public health center study. Stroke 42:2611-2614, 2011.
PubMed
21) Iso H, et al : Application of computer tomography-oriented criteria for stroke subtype classification in a prospective study. Ann Epidemiol 10:81-87, 2000.
 
22) Ueshima H, et al : Cigarette smoking as a risk factor for stroke death in Japan : NIPPON DATA80. Stroke 35:1836-1841, 2004.
PubMed
23) Mannami T, et al : Cigarette smoking and risk of stroke and its subtypes among middle-aged Japanese men and women : the JPHC Study Cohort I. Stroke 35:1248-1253, 2004.
PubMed
24) Shinton R, Beevers G : Meta-analysis of relation between cigarette smoking and stroke. BMJ 298:789-794, 1989.
PubMed
P.56 掲載の参考文献
1) Hata J, et al : Secular trends in cardiovascular disease and its risk factors in Japanese : half-century data from the Hisayama Study (1961-2009). Circulation 128:1198-1205, 2013.
PubMed
2) Gotoh S, et al : Trends in the incidence and survival of intracerebral haemorrhage by its location in a Japanese community : the Hisayama Study. Circ J 78:403-409, 2014.
 
3) Kubo M, et al : Secular trends in the incidence of and risk factors for ischemic stroke and its subtypes in Japanese population. Circulation 118:2672-2678, 2008.
PubMed
P.63 掲載の参考文献
1) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21:637-676, 1990.
PubMed
2) Adams HP Jr, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35-41, 1993.
 
3) Rothwell PM, et al ; Oxford Vascular Study : Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from, 1981 to 2004 (Oxford Vascular Study). Lancet 363:1925-1933, 2004.
PubMed
4) Ay H, et al : A computerized algorithm for etiologic classification of ischaemic stroke : the Causative Classification of Stroke System. Stroke 38:2979-2984, 2007.
PubMed
5) Amarenco P, et al : New approach to stroke subtyping : the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 27:502-508, 2009.
 
6) Bernard TJ, et al : Towards a consensus-based classification of childhood arterial ischemic stroke. Stroke 43:371-377, 2012.
PubMed
7) Sacco RL, et al ; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia ; Council on Cardiovascular Radiology and Intervention ; Council on Cardiovascular and Stroke Nursing ; Council on Epidemiology and Prevention : Council on Peripheral Vascular Disease ; Council on Nutrition, Physical Activity and Metabolism : An updated definition of stroke for the 21st century : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:2064-2089, 2013.
PubMed
8) Easton DJ, et al : Definition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council ; Council on Cardiovascular Surgery and Anesthesia ; Council on Cardiovascular Radiology and Intervention : Council on Cardiovascular Nursing ; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40:2276-2293, 2009.
 
9) A classification and outline of cerebrovascular diseases. II. Stroke 6:564-616, 1975.
PubMed
10) Wu CM, et al : Early risk of stroke after transient ischemic attack : a systematic review and metaanalysis. Arch Intern Med 167:2417-2422, 2007.
PubMed
11) Johnston SC, et al : Short-term prognosis after emergency department diagnosis of TIA. JAMA 284:2901-2906, 2000.
PubMed
12) Lisabeth LD, et al : Stroke risk after transient ischemic attack in a population-based setting. Stroke 35:1842-1846, 2004.
 
13) 篠原幸人ほか (編) : TIAの急性期治療と脳梗塞発症防止. 脳卒中治療ガイドライン 2009, p78-84, 協和企画, 2009.
 
P.68 掲載の参考文献
1) Adams HP Jr, et al : Classification of subtype of acute ischemic stroke. Difinitions for use in a multicenter clinical trial. Stroke 24:35-41, 1993.
 
2) Caplan LR : Intracranial branch atheromatous disease. Neurology 39:1246-1250, 1989.
PubMed
3) Amarenco P, et al : Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 331:1474-1479, 1994.
PubMed
4) Amarenco P, et al : The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 326 :221-225, 1992.
PubMed
5) 矢坂正弘 : 大動脈原性脳塞栓症の病態, 診断, 予防に関する研究. 循環器病研究委託費による研究18公-2「粥状硬化性機序による難治性脳梗塞の診断, 治療, 予防に関する研究」 平成20年度報告書.
 
6) Lee LJ, et al : Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography. Stroke 31:1081-1089, 2000.
PubMed
7) Gordon DL, et al : Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke : implications for clinical trials. The TOAST Investigators. Neurology 43:1021-1027, 1993.
PubMed
8) Amarenco P, et al : New approach to stroke subtyping : the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 27:502-508, 2009.
 
9) Amarenco P, et al : The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis 36:1-5, 2013.
PubMed
10) 岡田靖 : ATISによる脳卒中の急性期治療. 分子脳血管病 12(2):148-154, 2013.
Medical*Online
P.70 掲載の参考文献
1) Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21(4):637-676, 1990.
PubMed
2) Adams HP, et al : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1):35-41, 1993.
 
3) A classification and outline of cerebrovascular diseases. Neurology 8(5):395-434, 1958.
PubMed
4) A classification and outline of cerebrovascular diseases. II. Stroke 6(5): 564-616, 1975.
PubMed
5) 平井俊策 : 平成元年度厚生省循環器病委託研究費による研究報告集. 脳の動脈硬化性疾患および診断基準に関する研究, p80-89, 1990.
 
6) Albers GW, et al : Transient ischemic attack-proposal for a new definition. N Engl J Med 347(21):1713-1716, 2002.
PubMed
7) Easton JD, et al : Definition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council : Council on Cardiovascular Surgery and Anesthesia ; Council on Cardiovascular Radiology and Intervention ; Council on Cardiovascular Nursing ; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40(6):2276-2293, 2009.
PubMed
8) 上原敏志, 峰松一夫 : 平成21～23年度厚生労働科学研究費補助金による「TIAの診断基準の再検討, ならびにわが国の医療環境に則した適切な診断・治療システムの確立に関する研究」班. 「一過性脳虚血発作」の新展開と治療 日本脳卒中学会認定研修教育病院を対象とした一過性脳虚血発作 (TIA) の診療に関するアンケート調査. 脳卒中 32(6):710-718, 2010.
 
9) 上原敏志, 峰松一夫 : I. TIAの診断 1. 定義. 平成21～23年度厚生労働科学研究費補助金による「一過性脳虚血発作 (TIA) の診断基準の再検討, 適切な診断・治療システムの確立に関する研究」班. TIA診断マニュアル, p11-13, 2013.
 
10) Levy DE : How transient are transient ischemic attacks? Neurology 38(5):674-677, 1988.
PubMed
11) Albers GW : Acute cerebrovascular syndrome : time for new terminology for acute brain ischemia. Nat Clin Pract Cardiovasc Med 3(10):521, 2006.
PubMed
12) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326(5):310-318, 1992.
PubMed
13) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326(4):242-250, 1992.
PubMed
P.79 掲載の参考文献
1) Siesjo BK : Brain Energy Metabolism, John Wiley & Sons, Chichester, 1978.
 
2) Astrup J : Energy-requiring cell functions in the ischemic brain. Their critical supply and possible inhibition in protective therapy. J Neurosurg 56:482-497, 1982.
PubMed
3) Ringelstein EB, et al : Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli : comparison of CO2 to acetazolamide. J Cereb Blood Flow Metab 12:162-168, 1992.
PubMed
4) Kazumata K, et al : Dissociation of vasoreactivity to acetazolamide and hypercapnia. Comparative study in patients with chronic occlusive major cerebral artery disease. Stroke 27:2052-2058. 1996.
PubMed
5) Ogasawara K, et al : Stevens-Johnson syndrome associated with intravenous acetazolamide administration for evaluation of cerebrovascular reactivity. Case report. Neurol Med Chir (Tokyo) 46:161-163, 2006.
PubMed
6) Severinghaus JW, Cotev S : Carbonic acidosis and cerebral vasodilation after Diamox. Scand J Clin Lab Invest Suppl 102 : I : E, 1968.
 
7) Heuser D, et al : Brain carbonic acid acidosis after acetazolamide. Acta Physiol Scand 93:385-390, 1975.
PubMed
8) Kjallquist A, Siesjo BK : A hypothesis for the regulation of extracellular pH in the brain. J physiol 202 : 4P-5P, 1969.
 
9) Roth U, et al : Sulfur-35 labeled acetazolamide in cat brain. J pharmacol Exp Ther 125:128-136, 1959.
 
10) 黒田敏 : 脳血行再建と脳循環・代謝, 中外医学社, 2006.
 
11) Baron JC, et al : Reversal of focal "misery-perfusion syndrome" by extra-intracranial arterial bypass in hemodynamic cerebral ischemia. A case study with 150 positron emission tomography. Stroke 12:454-459, 1981.
 
12) Powers WJ : Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 29:231-240, 1991.
PubMed
13) Astrup J, et al : Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 8:51-57, 1977.
 
14) Jones TH, et al : Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 54:773-782, 1981.
PubMed
15) Kuroda S, et al : Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion : can acetazolamide test predict it? Stroke 32:2110-2116, 2001.
 
16) Kuroda S, et al : Clinical significance of STA-MCA double anastomosis for hemodynamic compromise in post-JET/COSS era. Acta Neurochir (Wien) 156:77-83, 2014.
PubMed
17) Kuroda S, et al : Cerebral oxygen metabolism and neuronal integrity in patients with impaired vasoreactivity attributable to occlusive carotid artery disease. Stroke 37:393-398, 2006.
PubMed
18) Kuroda S, et al : Reduced blood flow and preserved vasoreactivity characterize oxygen hypometabolism due to incomplete infarction in occlusive carotid artery diseases. J Nucl Med 45:943-949, 2004.
PubMed
P.85 掲載の参考文献
1) del Zoppo GJ : Stroke and neurovascular protection. N Engl J Med 354:553-555, 2006.
PubMed
2) Lo EH, et al : Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399-415, 2003.
PubMed
3) Kamouchi M, et al : Brain pericytes : emerging concepts and functional roles in brain homeostasis. Cell Mol Neurobiol 31:175-193, 2011.
PubMed
4) Lindahl P, et al : Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245, 1997.
PubMed
5) Soriano P : Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8:1888-1896, 1994.
PubMed
6) Armulik A, et al : Endothelial/pericyte interactions. Circ Res 97:512-523, 2005.
PubMed
7) Kamouchi M, et al : Calcium influx pathways in rat CNS pericytes. Brain Res Mol Brain Res 126:114-120, 2004.
PubMed
8) Matsuo R, et al : Clinical significance of plasma VEGF value in ischemic stroke-Research for Biomarkers in Ischemic Stroke (REBIOS) study. BMC Neurol 13:32, 2013.
PubMed
9) Arimura K, et al : PDGF receptorβ signaling in pericytes following ischemic brain injury. Curr Neurovasc Res 9:1-9, 2012.
 
10) Nakamura K, et al : Extracellular acidification activates cAMP responsive element binding protein via Na+/H+ exchanger isofoml 1-mediated Ca2+ oscillation in central nervous system pericytes. Arterioscler Thromb Vasc Biol 32:2670-2677, 2012.
PubMed
11) Ishitsuka K, et al : Neurotrophin production in brain pericytes during hypoxia : a role of pericytes for neuroprotection. Microvasc Res 83:352-359, 2012.
PubMed
12) Caplan AI : Why are MSCs therapeutic? New data : New insight. J Pathol 217:318-324, 2009.
 
13) Zlokovic BV : Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12:723-738, 2011.
PubMed
14) Bell RD, et al : Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512-516, 2012.
PubMed
15) Joutel A, et al : The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105:597-605, 2000.
PubMed
P.89 掲載の参考文献
1) Moskowitz MA, et al : The science of stroke : mechanisms in search of treatments. Neuron 67:181-198, 2010.
PubMed
2) 高橋愼一 : 脳を救え : 脳保護療法と再生医療. 循環器内科 72:295-301, 2012.
 
3) 高橋愼一 : 卒中専門医のためのミクロ解剖学 : アストロサイト (その機能と虚血時の反応). 分子脳血管病 5:82-91, 2006.
 
4) 高橋愼一 : 脳虚血とNeurovascular unit. 医学のあゆみ 31:339-346, 2009.
 
5) 高橋愼一 : NVUにおける脳血管関門の機能. 分子脳血管病 9:275-281, 2010.
 
6) 高橋愼一 : 脳血管とアストロサイト-neurovascular unitの概念について-. 神経内科 79:247-256, 2013.
 
7) 高橋愼一 : 血液脳関門および脳循環・代謝調節とアストロサイト. 実験医学 31:2195-2203, 2013.
Medical*Online
8) Mathiisen TM, et al : The perivascular astroglial sheath provides a complete covering of the brain microvessels : an electron microscopic 3D reconstruction. Glia 58:1094-1103, 2010.
PubMed
9) Garcia-Marin V, et al : Cajal's contributions to glia research. Trends Neurosci 30:479-487, 2007.
 
10) Report of the Stroke Progress Review Group. (National Institute of Neurological Disorders and Stroke, Maryland), p1-116, 2002. [http://www.nindsnih.gov/find_people/groups/stroke_prg/StrokePRGreport-4-23-02.pdf]
 
11) 高橋愼一ほか : 治療ターゲットとしての脳虚血後の炎症 : アストロサイトからみた脳虚血後の炎症. 脳循環代謝 23(2):66-74, 2012.
 
12) Takahashi S, et al : Astrogliopathy as a loss of astroglial protective function against glycoxidative stress under hyperglycemia. Rinsho Shinkeigaku 52:41-51, 2012.
PubMed
13) Takahashi S, et al : Astroglial pentose phosphate pathway rates in response to high-glucose environments. ASN Neuro 4(2) : pii : e00078. 10. 1042/AN20120002, 2012
 
14) 高橋愼一 : 脳の機能活動とエネルギー産生の時間的, 空間的プロファイル : ニューロン-アストロサイト連関から見たグルコース代謝. 脳循環代謝 9:1-17, 1997.
 
15) 高橋愼一 : アストロサイトと糖代謝. Clinical Neuroscience 29:1262-1267, 2011.
 
P.94 掲載の参考文献
1) Lehnardt S, et al : Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 100:8514-8519, 2003.
PubMed
2) Yenari MA, et al : Microglia potentiate damage to blood-brain barrier constituents : improvement by minocycline in vivo and in vitro. Stroke 37:1087-1093, 2006.
PubMed
3) Zhao BQ, et al : Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441-445, 2006.
PubMed
4) Parkhurst CN, et al : Microglia promote learning-dependent synapse formation through brainderived neurotrophic factor. Cell 155:1596-1609, 2013.
PubMed
5) Perego C, et al : Temporal pattern of expression and colocalization of microglia/macrophage phenotype markers following brain ischemic injury in mice. J Neuroinflammation 8:174, 2011.
PubMed
6) Hu X, et al : Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 43:3063-3070, 2012.
PubMed
7) Wake H, et al : Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 29:3974-3980, 2009.
PubMed
8) Wake H, et al : Microglia : actively surveying and shaping neuronal circuit structure and function. Trends Neurosci 36:209-217, 2013.
PubMed
9) Koizumi S, et al : UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature 446:1091-1095, 2007.
PubMed
10) Neher JJ, et al : Phagocytosis executes delayed neuronal death after focal brain ischemia. Proc Natl Acad Sci USA 110 : E4098-4107, 2013.
PubMed
11) Graeber MB : Changing face of microglia. Science 330:783-788, 2010.
PubMed
P.99 掲載の参考文献
1) Astrup J, et al : Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia, Stroke 8:51-57, 1977.
 
2) Sharp FR, et al : Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 20:1011-1032, 2000.
PubMed
3) Lo EH : A new penumbra : transitioning from injury into repair after stroke. Nat Med 14:497-500, 2008.
PubMed
4) Siesjo BK, et al : Mechanisms of secondary brain damage in global and focal ischemia : a speculative synthesis. J Neurotrauma 12:943-956, 1995.
PubMed
5) Wang X, et al : Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35:2726-2730, 2004.
PubMed
6) Chavez JC, et al : Pharmacologic interventions for stroke : looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 40:e558-563, 2009.
 
7) Iadecola C : Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci 20:132-139, 1997.
 
8) Katsura K, et al : Combination therapy with transductive anti-death FNK protein and FK506 ameliorates brain damage with focal transient ischemia in rat. J Neurochem 106:258-270, 2008.
 
9) del Zoppo GJ : Relationship of neurovascular elements to neuron injury during ischemia. Cerebrovasc Dis 27(Suppl 1):65-76, 2009.
 
10) Yamashita T, et al : Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 29:715-725, 2009.
 
11) Kanazawa M, et al : Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab 31:1461-1474, 2011.
PubMed
12) Kuroda S : Bone marrow stromal cell transplantation for ischemic stroke-its multi-functional feature. Acta Neurobiol Exp (Wars) 73:57-65, 2013.
PubMed
13) Shichita T, et al : Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18:911-917, 2012.
PubMed
P.105 掲載の参考文献
1) Kerr JF, et al : Apoptosis : a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257, 1972.
PubMed
2) Clarke PG : Developmental cell death : morphological diversity and multiple mechanisms. Anat Embryol 181:195-213, 1990.
PubMed
3) Zou H, et al : Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413, 1997.
 
4) Kawane K, Nagata S : Nucleases in programmed cell death. Methods Enzymol 442:271-287, 2008.
PubMed
5) Nagata S : DNA degradation in development and programmed cell death. Annu Rev Immunol 23:853-875, 2005.
PubMed
6) Broughton BR, et al : Apoptotic mechanisms after cerebral ischemia. Stroke 40 : e331-e339, 2009.
PubMed
7) Le DA, et al : Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 99:15188-15193, 2002.
PubMed
8) Hong LZ, et al : p53-mediated neuronal cell death in ischemic brain injury. Neurosci Bull 26:232-240, 2010.
PubMed
9) Martin-Villalba A, et al : CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosisinducing Iigand mediate ischemia-induced apoptosis in neurons. J Neurosci 19:3809-3817, 1999.
 
10) Kirino T : Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res 239:57-69, 1982.
 
11) Nitatori T, et al : Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci 15:1001-1011, 1995.
PubMed
12) Jin K, et al : Fas (CD95) may mediate delayed cell death in hippocampal CA1 sector after global cerebral ischemia. J Cereb Blood Flow Metab 21:1411-1421, 2001.
PubMed
13) Cao G, et al : Cloning and characterization of rat caspase-9 : implications for a role in mediating caspase-3 activation and hippocampal cell death after transient cerebral ischemia. J Cereb Blood Flow Metab 22:534-546, 2002.
PubMed
14) Endo H, et al : Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats. J Neurosci 26:7974-7983, 2006.
PubMed
15) Koike M, et al : Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxicischemic injury. Am J pathol 172:454-469, 2008.
PubMed
P.109 掲載の参考文献
1) Narendra D, et al : Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183(5):795-803, 2008.
PubMed
2) Cuervo AM, Dice JF : A receptor for the selective uptake and degradation of proteins by lysosomes. Science 273(5274):501-503, 1996.
PubMed
3) Kaushik S, Cuervo AM : Chaperone-mediated autophagy : a unique way to enter the lysosome world. Trends Cell Biol 22(8):407-417, 2012.
PubMed
4) Mizushima N, Levine B : Autophagy in mammalian development and differentiation. Nat Cell Biol 12(9):823-830, 2010.
PubMed
5) Nitatori T, et al : Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci 15(2):1001-1011, 1995.
PubMed
6) Aggoun-Zouaoui D, et al : Ultrastructural morphology of neuronal death following reversible focal ischemia in the rat. Apoptosis 3(2):133-141, 1998.
PubMed
7) Wen YD, et al : Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways. Autophagy 4(6):762-769, 2008.
PubMed
8) Tian F, et al : In vivo imaging of autophagy in a mouse stroke model. Autophagy 6(8):1107-1114, 2010.
 
9) Meloni BP, et al : Characterisation of neuronal cell death in acute and delayed in vitro ischemia (oxygen-glucose deprivation) models. J Neurosci Methods 195(1):67 -74, 2011.
 
10) Rami A, et al : Focal cerebral ischemia induces upregulation of Beclin 1 and autophagy-like cell death. Neurobiol Dis 29(1):132-141, 2008.
PubMed
11) Puyal J, et al : Postischemic treatment of neonatal cerebral ischemia should target autophagy. Ann Neurol 66(3):378-389, 2009.
PubMed
12) Tanaka S, et al : Synergistic induction of HSP40 and HSC70 in the mouse hippocampal neurons after cerebral ischemia and ischemic tolerance in gerbil hippocampus. J Neurosci Res 67(1):37-47, 2002.
PubMed
13) Seki T, et al : Establishment of a novel fluorescence-based method to evaluate chaperone-mediated autophagy in a single neuron. PLoS One 7(2):e31232, 2012.
 
14) Dohi E, et al : Hypoxic stress activates chaperone-mediated autophagy and modulates neuronal cell survival. Neurochem Int 60 (4):431-442, 2012.
PubMed
15) Bauer PO, et al : Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein, Nat Biotechnol 28(3):256-263, 2010.
PubMed
P.115 掲載の参考文献
1) Iadecola C, Anrather J : The immunology of stroke : from mechanisms to translation. Nat Med 17:796-808, 2011.
PubMed
2) Lemaitre B, et al : The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifUngal response in Drosophila adults. Cell 86:973-983, 1996.
 
3) Chen CJ, et al : Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 13:851-856, 2007.
PubMed
4) Zhang J, et al : Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42:1420-1428, 2011.
PubMed
5) Shichita T, et al : Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18:911-917, 2012.
PubMed
6) Becker KJ : Sensitization and tolerization to brain antigens in stroke. Neuroscience 158:1090-1097, 2009.
PubMed
7) Shichita T, et al : Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med 15:946-950, 2009.
PubMed
8) Wei Y, et al : Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol 69:119-129, 2011.
PubMed
9) Meisel C, Meisel A : Suppressing immunosuppression after stroke. N Engl J Med 365:2134-2136, 2011.
PubMed
10) Buckley CD, et al : The resolution of inflammation. Nat Rev Immunol 13:59-66, 2013.
 
11) Ooboshi H, et al : Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 111:913-919, 2006.
 
12) Arac A, et al : Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. Proc Natl Acad Sci USA 108:13287-13292, 2011.
PubMed
13) Li P, et al : Adoptive regulatory T-cell therapy protects against cerebral ischemia. Ann Neurol 74:458-471, 2013.
PubMed
14) Est6vez AG, et al : Arginase 1 regulation of nitric oxide production is key to survival of trophic factor-deprived motor neurons. J Neurosci 26:8512-8516, 2006.
 
15) Desestret V, et al : In vitro and in Vivo models of cerebral ischemia show discrepancy in therapeutics effects of M2 macrophages. PLoS One 8:e67063, 2013.
PubMed
P.119 掲載の参考文献
1) Wang S, Kaufman RJ : The impact of the unfolded protein response on human disease. J Cell Biol 197(7):857-867, 2012.
 
2) Hori O, et al : Exposure of astrocytes to hypoxia/reoxygenation enhances expression of glucose-regulated protein 78 facilitating astrocyte release of the neuroprotective cytokine interleukin 6. J Neurochem 66(3):973-979, 1996.
PubMed
3) Kuwabara K, et al : Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J Biol Chem 271(9):5025-5032, 1996.
 
4) Yamaguchi A, et al : Stress-associated endoplasmic reticulum protein 1(SERP1) /Ribosome-associated membrane protein 4 (RAMP4) stabilizes membrane proteins during stress and facilitates subsequent glycosylation. J Cell Biol 147(6):1195-1204, 1999.
PubMed
5) Hori O, et al : Role of Herp in the endoplasmic reticulum stress response. Genes Cells 9(5):457-469, 2004.
PubMed
6) Tamatani M, et al : ORP150 protects against hypoxia/ischemia-induced neuronal death. Nat Med 7(3):317-323, 2001.
PubMed
7) Eura Y, et al : Derlin-1 deficiency is embryonic lethal, Derlin-3 deficiency appears normal, and Herp deficiency is intolerant to glucose load and ischemia in mice. PLoS One 7(3): e34298, 2012.
PubMed
8) Tajiri S, et al : Ischemia-induced neuronal cell death is mediated by the endoplasmic reticulum stress pathway involving CHOP. Cell Death Differ 11(4):403-415, 2004.
PubMed
9) Page AB, et al : Persistent eIF2alpha (P) is colocalized with cytoplasmic cytochrome c in vulnerable hippocampal neurons after 4 hours of reperfusion following 10-minute complete brain ischemia. Acta Neuropathol (Berl) 106(1):8-16, 2003.
PubMed
10) Li F, et al : The protective effect of dantrolene on ischemic neuronal cell death is associated with reduced expression of endoplasmic reticulum stress markers. Brain Res 1048(1-2): 59-68, 2005.
PubMed
11) Qi X, et al : Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 66(4):899-908, 2004.
PubMed
12) Nakka VP, et al : Endoplasmic reticulum stress plays critical role in brain damage after cerebral ischemia/reperfusion in rats. Neurotox Res 17(2):189-202, 2010.
PubMed
13) Kudo T, et al : A molecular chaperone inducer protects neurons from ER stress. Cell Death Differ 15(2):364-375, 2008.
 
14) Takano K, et al : A dibenzoylmethane derivative protects dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress. Am J Physiol Cell Physiol 293(6):C1884-1894, 2007.
 
15) Hashida K, et al : ATF6alpha promotes astroglial activation and neuronal survival in a chronic mouse model of Parkinson's disease. PLoS One 7(10):e47950, 2012.
 
P.125 掲載の参考文献
1) Kojima F, et al : New insights into eicosanoid biosynthetic pathways : implications for arthritis. Expert Rev Clin Immunol 2:277-291, 2006.
PubMed
2) Vane JR : Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232-235, 1971.
PubMed
3) Iadecola C, et al : Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 98:1294-1299, 2001.
 
4) Bonventre JV, et al : Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature 390:622-625, 1997.
PubMed
5) Ikeda-Matsuo Y, et al : Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. Proc Natl Acad Sci USA 103:11790-11795, 2006.
PubMed
6) Yuhki K, et al : Roles of prostanoids in the pathogenesis of cardiovascular diseases : Novel insights from knockout mouse studies. Pharmacol Ther 129:195-205, 2011.
PubMed
7) Nogawa S, et al : Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755, 1997.
PubMed
8) Kawano T, et al : Prostaglandin E2 EP1 receptors : downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229, 2006.
PubMed
9) Ahmad M, et al : Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmnol 184:172-179, 2007.
PubMed
10) McCullough L, et al : Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24:257-268, 2004.
PubMed
11) Liang X, et al : Signaling via the prostaglandin E2 receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia. J Clin Invest 121:4362-4371, 2011.
 
12) Saleem S, et al : PGF2α FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res 15:62-70, 2009.
 
13) Saleem S, et al : PGD2 DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 26:73-78, 2007.
PubMed
14) Ma H, et al : Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP3. Circulation 104:1176-1180, 2001.
PubMed
15) Kuriyama S, et al : Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 104:796-803, 2010.
PubMed
16) Xiao CY, et al : Roles of prostaglandin I, and thromboxane A, in cardiac ischemia-reperfusion injury : a study using mice lacking their respective receptors. Circulation 104:2210-2215, 2001.
PubMed
17) Xiao CY, et al : Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 109:2462-2468, 2004.
PubMed
18) Kawabe J, et al : Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol 30:464-470, 2010.
PubMed
P.129 掲載の参考文献
1) Zhang X, et al : Temporal and spatial differences of multiple protein expression in the ischemic penumbra after transient MCAO in rats. Brain Res 1343:143-152, 2010.
PubMed
2) Lo EH, et al : Extracellular proteolysis in brain injury and inflammation : role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 69:1-9, 2002.
PubMed
3) Kono S, et al : Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. J Stroke Cerebrovasc Dis 22:190-196, 2013.
PubMed
4) Shobha N, et al : Canadian Alteplase for Stroke Effectiveness Study (CASES) : Thrombolysis at 3-4.5 hours after acute ischemic stroke onset evidence from the Canadian Alteplag. e for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 31:223-228, 2011.
 
5) Yamashita T, et al : Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab 29:715-725, 2009.
 
6) Tian F, et al : In vivo optical imaging correlates with improvement of cerebral ischemia treated by intravenous BMSCs and edaravone. Neurol Res 35:1051-1058. 2013.
PubMed
P.132 掲載の参考文献
1) Ross R : Arteriosclerosis-an inflammatory disease. N Engl J Med 340:115-126, 1999.
PubMed
2) 平田恭信 : NOと動脈硬化. 綜合臨牀 53:2739-2740, 2004.
Medical*Online
3) 菅原基晃, 仁木清美 : 頸動脈内の血流の特性. Modern Physician 27:1329-1336, 2007.
 
4) Griendling KK, FitzGerald GA : Oxidative stress and cardiovascular injury : Part II : Animal and human studies. Circulation 108:2034-2040, 2003.
PubMed
5) Lavioe JL, Sigmund CD : Minireview : overview of the renin-angiotension system-an endocrine and paracrine system. Endocrinology 144:2179-2183, 2003.
 
6) Martin-Gallan P, et al : Biomarkers of diabetes-associated oxidative stress and anti-oxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34:1563-1574, 2003.
 
7) 久米典昭 : 頸動脈硬化病変の形成, 分子生物学的検討-酸化LDL受容体の役割を中心に. 脳卒中 23:351-356, 2001.
 
8) 野間玄督, 東幸仁 : 病態と血管内皮機能. 分子血管病 10:393-400, 2009.
 
9) Espinola-Klein C, et al : Impact of infectious burden on progression of carotid atherosclerosis. Stroke 33:2581-2586, 2002.
PubMed
10) Rao GN, Berk BC : Active oxygen species stimulate vascular smooth muscle cell growth and protooncogene expression. Circ Res 70:593-599, 1992.
PubMed
11) 坂田則行 : 酸化ストレスと動脈障害. J Jpn Coll Angiol 43:685-689, 2003.
 
12) 山下篤, 浅田祐士郎 : 血栓の増大・成長の病理基盤. 血管医学 12:115-121, 2011.
Medical*Online
13) 居石克夫 : プラーク内新生血管のメカニズムと病態学的意義. 病理と臨床 21:994-997, 2003.
 
14) Kolodgie FD, et al : Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 349:2316-2325, 2003.
PubMed
15) Smilde TJ, et al : Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP) : a prospective, randomised, double-blind trial. Lancet 357:577-581, 2001.
 
P.139 掲載の参考文献
1) 浦野哲盟, 後藤信哉 : 血栓形成と凝固・線溶 治療に生かせる基礎医学, メディカル・サイエンス・インターナショナル, 2013.
 
2) Miyata T, et al : Genetic risk factors for deep vein thrombosis among Japanese : importance of protein S K196E mutation. Int J Hematol 83(3):217-223, 2006.
PubMed
3) 鈴木優子 : 血管内皮細胞表面における滞留tPA惹起線溶活性増幅機構のイメージング解析. 日血栓止血会誌 22(6):374-376, 2011.
 
4) 浦野哲盟 : 線溶機序. 脈管学 51:293-299, 2011.
 
5) 鈴木優子, 浦野哲盟 : 動脈硬化 血栓性疾患発症予防におけるスタチンの特殊な位置付け. 動脈硬化予防 12(2):56-63, 2013.
Medical*Online
6) Libby P, Theroux P : Pathophysiology of coronary artery disease. Circulation 111(25):3481-3488, 2005.
PubMed
7) Iwaki T, et al : PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157(3):291-298, 2012.
PubMed
8) Li Z, et al : Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30(12):2341-2349, 2010.
PubMed
9) Gresele P, et al : Potentiation and priming of platelet activation : a potential target for antiplatelet therapy. Trends Pharmacol Sci 29(7):352-360, 2008.
PubMed
10) Stoll G, Bendszus M : Inflammation and atherosclerosis : novel insights into plaque formation and destabilization. Stroke 37(7):1923-1932, 2006.
PubMed
P.143 掲載の参考文献
1) Zlokovic BV : The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178-201, 2008.
PubMed
2) Moskowitz MA, et al : The science of stroke : mechanisms in search of treatments. Neuron 67:181-198, 2010.
PubMed
3) Shuaib A, et al ; SAINT II Trial lnvestigators : NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562-571, 2007.
PubMed
4) Tomimoto H, et al : Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol 106:527-534, 2003.
PubMed
5) Ihara M, Tomimoto H : Lessons from a mouse model characterizing features of vascular cognitive impairment with white matter changes. J Aging Res 2011:978761, 2011.
PubMed
6) Nishio K, et al : A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 41:1278-1284, 2010.
PubMed
7) Ihara M, et al : Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J Cereb Blood Flow Metab 21:828-834, 2001.
PubMed
8) Nakaji K, et al : Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Stroke 37:2816-2823, 2006.
 
9) Seo JH, et al : Oligodendrocyte precursors induce early blood-brain barrier opening after white matter injury. J Clin Invest 123:782-786, 2013.
PubMed
10) 冨本秀和 : 皮質下血管性認知症の診断と治療. 臨床神経学 50:539-546, 2010.
 
11) Mandai K, et al : Ischemic damage and subsequent proliferation of oligodendrocytes in focal cerebral ischemia. Neuroscience 77:849-861, 1997.
PubMed
12) Hayakawa K, et al : Vascular endothelial growth factor regulates the migration of oligodendrocyte precursor cells. J Neurosci 31:10666-10670, 2011.
PubMed
13) Maki T, et al : Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 42:1122-1128, 2011.
PubMed
14) Nishiyama A, et al : Polydendrocytes (NG2 cells) : multifunctional cells with lineage plasticity. Nat Rev Neurosci 10:9-22, 2009.
PubMed
15) 眞木崇州, 猪原匡史 : Neurovascular Unitの概念から導きだされる中枢神経疾患の治療戦略. 実験医学 31:2230-2236, 2013.
Medical*Online
P.147 掲載の参考文献
1) Pantoni L : Cerebral small vessel disease : from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 9:689-701, 2010.
PubMed
2) 冨本秀和 : 脳小血管病の概念と分類. 脳卒中 35:128-132, 2013.
Medical*Online
3) Fisher CM : Lacunar infarcts. A review. Cerebrovasc Dis 1:311-320, 1991.
 
4) Yata K, Tomimoto H : Chronic cerebral hypoperfusion and dementia. Neurol Clin Neurosci. (in printing)
 
5) Poirier J, Derouesne C : Cerebral lacunae. A proposed new classification. Clin Neuropathol 3:266, 1984.
PubMed
6) Hernandez Mdel C, et al : Towards the automatic computational assessment of enlarged perivascular spaces on brain magnetic resonance images : a systematic review. J Magn Reson Imaging 38:774-785, 2013.
PubMed
7) Potter GM, et al : Enlarged perivascular spaces and cerebral small vessel disease. Int J Stroke, 2013. [Epub ahead of print]
 
8) Adams HH, et al : Rating method for dilated Virchow-Robin spaces on magnetic resonance imaging. Stoke 44:1732-1735, 2013.
 
9) Caplan LR : Intracranial branch atheromatous disease : a neglected, understudied, and underused concept. Neurology 39:1246-1250, 1989.
PubMed
10) Bladin PF, Berkovic SF : Striatocapsular infarction : large infarcts in the lenticulostriate arterial territory. Neurology 34:1423-1430, 1984.
PubMed
11) 鄭秀明ほか : Striatocapsular infarctionの臨床的検討. 臨床神経 33:294-300, 1993.
 
12) Ringelstein EB, et al : Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology 42:289-293, 1992.
PubMed
13) Kwa VI, et al : T2-weighted hyperintense MRI lesions in the pons in patients with atherosclerosis. Amsterdam Vascular Medicine Group. Stoke 28:1357-1360, 1997.
 
14) 大根田玄寿 : 脳出血の病理, 文光堂, 1974.
 
15) Fazekas F, et al : Histopathologic analysis of foci of signal loss on gradient-echo-T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage : evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol 20:637-642, 1999.
PubMed
P.151 掲載の参考文献
1) Okeda R, et al : Pathology of the cerebral artery in the aged : Observation by serial sections and morphometry of the cerebral arteries. Neuropathology 24:21-29, 2004.
PubMed
2) Arima K, et al : Cerebral arterial pathology of CADASIL and CARASIL (Maeda syndrome). Neuropathology 23:327-334, 2003.
PubMed
3) Dziewulska D, Lewandowska E : Pericytes as a new target for pathological processes in CADASIL Neuropathology 32:515-521, 2012.
PubMed
4) Chabriat H, et al : CADASIL Lancet Neurol 8:643-653, 2009.
PubMed
5) Mizuno T : Pathomechanisms and treatment of CADASIL Brain Nerve 65:811-823, 2013.
PubMed
6) Watanabe-Hosomi A, et al : Transendocytosis is impaired in CADASIL-mutant NOTCH3. Exp Neurol 233:303-311, 2012.
PubMed
7) Karlstr6m H, et al : ACADASIL-mutated Notch 3 receptor exhibits impaired intracellular trathcking and maturation but normal ligand-induced signaling. Proc Natl Acad Sci USA 99:17119-17124, 2002.
 
8) Monet-Lepretre M, et al : Abnormal recruitment of extracellular matrix proteins by excess Notch3ECD : a new pathomechanism in CADASIL. Brain 136:1830-1845, 2013.
PubMed
9) Joutel A : Pathogenesis of CADASIL : transgenic and knock-out mice to probe function and dysfunction of the mutated gene, Notch3, in the cerebrovasculature. Bioessays 33:73-80, 2010.
PubMed
10) Nozaki H, et al : Clinical and molecular features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke, 2014. (in press)
 
11) Yanagawa S, et al : Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology 58:817-820, 2002.
PubMed
12) Hara K, et al : Association of HTRA1 mutations and familial ischemic small-vessel disease. N Engl J Med 360:1729-1739, 2009.
PubMed
13) Truebestein L, et al : Substrate-induced remodeling of the active site regulates human HTRA activity. Nat Struct Mol Biol 18:386-388, 2011.
 
14) Nishimoto Y, et al : A novel mutation in the HTRA1 gene causes CARASIL without alopecia. Neurology 76:1353-1357, 2011.
PubMed
15) Shiga A, et al : Cerebral small-vessel disease protein HTRA1 controls the amount of TGF-β1 via cleavage of proTGF-β1. Hum Mol Genet 20:1800-1810, 2011.
 
P.157 掲載の参考文献
1) Ito S, et al : Strain vessel hypothesis : a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. Hypertens Res 32:115-121, 2009.
PubMed
2) Lasjaunias P : Vascular Disease in Neonates, Infants and Children : Interventional Neuroradiology Management, p203-319, Springer-Verlag, Berlin, 1997.
 
3) 里見淳一郎, 永廣信治 : 脳動静脈奇形と硬膜動静脈瘻の成因と自然歴. 脳神経外科ジャーナル 22:898-903, 2013.
 
4) Kim H, et al : Genetic considerations relevant to intracranial hemorrhage and brain arteriovenous malformations. Acta Neurochir Suppl 105:199-206, 2008.
PubMed
5) Fischer A, et al : Cerebral cavernous malformations : from CCM genes to endothelial cell homeostasis. Trends Mol Med 19:302 -308, 2013.
 
6) Dashti SR, et al : Molecular genetics of familial cerebral cavernous malformations. Neurosurg Focus 21:e2, 2006.
PubMed
7) Koike T, et al : High incidence of radiation-induced cavernous hemangioma in long-term survivors who underwent hematopoietic stem cell transplantation with radiation therapy during childhood or adolescence. Biol Blood Marrow Transplant 18:1090-1098, 2012.
PubMed
8) 高木健治ほか : 海綿状血管奇形の特徴と治療. 脳神経外科ジャーナル 22:28-36, 2013.
 
9) Nishijima M, et al : Etiological evaluation of dural arteriovenous malformations of the lateral and sigmoid sinuses base on histopathological examinations. J Neurosurg 76:600-606, 1992.
 
10) Terada T, et al : The role of angiogenic factor bFGF in the development of dural AVFs. Acta Neurochir (Wien) 138:877-883, 1996.
PubMed
11) Uranishi R, et al : Expression of angiogenic factors in dural arteriovenous fistulas. J Neurosurg 91:781-786, 1999.
PubMed
12) van Dijk JM, et al : Thrombophilic factors and the formation of dural arteriovenous fistulas. J Neurosurg 107:56-59, 2007.
PubMed
13) Nah HW, et al : Moyamoya disease-related versus primary intracerebral hemorrhage : [corrected] location and outcomes are different. Stroke 43:1947-1950, 2012.
PubMed
14) 森岡基浩ほか : 出血型モヤモヤ病の再出血の特徴. 脳循環代謝 16:259-266, 2004.
 
15) Yoshino A, et al : Apoplexy accompanying pituitary adenoma as a complication of preoperative anterior pituitary fUnction tests. Acta Neurochir (Wien) 149:557-565, 2007.
PubMed
16) 鈴木康裕 : 血栓動物病態モデルにおける抗血栓薬の評価. 薬学雑誌 132:1019-1024, 2012.
 
17) Okada T, et al : Magnetic resonance imaging of vascular encephalopathy related to pregnancy. Neurol Med Chir (Tokyo) 53:520-525, 2013.
PubMed
P.161 掲載の参考文献
1) van Gijn J, Rinkel GJ : Subarachnoid haemorrhage : diagnosis, causes and management. Brain 124:249-278, 2001.
PubMed
2) Stehbens WE : Pathology of the Cerebral Blood Vessels, p351-470, Mosby, St Louis, 1972.
 
3) Sasaki T, et al : Loss and apoptosis of smooth muscle cells in intracranial aneurysms. Studies with in situ DNA end labeling and antibody against single-stranded DNA Acta Neurochir (Wien) 139:469-474, 1997.
 
4) Brune G, et al : Vascular extracellular matrix (remodeling in cerebral aneurysms. J Neurosurg 89:431-440, 1998.
 
5) Chyatte D, et al : Inflammation and intracranial aneurysms. Neurosurgery 45:1137-1146, 1999.
PubMed
6) Kataoka K et al : Difference in nature of ruptured and unruptured cerebral aneurysms. Lancet 355:203, 2000.
 
7) Wiebers DO, et al : Unruptured intracranial aneurysms : natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362:103-110, 2003.
PubMed
8) Morita A, et al : The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366:2474-2482, 2012.
 
9) Hashimoto N, et al : Experimentally induced cerebral aneurysms in rats. Surg Neurol 10:3-8, 1978.
PubMed
10) Hashimoto N, et al : Experimental induction of cerebral aneurysms in monkeys. J Neurosurg 67:903-905, 1987.
PubMed
11) Morimoto M, et al : Mouse model of cerebral aneurysm : experimental induction by renal hypertension and local hemodynamic changes. Stroke 33:1911-1915, 2002.
PubMed
12) Aoki T, et al : Macrophage-derived matrix metalloproteinase-2 and-9 promote the progression of cerebral aneurysms in rats. Stroke 38:162-169, 2007.
PubMed
13) Aoki T, et al : Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke 40:942-951, 2009.
PubMed
14) Aoki T, et al : NF-kappaB is a key mediator of cerebral aneurysm formation. Circulation 116:2830-2840, 2007.
PubMed
15) Aoki T, et al : Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 39:1276-1285, 2008.
PubMed
P.166 掲載の参考文献
1) Ecker A, Riemenschneider PA : Arteriographic demonstration of spasm of the intracranial arteries. J Neurosurg 8:660-667, 1951.
PubMed
2) Shirao S, et al : A proposed definition of symptomatic vasospasm based on treatment of cerebral vasospasm after subarachnoid hemorrhage in Japan : Consensus 2009, a project of the 25 Spasm Symposium. Surg Neurol Int 2:74, 2011.
PubMed
3) Catterall WA : Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 16:521-555, 2000.
PubMed
4) Tani E, Matsumoto T : Continuous elevation of intracellular Ca2+ is essential for the development of cerebral vasospasm. Curr Vasc Pharmacol 2:13-21, 2004.
PubMed
5) Rinkel GJE, et al : Calcium antagonists in aneurismal subarachnoid hemorrhage. Stroke 36:1816-1817, 2005.
 
6) Kasuya H, et al : Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke 33:1011-1015, 2002.
PubMed
7) Sasaki T, et al : Role of p38 mitogen-activated protein kinase on cerebral vasospasm following subarachnoid hemorrhage. Stroke 35:1466-1470, 2004.
 
8) Sasahara A, et al : Gene-expression in a canine basilar artery vasospasm model : a genome-wide network-based analysis. Neurosurg Rev 31:283-290, 2008.
 
9) Matsui T, et al : Possible role of protein kinase C-dependent smooth muscle contraction in the pathogenesis of chronic cerebral vasospasm. J Cereb Blood Flow Metab 11:143-149, 1991.
PubMed
10) Sato M, et al : Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 87:195-200, 2000.
PubMed
11) Shibuya M, et al : Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:571-577, 1992.
 
12) Macdonald RL, et al : Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping : a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618-625, 2011.
PubMed
13) Kanamaru K, et al : Endothelium-dependent relaxation of canine basilar arteries. Part 2 : Inhibition by hemoglobin and cerebrospinal fluid from patients with aneurysmal subarachnoid hemorrhage. Stroke 18:938-943, 1987.
PubMed
14) Fisher CM, et al : Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6:1-9, 1980.
PubMed
15) Macdonald RL, Weir BK : A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 22:971-982, 1991.
PubMed
P.170 掲載の参考文献
1) Russell DS, Rubinstein LJ : Pathology of the Nervous System, 2nd ed, p345, Williams & Wilkins, New York, 1963.
 
2) Asahara T, et al : Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997.
PubMed
3) Gao PG, et al : Evidence of endothelial progenitor cells in the human brain and spinal cord arteriovenous malformations. Neurosurgery 67:1029-1035, 2010.
 
4) Lasjaunias P : A revised concept of the congenital nature of cerebral arteriovenous malformations. Interv Neuroradiol 3:275-281, 1997.
PubMed
5) Brouillard R Vikkula M : Genetic causes of vascular malformations. Hum Mol Genet 16:R140-149, 2007.
 
6) Pawlikowska L, et al : Polymorphisms in transforming growth factor-β-related genes ALK1 and ENG are associated with sporadic brain arteriovenous malformations. Stroke 36:2278-2280, 2005.
 
7) Leblanc GG, et al ; Biology of Vascular Malformations of the Brain NINDS Workshop Collaborators : Biology of vascular malformations of the brain. Stroke 40:e694-e702, 2009.
PubMed
8) Shovlin CL, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91:66-67, 2000.
PubMed
9) Revencu N, et al : Parkes Weber syndrome, vein of Galen malformation, and other fast-flow vascular anomalies are caused by RISA1 mutations. Hum Mutat 29:959-965, 2008.
PubMed
10) Labauge P, et al : Genetics of cavernous angiomas, Lancet Neurol 6:237-244, 2007.
PubMed
11) Aboian MS, et al : The putative role of the venous system in the genesis of vascular malformation. Neurosurg Focus 27:E9, 2009.
PubMed
12) Komiyama M, et al : Venous angiomas with arteriovenous shunts. Report of three cases and review of the literature. Neurosurgery 44:1328-1335, 1999.
PubMed
13) Mullan S, et al : Cerebral venous malformation-arteriovenous malfomlation transition forms. J Neurosurg 85:9-13, 1996.
PubMed
14) Perrini P, Lanzino G : The association of venous developmental anomalies and cavernous malformations : pathophysiological, diagnostic, and surgical considerations. Neurosurg Focus 21:e5, 2006.
PubMed
15) Awad IA, et al : MiXed vascular malformations of the brain : clinical and pathogenetic considerations. Neurosurgery 33:179-188, 1993.
PubMed
P.181 掲載の参考文献
1) Kario K : Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation. Hypertens Res 36:478-484, 2013.
PubMed
2) Perkovic V, et al : The burden of blood pressure-related disease : a neglected priority for global health. Hypertension 50:991-997, 2007.
PubMed
3) Morimoto A, et al : Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 350 (9093):1734-1737, 1997.
PubMed
4) Chen J, et al ; GenSalt Collaborative Research Group : Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China : adietary intervention study. Lancet 373:829-835, 2009.
 
5) Ishikawa Y, et al ; Jichi Medical School Cohort Investigators Group : Prevalence and determinants of prehypertension in a Japanese general population : the Jichi Medical School Cohort Study, Hypertens Res 31:1323- 1330, 2008.
 
6) Greenlund KI, et al : Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000. Arch Intern Med 164:2113-2118, 2004.
 
7) Watanabe H, et al : Metabolic syndrome and risk of development of atrial fibrillation : the Niigata preventive medicine study. Circulation 117:1255-1260, 2008.
PubMed
8) Kario K, Pickering TG : Blood pressure variability in elderly patients. Lancet 355:1645-1646, 2000.
PubMed
9) Kario K, et al : Silent and clinically overt stroke in older Japanese subjects with white-coat and sustained hypertension. J Am Coll Cardiol 38(1):238-245, 2001.
PubMed
10) Eguchi K, et al : Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts. Stroke 34(10):2471-2474, 2003.
PubMed
11) Kario K et al : Nocturnal fall of blood pressure and silent cerebrovascular damage in elderly hypertensive patients, Advanced silent cerebrovascular damage in extreme dippers. Hypertension 27:130-135, 1996.
PubMed
12) Kario K, et al : Hyperinsulinemia and hemostatic abnormalities are associated with silent lacunar cerebral infarcts in elderly hypertensive subjects. J Am Coll Cardiol 37(3):871-877, 2001.
PubMed
13) Kario K, et al : Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. Eur Heart J 32(5):574-580, 2011.
PubMed
14) 日本高血圧学会 (編) : 高血圧治療ガイドライン 2014, 2014.
 
15) Kario K et al : Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertension. A prospective study. Circulation 107:1401-1406, 2003.
PubMed
16) Kario K, et al : Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension 38:852-857, 2001.
PubMed
17) Kario K : Morning surge in blood pressure in hypertension : clinical relevance, prognostic significance and therapeutic approach. In : Special Issues in Hypertension (ed by Berbari AE, Mancia G), p71-89, Springer Inc, 2012.
 
18) Kario K : Orthostatic hypertension-a new haemodynamic cardiovascular risk factor. Nat Rev Nephrol 9:726-738, 2013.
PubMed
19) Mancia G, et al ; Task Force Members : 2013 ESH/ESC Guidelines for the management of arterial hypertension : the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 31(7):1281-1357, 2013.
 
20) James PA, et al : 2014 evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:507-520, 2014.
 
21) Weber MA, et al : Clinical practice guidelines for the management of hypertension in the community : a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 16(1):14-26, 2014.
PubMed
22) ACCORD Study Group ; ACCORD Eye Study Group : Chew EY, et al : Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233-244, 2010.
 
P.186 掲載の参考文献
1) Nguyen G, et al : Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109(11):1417-1427, 2002.
PubMed
2) Ichihara A, et al : Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 17(9):2495-2503, 2006.
PubMed
3) Ichihara A, et al : Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 47(5):894-900, 2006.
PubMed
4) Ichihara A, et al : Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice. J Am Soc Hypertens 2(5): 332-340, 2008.
PubMed
5) Kaneshiro Y, et al : Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro) renin receptor-transgenic rats. J Am Soc Nephrol 18(6):1789-1795, 2007.
PubMed
6) Cousin C, et al : Soluble form of the (pro) renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 53(6):1077-1082, 2009.
PubMed
7) Ludwig J, et al : Identification and characterization of a novel 92-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem 273(18):10939-10947, 1998.
PubMed
8) Kinouchi K, et al : The (pro) renin receptor/ATP6AP2 is essential for vacuolar H+ -ATPase assembly in murine cardiomyocytes. Circ Res 107(1):30-34, 2010.
PubMed
9) Gonzalez AA, et al : Soluble form of the (pro) renin receptor is augmented in the collecting duct and urine of chronic angiotensin II-dependent hypertensive rats. Hypertension 57(4): 859-864, 2011.
PubMed
10) Maruyama N, et al : Novel sandwich ELISA for detecting the human soluble (pro) renin receptor. Front Biosci 5:583-590, 2013.
PubMed
11) Cruciat CM, et al : Requirement of prorenin receptor and vacuolar H+- ATPase-mediated acidification for Wnt signaling. Science 327(5964):459-463, 2010.
PubMed
12) Watanabe N, et al : Soluble (pro) renin receptor and blood pressure during pregnancy : a prospective cohort study. Hypertension 60(5):1250-1256, 2012.
PubMed
13) Watanabe N, et al : Prediction of gestational diabetes mellitus by soluble (pro) renin receptor during the first trimester. J Clin Endocrinol Metab 98(6):2528-2535, 2013.
PubMed
14) Morimoto S, et al : Serum soluble (pro) renin receptor levels in patients with essential hypertension. Hypertens Res, 2014. [Epub ahead of print]
 
15) Hamada K, et al : Serum level of soluble (pro) renin receptor is modulated in chronic kidney disease.
PubMed
P.192 掲載の参考文献
1) ACTIVE I Investigators : Yusuf S, et al : Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928-938, 2011.
PubMed
2) Vacher E, et al : Effects of losartan on cerebral arteries in stroke-prone spontaneously hypertensive rats. J Hypertens 14:1341-1348, 1996.
PubMed
3) Gelosa P, et al : Stimulation of AT2 receptor exerts beneficial effects in stroke下rone rats : focus on renal damage. J Hypertens 27:2444-2451, 2009.
 
4) Sumners, et al : Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol 40:580-588, 2013.
PubMed
5) Ohshima K, et al : Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin- (1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension 63:e53-59, 2014.
PubMed
6) Mecca AP, et al : Cerebroprotection by angiotensin- (1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol 96:1084-1096, 2011.
PubMed
7) Regenhardt RW, et al : Centrally administered angiotensin- (1-7) increases the survival of stroke prone spontaneously hypertensive rats. Exp Physiol 99:442-453, 2014.
PubMed
8) Lew RA, et al : Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 86:344-350, 2003.
PubMed
9) Pham V, et al : Insulin-regulated aminopeptidase deficiency provides protection against ischemic stroke in mice. J Neurotrauma 29:1243-1248, 2012.
PubMed
10) Dahlof B, et al : Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE) : a randomised trial against atenolol. Lancet 359:995-1003, 2002.
PubMed
11) Lithell H, et al ; SCOPE Study Group : The Study on Cognition and Prognosis in the Elderly (SCOPE) : principal results of a randomized double-blind intervention trial. J Hypertens 21:875-886, 2003.
 
12) Julius S, et al : Feasibility of treating prehypertension With an angiotensin-receptor blocker. N Engl J Med 354:1685-1697, 2006.
PubMed
13) ONTARGET Investigators ; Yusuf S, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.
 
14) Yusuf S, et al : Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : A randomised controlled trial. Lancet 372:1174-1183, 2008.
PubMed
15) Yusuf S, et al : Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225-1237, 2008.
PubMed
16) Hosomi N, et al : Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134:225-231, 2005.
PubMed
17) Lu J, et al : The expression of angiotensin-converting enzyme 2-angiotensin- (1-7) -mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides 47:289-295, 2013.
PubMed
18) Mogi M, et al : Serum levels of renin-angiotensin system components in acute stroke patients. Geriatr Gerontol Int, 2013. [Epub ahead of print]
 
19) Fuentes B, et al : Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens 28:575-581, 2010.
PubMed
20) Kuwashiro T, et al : The factors associated with a functional outcome after ischemic stroke in diabetic patients : the Fukuoka Stroke Registry. J Neurol Sci 313:110-114, 2012.
 
21) Sandset EC, et al : The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST) : a randomised, placebo-controlled, double-blind trial. Lancet 377:741-750, 2011.
PubMed
22) He J, et al : Blood pressure reduction among acute ischemic stroke patients (CATIS) : A randomized controlled clinical trial. AHA Scientific Session 2013, Dallas, 2013.
 
P.197 掲載の参考文献
1) Dinh QN, et al : Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke. Exp Transl Stroke Med 4:21, 2012.
PubMed
2) Huang BS, et al : Mineralocorticoid actions in the brain and hypertension. Curr Hypertens Rep 13:214-220, 2011.
PubMed
3) Milliez P, et al : Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45:1243-1248, 2005.
PubMed
4) Kisaka T, et al : Association of elevated plasma aldosterone-to-renin ratio with fUture cardiovascular events in patients with essential hypertension. J Hypertens 30:2322-2330, 2012.
PubMed
5) Lacolley P, et al : Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats : effects of eplerenone. Circulation 106:2848-2853, 2002.
PubMed
6) Rizzoni D, et al : Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 91:2638-2642, 2006.
PubMed
7) Osmond JM, et al : Is the mineralocorticoid receptor a potential target for stroke prevention? Clin Sci (Lond) 114:37-47, 2008.
PubMed
8) Pimenta E, et al : Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 51:339-344, 2008.
PubMed
9) du Cailar G, et al : Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension 56:865-870, 2010.
PubMed
10) Funder JW : Mineralocorticoid receptor activation and oxidative stress. Hypertension 50:840-841, 2007.
PubMed
11) Frieler RA, et al : Myeloid-specific deletion of the mineralocorticoid receptor reduces infarct volume and alters inflammation during cerebral ischemia. Stroke 42:179-185, 2011.
PubMed
12) Oyamada N, et al : The role of mineralocorticoid receptor expression in brain remodeling after cerebral ischemia. Endocrinology 149:3764-3777, 2008.
PubMed
13) Catena C, et al : Aldosterone, organ damage and dietary salt. Clin Exp Pharmacol Physiol 40:922-928, 2013.
PubMed
14) Smeda J, et al : Effect of poststroke captopril treatment on mortality associated with hemorrhagic stroke in stroke-prone rats. J Pharmacol Exp Ther 291:569-575, 1999.
PubMed
15) Sato A, et al : Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64-68, 2003.
PubMed
P.201 掲載の参考文献
1) Feletou M, Vanhoutte PM : EDHF : an update. Clin Sci 117:139-155, 2009.
PubMed
2) Shimokawa H, et al : The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol 28:703-711, 1996.
PubMed
3) Vanhoutte PM, et al : Endothelial dysfunction and vascular disease. Acta Physiol 196:193-222, 2009.
PubMed
4) Ohashi J, et al : Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. Circ J 76:1768-1779, 2012.
PubMed
5) Shimokawa H : Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch Eur J Physiol 459:915-922, 2010.
 
6) Matoba T, et al : Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 106:1521-1530, 2000.
PubMed
7) Matoba T, et al : Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. Biochem Biophys Res Commun 290:909-913, 2002.
PubMed
8) Takaki A, et al : Crucial role of endothelial nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med 205:2053-2063, 2008.
PubMed
9) Nakata S, et al : Spontaneous myocardial infarction in mice lacking all nitric oxide synthase isoforms. Circulation 117:2211-2223, 2008.
PubMed
10) Prysyazhna O, et al : Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med 18:286-290, 2012.
PubMed
11) Yada T, et al : Important role of endogeneous hydrogen peroxide in pacing-induced metabolic coronary vasodilation in dogs in vivo. J Am Coll Cardilol 50:1272-1278, 2007.
PubMed
12) Nakajima S, et al : Essential role of bone marrow for microvascular endothelial and metabolic functions in mice. Circ Res 111:87-96, 2012.
PubMed
13) Shimokawa H : Primary endothelial dysfunction : Atherosclerosis. J Mol Cell Cardiol 31:23-37, 1999.
PubMed
14) Hosoya M, et al : Combination therapy with olmesartan and azelnidipine improves EDHF-mediated responses in diabetic apolipoprotein E-deficient mice. Circ J 74:798 -806, 2010.
 
15) Matsuzawa Y, et al : Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol 55:1688-1696, 2010.
PubMed
P.207 掲載の参考文献
1) Yanagisawa M, et al : A novel potent vasconstrictor peptide produced by vascular endothelial cells. Nature 332:411-415, 1998.
 
2) Inoue A, et al : The human endothelin family : three structurally and pharmacologically distinct isopeptides by three separate genes. Proc Natl Acad Sci USA 86:2863-2867, 1989.
PubMed
3) Emori T, et al : Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 133:2474-2480, 1993.
PubMed
4) Dhaun N, et al : Role of endothelin-1 in clinical hypertension : 20 years on. Hypertension 52:452-459, 2008.
PubMed
5) Abe Y, et al : Subtype-specific trafficking of endothelin receptors. J Biol Chem 275:8664-8671, 2000.
PubMed
6) Arai H, et al : Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730-732, 1990.
PubMed
7) Sakurai T, et al : Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348:732-735, 1990.
PubMed
8) Kasuya Y, et al : Endothelin-1 activates mitogen-activated protein kinases through two independent signalling pathways in rat astrocytes. Biochem Biophys Res Commun 204:1325-1333, 1994.
PubMed
9) Browatzki M, et al : Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 95:98-105, 2000.
PubMed
10) Pernow J, et al : New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sci 91:507-516, 2012.
PubMed
11) Zhang RL, et al : Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke. Stroke 39:2830-2836, 2008.
PubMed
12) Kelly-Cobbs AI, et al : Endothelial endothelin B receptor-mediated prevention of cerebro-vascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther 337:9-15, 2011.
 
13) Aaslid R : Hemodynamics of cerebrovascular spasm. Acta Neurochir Suppl 72:47-57, 1999.
PubMed
14) Seifert V, et al : Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg 82:55-62, 1995.
PubMed
15) Macdonald RL, et al : Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping : a randomised, double-blind, placebocontrolled phase 3 trial (CONSCIOUS-2). Lancet Neurol 10:618-625, 2011.
PubMed
P.212 掲載の参考文献
1) Goldstein DS, Eisenhofer G : Catecholamine synthesis, release, reuptake, and metabohsm. In : Hypertension Primer 4th ed (ed by Izzo JL Jr, et al), p37-39, Lippincott Williams & Wilkins, Philadelphia, 2008.
 
2) Berecek KH, Carey RM : Adrenergic and dopaminergic receptors and actions. In : Hypertension Primer 4th ed (ed by Izzo JL Jr, et al), p39-43, Lippincott Williams & Wilkins, Philadelphia, 2008.
 
3) Goldstein DS : Plasma catecholamines and essential hypertension. An analytical review. Hypertension 5:86-99, 1983.
PubMed
4) Davis JT, et al : Autonomic and hemodynamic origins of pre-hypertension. J Am Coll Cardiol 59:2206-2216, 2012.
PubMed
5) Sanada H, et al : Dopamine-1 receptor coupling defect in renal proximal tubule cells in hypertension. Hypertension 33:1036-1042, 1999.
PubMed
6) Meyer JS, et al : Catecholamine concentrations in CSF and plasma of patients with cerebral infarction and haemorrhage. Brain 96:277-288, 1973.
PubMed
7) Moussouttas M, et al : Cerebrospinal fluid catecholamine levels as predictors of outcome in subarachnoid hemorrhage. Cerebrovasc Dis 33:173-181, 2012.
PubMed
8) Yano Y, et al : Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis 219:273-279, 2011.
PubMed
P.217 掲載の参考文献
1) Kitamura K et al : Adrenomedullin : a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biopys Res Commun 192:553-560, 1993.
 
2) Eto T, et al : Regulation of production and secretion of adrenomedullin in the cardiovascular system. Regul Pept 112:61-69, 2003.
PubMed
3) McLatchie LM, et al : RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339, 1998.
PubMed
4) Nishikimi T, et al : Adrenomedullin in cardiovascular disease : a useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci 14:256-267, 2013.
PubMed
5) Kato J, et al : Plasma adrenomedullin level and development of hypertension. J Hum Hypertens 20:566-570, 2006.
PubMed
6) Miyao Y, et al : Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 79:39-44, 1998.
 
7) Kahn SQ, et al : Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction : the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49:1525-1532, 2007.
 
8) Kataoka Y, et al : The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J Cardiovasc Pharmacol 56:413-419, 2010.
PubMed
9) Nishikimi T, et al : Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26:1424-1431, 1995.
PubMed
10) Gegenhuber A, et al : Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13:42-49, 2007.
 
11) Nishikimi T, et al : Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure : a pilot study. Circ J 73:892-898, 2009.
PubMed
12) Yoshibayashi M, et al : Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients<20 years of age. Am J Cardiol 79:1556-1558, 1997.
PubMed
13) Nagaya N, et al : Efiiects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 109:351-356, 2004.
PubMed
14) Kronenberg F : Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 5:677-689, 2009.
PubMed
15) Nambu T, et al : Expression of the adrenomedullin gene in adipose tissue. Regul Pept 132:17-22, 2005.
PubMed
16) Nishio K et al : Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 25:953-957, 1997.
PubMed
17) Ashizuka S, et al : Adrenomedullin treatment reduces intestinal inflammation and maintains epithelial barrier function in mice administered dextran sulphate sodium. Microbiol Immunol 53:573-581, 2009.
PubMed
18) Miyashita K, et al : The neuroprotective and vasculo-neuro-regenerative roles of adrenomedullin in ischemic brain and its therapeutic potential. Endocrinology 147:1642-1653, 2006.
PubMed
19) Maki T, et al : Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 42:1122-1128, 2011.
PubMed
20) 北村和雄 : アドレノメデュリン. 日本臨牀 68(増刊号 7):630-632, 2010.
 
21) 荒井宏司ほか : アドレノメデュリン. 日本臨牀 69(増刊号 1):346-350, 2011.
 
P.225 掲載の参考文献
1) 糖尿病診断基準に関する調査検討委員会 : 糖尿病の分類と診断基準に関する委員会報告. 糖尿病 53:450-467, 2010.
 
2) 糖尿病診断基準検討委員会 : 糖尿病の分類と診断基準に関する委員会報告, 糖尿病 42:385-404, 1999.
 
3) HAPO Study Cooperative Research Group : Metzger BE, et al : Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991-2002, 2008.
 
4) IADPSG Consensus Panel ; Metzger BE, et al : International association of diabetes and pregnancy study groups recommendation on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676-682, 2010.
 
5) 日本糖尿病学会 (編) : 科学的根拠に基づく糖尿病診療ガイドライン 2013, p21-30, 南江堂, 2013.
 
6) 日本糖尿病学会 (編) : 糖尿病治療ガイド2012-2013 血糖コントロール目標改訂版, p24-26, 文光堂, 2013.
 
7) Ohkubo Y, et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995.
PubMed
8) The Diabetes Control and Complications Trial (DCCT) Research Group : The effect of intensive treatment of diabetes on the development and progression of long-team complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993.
 
9) United Kingdom Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352:837-853, 1998.
 
10) Sone H, et al ; Japan Diabetes Complications Study Group : Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes : subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96:3448-3456, 2011.
 
11) Yokoyama H, et al : Low incidence of cardiovascular events in Japanese patients with type 2 diabetes in primary care settings : a prospective cohort study (JDDM). Diabet Med 28:1221-1228, 2011.
PubMed
12) Nathan DM, et al ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group : Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005.
 
13) Holman RR, et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589, 2008.
PubMed
14) Gerstein HC, et al ; Action to Control Cardiovascular Risk in Diabetes Study Group : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559, 2008.
 
P.230 掲載の参考文献
1) Doi Y, et al : Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population : the Hisayama study. Stroke 41:203-209, 2010.
 
2) Cui R, et al : Diabetes mellitus and risk of stroke and its subtypes among Japanese : the Japan public health center study. Stroke 42:2611-2614, 2011.
PubMed
3) Facchini FS, et al : Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 86:3574-3578, 2001.
PubMed
4) Rundek T, et al : Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study. Arch Neurol 67:1195-1200, 2010.
PubMed
5) Ruige JB, et al : Insulin and risk of cardiovascular disease : a meta-analysis. Circulation 97:996-1001, 1998.
PubMed
6) Sarwar N, et al : Circulating concentrations of insulin markers and coronary heart disease : a quantitative review of 19 Western prospective studies. Eur Heart J 28:2491-2497, 2007.
 
7) Folsom AR, et al : Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 22:1077-1083, 1999.
 
8) Defronzo RA : Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl 7:11-15, 2006.
PubMed
9) Wang CC, et al : Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53:2735-2740, 2004.
PubMed
10) ORIGIN Trial Investigators ; Gerstein HC, et al : Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328, 2012.
PubMed
11) Sone H, et al ; Japan Diabetes Complications Study Group : Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes : a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia 53:419-428, 2010.
 
12) UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998.
PubMed
13) Dormandy JA, et al ; PROactive investigators : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366:1279-1289, 2005.
PubMed
14) Wilcox R, et al ; PROactive investigators : Eiifects of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007.
 
P.234 掲載の参考文献
1) Piotrowski K, et al : Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovasc Diabetol 12:117, 2013.
PubMed
2) Koska J, et al : Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 33:1028-1030, 2010.
PubMed
3) Hsieh J, et al : The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53:552-561, 2010.
PubMed
4) Briand E et al : Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice. Diabetes Obes Metab 14:662-665, 2012.
 
5) Yamamoto H, et al : Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110:43-52, 2002.
PubMed
6) Moreno C, et al : Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 434:163-167, 2002.
PubMed
7) Richter G, et al : GLP-1stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265:L374-381, 1993.
 
8) Nystrom T, et al : Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 287:E1209-1215, 2004.
PubMed
9) Arakawa M, et al : Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59:1030-1037, 2010.
PubMed
10) Panjwani N, et al : GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male apoE-/-mice. Endocrinology 154:127-139, 2013.
 
11) Goto H, et al : Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 405:79-84, 2011.
PubMed
12) Li Y, et al : GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106:1285-1290, 2009.
PubMed
13) Darsalia V, et al : Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 122:473-483, 2012.
PubMed
14) Teramoto S, et al : Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31:1696-1705, 2011.
PubMed
P.239 掲載の参考文献
1) Zhang Y, et al : Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994.
PubMed
2) Dalamaga M, et al : Leptin at the intersection of neuroendocrinology and metabolism : current evidence and therapeutic perspectives. Cell Metab 18:29-42, 2013.
PubMed
3) Komori T, et al : Induction of brain-derived neurotrophic factor by leptin in the ventromedial hypothalamus. Neuroscience 139:1107-1115, 2006.
PubMed
4) Lopez M, et al : Leptin regulation of prepro-orexin and orexin receptor mRNA levels in the hypothalamus. Biochem Biophys Res Commun 269:41-45, 2000.
PubMed
5) Marino JS, et al : Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol Metab 22:275-285, 2011.
PubMed
6) Myers MG Jr, et al : Obesity and leptin resistance : distinguishing cause from effect. Trends Endocrinol Metab 21:643-651, 2010.
PubMed
7) Konner AC, Bruning JC : Selective insulin and leptin resistance in metabolic disorders. Cell Metab 16:144-152, 2012.
PubMed
P.244 掲載の参考文献
1) Watters O, O'Connor J : A role for tumor necrosis factor-α in ischemia and ischemic preconditioning. J Neuroinflammation 8:87, 2011.
 
2) Hotamisligil GS, et al : Adipose expression of tumor necrosis factor-alpha : direct role in obesitylinked insulin resistance. Science 259:87-91, 1993.
PubMed
3) Hotamisligil GS : Inflammation and metabolic disorders. Nature 444:860-867, 2006.
PubMed
4) 水上浩哉, 八木橋操六 : 病態生理・機能異常サイトカイン. 日本臨牀 68(増刊号 9):563-567, 2010.
 
5) Pan W, et al : Stroke upregulates TNF-α transport across the blood-brain barrier. Exp Neurol 198:222-233, 2006.
 
6) Ohtaki H, et al : Expression of tumor necrosis factorα in nerve fibers and oligodendrocytes after transient focal ischemia in mice. Neurosci Lett 368:162-166, 2004.
 
7) Yin L, et al : Delayed expressed TNFR1 co-localize with ICAM-1 in astrocyte in mice brain after transient focal ischemia. Neurosci Lett 370:30-35, 2004.
PubMed
8) Shohami E, et al : Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 10:119-130, 1999.
PubMed
9) Bruce AJ, et al : Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 2:788-794, 1996.
PubMed
10) Kim GM, et al : Tumor necrosis factor receptor deletion reduces nuclear factor-kappaB activation, cellular inhibitor of apoptosis protein 2 expression, and functional recovery after traumatic spinal cord injury. J Neurosci 21:6617-6625, 2001.
PubMed
11) Ohtaki H, et al : Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA 105:14638-14643, 2008.
PubMed
12) Lee RH, et al : Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54-63, 2009.
PubMed
13) Danchuk S, et al : Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6. Stem Cell Res Ther 2:27, 2011.
 
14) Choi H, et al : Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosaninduced mouse peritonitis by decreasing TLR2/NF-κB signaling in resident macrophages. Blood 118:330-338, 2011.
 
15) Watanabe J, et al : Administration of TSG-6 improves memory after traumatic brain injury in mice. Neurobiol Dis 59:86-99, 2013.
PubMed
P.249 掲載の参考文献
1) Steppan CM, et al : The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001.
PubMed
2) Patel L, et al : Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300:472-476, 2003.
PubMed
3) Steppan C, Lazar M : The current biology of resistin. J Intern Med 255:439-447, 2004.
PubMed
4) Benomar Y, et al : Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 62:102-114, 2013.
PubMed
5) Osawa H, et al : Plasma resistin, associated with single nucleotide polymorphism-420, is correlated with insulin resistance, lower HDL, and high sensitivity CRP in the Japanese general population. Diabetes Care 30:1501-1506, 2007.
PubMed
6) Chen BH, et al : Circulating levels of resistin and risk of type 2 diabetes in men and women : results from two prospective cohorts. Diabetes Care 32:329-334, 2009.
PubMed
7) Nagaev I, et al : Human resistin is a systemic immune-derived proinnammatory cytokine targeting both leukocytes and adipocytes. PLoS One 1 : e31, 2006.
PubMed
8) Lehrke M, et al : An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1:e45, 2004.
PubMed
9) Qatanani M, et al : Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 119:531-539, 2009.
PubMed
10) Osawa H, et al : Serum resistin is positively correlated with the accumulation of metabolic syndrome factors in type 2 diabetes. Clin Endocrinol (Oxf) 69:74-80, 2008.
PubMed
11) Osawa H, et al : Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population : the Hisayama Study. Cardiovasc Diabetol 8:60, 2009.
 
12) Weikert C, et al : Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 93:2647-2653, 2008.
PubMed
13) Jamaluddin MS, et al : Resistin : functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 165:622-632, 2011.
 
14) Shyu KG, et al : Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin Sci (Lond) 120:121-129, 2011.
PubMed
15) Osawa H, et al : The G/G genotype of a resistin single-nucleotide polymorphism at-420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75:678-686, 2004.
 
16) Osawa H, et al : Is rs348611920r rs1862513a more promising variant for determining plasma resistin in an aged Japanese population? Diabetologia 53:795-797, 2010.
 
17) Onuma H, et al : A at single nucleotide polymorphism-358 is required for G at-420 to confer the highest plasma resistin in the general Japanese population. PLoS One 5:e9718, 2010.
 
18) Onuma H, et al : Plasma resistin is associated with single nucleotide polymorphisms of a possible resistin receptor, the decorin gene, in the general Japanese population. Diabetes 62:649-652, 2013.
PubMed
19) Hivert MF, et al : Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes 58:750-756, 2009.
PubMed
P.252 掲載の参考文献
1) Maeda K, et al : cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996.
PubMed
2) Arita Y, et al : Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999.
PubMed
3) Yamauchi T, Kadowaki T : Adiponectin receptor as a key player in healthy longevity and obesityrelated diseases. Cell Metab 17:185-196, 2013.
PubMed
4) Weyer C, et al : Hypoadiponectinemia in obesity and type 2 diabetes : close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001.
PubMed
5) Iwashima Y, et al : Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43:1318-1323, 2004.
PubMed
6) Kumada M, et al : Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89, 2003.
PubMed
7) Efstathiou SP, et al : Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36:1915-1919, 2005.
PubMed
8) Chen MP, et al : Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 25:821-826, 2005.
PubMed
9) 永沢光ほか : 血清アディポネクチン濃度の脳卒中病型による差異. 脳卒中 30:33-37, 2008.
 
10) Nishimura M, et al : Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 117:216-223, 2007.
PubMed
11) Chen B, et al : Adiponectin protects against cerebral ischemia-reperfusion injury through antiinflammatory action. Brain Res 1273:129-137, 2009.
PubMed
12) Maeda N, et al : PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001.
PubMed
13) Sugiyama S, et al : Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 194:e43-e51, 2006.
PubMed
14) Wilcox R, et al : Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke : results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873, 2007.
 
15) Okada-Iwabu M, et al : A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493-499, 2013.
PubMed
P.257 掲載の参考文献
1) Kubo M, et al : Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community : the Hisayama study. Stroke 34: 2349-2354, 2003.
 
2) 山口武典 : わが国の脳卒中診療の現状と21世紀の展望. 脳卒中 23:261-268, 2001.
Medical*Online
3) 永金義成ほか : 病型別にみた脳梗塞危険因子. 脳卒中データバンク 2009 (小林祥泰編), p60-61, 中山書店, 2009.
 
4) 日地正典ほか : 糖尿病患者における脳梗塞に対する診療の実際. Mebio 22:41-48, 2005.
Medical*Online
5) Johnston SC, et al : Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369:283-292, 2007.
PubMed
6) Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 352:1801-1807, 1998.
 
7) Nakaya N, et al : Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia : sub-analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 69:1016-1021, 2005.
 
8) Baigent C, et al : Efiicacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376:1670-1681, 2010.
 
9) Feigin V, et al : Smoking and elevated blood pressure are the most important risk factors for subarachnoid hemorrhage in the Asia-Pacific region : an overview of 26 cohorts involving 306,620 participants. Stroke 36:1360-1365, 2005.
 
P.264 掲載の参考文献
1) 厚生省特定疾患 : 原発性高脂血症調査研究班. 昭和60年度研究報告書 (班長. 垂井清一郎), 1986.
 
2) Prospective Studies Collaboration ; Lewington S, et al : Blood cholesterol and vascular mortality by age, sex, and blood pressure : a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829-1839, 2007.
PubMed
3) Iso H, et al : Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904-910, 1989.
 
4) Nakaya N, et al : Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia : sub-analysis of the Japan. Circ J 69:1016-1021, 2005.
PubMed
5) Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Lancet 352:1801-1807, 1998.
 
6) 馬渕宏 : 家族性高コレステロール血症, 南江堂, 1991.
 
7) Landau WM : Is cholesterol a risk factor for stroke? No. Arch Neurol 56:1521-1524, 1999.
PubMed
8) Okamura T, et al ; NIPPON DATA80 Research Group : The relationship between serum total cholesterol and all-cause or cause-specific mortality in a 17.3-year study of a Japanese cohort. Atherosclerosis 190:216-223, 2007.
 
9) Nakamura H, et al ; MEGA Study Group : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006.
 
10) Sasaki J, et al : Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men : the Kyushu Lipid Intervention Study. Circ J 67 : 473-478, 2003.
PubMed
11) Taylor FC, et al : Statin therapy for primary prevention of cardiovascular disease. JAMA 310:2451-2452, 2013.
PubMed
12) Amarenco P, et al ; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators : High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549-559, 2006.
PubMed
13) Mizuno K et al : Usefulness of pravastatin in primary prevention of cardiovascular events in women : analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Grculation 117:494-502, 2008.
PubMed
14) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防ガイドライン2012年版.
 
15) Stone NJ, et al : 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2013. [Epub ahead of print]
 
P.269 掲載の参考文献
1) Shinozaki S, et al : Diabetic lipemia with eruptive xanthomatosis in a lean young female with apolipoprotein E4/4. Diabetes Res Clin Pract 70:183-192, 2005.
 
2) Taniguchi A, et al : The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-dependent diabetic patients. Metabolism 49:1001-1005, 2000.
PubMed
3) Taniguchi A, et al : Remnant-like particle cholesterol triglycerides and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care 23:1766-1769, 2000.
PubMed
4) Asia Pacific Cohort Studies Collaboration : Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 110:2678-2686, 2004.
 
5) Labreuchea J, et al : Plasma triglyceride levels and risk of stroke and carotid atherosclerosis : a systematic review of the epidemiological studies. Atherosclerosis 203:331-345, 2009.
 
6) Varbo A, et al : Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population. Ann Neurol 69:628-634, 2011.
PubMed
7) Berger JS, et al : Lipid and lipoprotein biomarkers and the risk of ischemic stroke in postmenopausal women. Stroke 43:958-966, 2012.
PubMed
8) Nakaya N, et al : Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia. Sub-analysis of the Japan Lipid Intervention Trial (J-LIT). Circ J 69:1016-1021, 2005.
 
9) Niwa Y, et al : Association between stroke and metabolic syndrome in a Japanese population : Jichi Medical School (JMS) Cohort Study. J Epidemiol 20:62-69, 2010.
 
10) Sone H, et al : Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes ; subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 96:3448-3456, 2011.
PubMed
11) Rubins HB, et al : Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol : The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103:2828-2833, 2001.
 
12) The BIP Study Group : Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102:21-27, 2000.
 
13) The FIELD study investigators : Effects of long-term fenofibrate therapy on cardiovascular events in 9795people with type 2 diabetes mellitus (the FIELD study) : randomised controlled trial. Lancet 366:1849-1861, 2005.
 
14) The ACCORD Study Group : Effects of Combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563-1574, 2010.
 
15) Yatagai T, et al : Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274-1278, 2003.
PubMed
P.276 掲載の参考文献
1) 最上 (西巻) 知子 : 多価不飽和脂肪酸の化学と代謝. 治療学 43:815-818, 2009.
Medical*Online
2) Sydenham E, et al : Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev 6:CD005379, 2012.
PubMed
3) Rizos EC, et al : Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events : a systematic review and meta-analysis. JAMA 308:1024-1033, 2012.
PubMed
4) Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS) : a randomised open-label, blinded endpoint analysis. Lancet 369:1090-1098, 2007.
PubMed
5) Tanaka K et al : Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients : subanalysis of the JELIS trial. Stroke 39:2052-2058, 2008.
PubMed
6) 田中耕太郎, 折笠秀樹 : 高コレステロール血症患者の脳卒中発症に対するEPAの効果-JELISサブ解析. 脳卒中 29:762-766, 2007.
Medical*Online
7) Tanaka K, et al : Relationship of ischemic stroke with serum lipid levels, and influence of plasma eicosapentaenoic acid (EPA) concentration in patients with hypercholesterolemia. The 6th World Stroke Congress, Vienna, Austria, 2008.
 
8) Cawood AL, et al : Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212:252-259, 2010.
PubMed
9) Thies F, et al : Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques : a randomised controlled trial. Lancet 361:477-485, 2003.
 
10) 田口芳治ほか : Cerebral microbleedsと多価不飽和脂肪酸の関連についての検討. 第54回日本神経学会学術大会, 2013年5月31日, 東京.
 
11) Siriwardhana N, et al : Health benefits of n-3 polyunsaturated fatty acids : eicosapentaenoic acid and docosahexaenoic acid. Adv Food Nutr Res 65:211-222, 2012.
 
12) Marangoni F, Poli A : Clinical pharmacology of n-3 polyunsaturated fatty acids : non-lipidic metabolic and hemodynamic effects in human patients. Atheroscler Suppl 14:230-236, 2013.
 
13) Mita T, et al : Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. Atherosclerosis 191:162-167, 2007.
PubMed
P.281 掲載の参考文献
1) Kimura K, et al : Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study. Cerebrovasc Dis 18:47-56, 2004.
PubMed
2) Kimura K et al : Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 76:679-683, 2005.
PubMed
3) Ogawa S, et al : Antithrombotic therapy in atrial fibrillation : evaluation and positioning of new oral anticoagulant agents. Circ J 75:1539-1547, 2011.
PubMed
4) Heidbuchel H, et al : European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 15:625-651, 2013.
 
5) Camm AJ, et al : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-2747, 2012.
PubMed
6) 井上博ほか ; 日本循環器学会学術委員会合同研究班 (編) : 心房細動治療 (薬物) ガイドライン (2013年改訂版), 2013. (2014年5月1日, 日本循環器学会HP閲覧, 最新情報は [http://www.j-circ.or.jp/guideline/] をご確認下さい).
 
7) Healey JS, et al : Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : a meta-analysis. J Am Coll Cardiol 45:1832-1839, 2005.
PubMed
8) Fuster V, et al : ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48:854-906, 2006.
 
9) Oral H, et al : Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354:934-941, 2006.
PubMed
10) Damiano RJ, et al : The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg 126:2016-2021, 2003.
 
11) Hohnloser SH, et al : Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy : an ACTIVE W Substudy. J Am Coll Cardiol 50:2156-2161, 2007.
PubMed
12) Ruff CT, et al : Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet 383:955-962, 2014.
PubMed
13) 藤本一眞ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. Gastroenterol Endosc 54:2073-2102, 2012.
 
14) Yamashita T, et al : Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 108:2450-2452, 2003.
PubMed
15) Shibazaki K, et al : Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 331:90-93, 2013.
PubMed
P.286 掲載の参考文献
1) Tsutamoto T, et al : Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure : prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfUnction. Circulation 96:509-516, 1997.
PubMed
2) Makikallio AM, et al : Natriuretic peptides and mortality after stroke. Stroke 36:1016-1020, 2005.
PubMed
3) Shibazaki K, et al : Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med 48:259-264, 2009.
PubMed
4) Shibazaki K, et al : Heart failure may be associated with the onset of ischemic stroke with atrial fibrillation : a brain natriuretic peptide study. J Neurol Sci 281:55-57, 2009.
PubMed
5) Shibazaki K, et al : Plasma brain natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic stroke. Intern Med 48:1601-1606, 2009.
PubMed
6) Okada Y, et al : Brain natriuretic peptide as a predictor of delayed atrial fibrillation after ischaemic stroke and transient ischaemic attack. Eur J Neurol 17:326-331, 2010.
PubMed
7) Kimura K, et al : The combination of elevated BNP and AF as a predictor of no early recanalization after IV-t-PA in acute ischemic stroke. J Neurol Sci 290:37-40, 2010.
 
8) Shibazaki K, et al : Plasma brain natriuretic peptide predicts death during hospitalization in acute ischaemic stroke and transient ischaemic attack patients with atrial fibrillation. Eur J Neurol 18:165-169, 2011.
PubMed
9) Okada Y, et al : Brain natriuretic peptide is a marker associated with thrombus in stroke patients with atrial fibrillation, J Neurol Sci 301:86-89, 2011.
PubMed
10) Shibazaki K, et al : Differences in brain natriuretic peptide value between transient ischemic attack and stroke patients with atrial fibrillation. Eur Neurol 66:271-276, 2011.
PubMed
11) Shibazaki K, et al : Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol 109:1303-1307, 2012.
PubMed
12) Sakai K, et al : Brain natriuretic peptide as a predictor of cardioembolism in acute ischemic stroke patients : brain natriuretic peptide stroke prospective study. Eur Neurol 69:246-251, 2013.
PubMed
13) Fujii S, et al : A simple score for predicting Paroxysmal atrial fibrillation in acute ischemic stroke. J Neurol Sci 328:83-86, 2013.
PubMed
14) Shibazaki K et al : Brain natriuretic peptide on admission as a biological marker of long-term mortality in ischemic stroke survivors. Eur Neurol 70:218-224, 2013.
PubMed
15) 城本高志ほか : たこつぼ型心筋障害を合併した小脳出血の1例. 臨床神経学 52:778-781, 2012.
 
P.292 掲載の参考文献
1) 朝倉英策 : 止血の生理と血栓の病態. 臨床に直結する血栓止血学 (朝倉英策編), p2-11, 中外医学社, 2013.
 
2) 家子正裕 : 抗リン脂質抗体症候群 (APS). 臨床に直結する血栓止血学 (朝倉英策編), p275-281, 中外医学社, 2013.
 
3) Crowther MA, et al : A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349:1133-1138, 2003.
Medical*Online
4) Marchioli R et al : Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224-2232, 2005.
 
5) Chim CS, et al : Long-term outcome of 231 patients with essential thrombocythemia : prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165:2651-2658, 2005.
PubMed
6) Campbell PJ, et al : Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status : a prospective study. Lancet 366:1945-1953, 2005.
PubMed
7) Colaizzo D, et al : The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5:55-61, 2007.
PubMed
8) Kiladjian JJ, et al : The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis : a report on 241 cases. Blood 111:4922-4929, 2008.
PubMed
9) Sozer S, et al : The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 113:5246-5249, 2009.
PubMed
10) 朝倉英策 : トラネキサム酸 (トランサミン). 臨床に直結する血栓止血学 (朝倉英策編), p370-374, 中外医学社, 2013.
 
11) 朝倉英策 : 播種性血管内凝固症候群 (DIC). 臨床に直結する血栓止血学 (朝倉英策編). p168-178, 中外医学社, 2013.
 
P.297 掲載の参考文献
1) Shinton R, Beevers G : Meta-analysis of relation between cigarette smoking and stroke. BMJ 298:789-794, 1989.
PubMed
2) Schurks M, et al : Migraine and cardiovascular disease : systematic review and meta-analysis. BMJ 339:b3914, 2009.
PubMed
3) Ueshima H, et al : Cigarette smoking as a risk factor for stroke death in Japan : NIPPON DATA80. Stroke 35:1836-1841, 2004.
PubMed
4) Mannami T, et al : Cigarette smoking and risk of stroke and its subtypes among middle-aged Japanese men and women : the JPHC Study Cohort I. Stroke 35:1248-1253, 2004.
PubMed
5) Iso H, et al : Smoking cessation and mortality from cardiovascular disease among Japanese men and women : the JACC Study. Am J Epidemiol 161:170-179, 2005.
PubMed
6) Honjo K, et al : The effects of smoking and smoking cessation on mortality from cardiovascular disease among Japanese : pooled analysis of three large-scale cohort studies in Japan. Tob Control 19:50-57, 2010.
 
7) Bonita R, et al : Passive smoking as well as active smoking increases the risk of acute stroke. Tob Control 8:156-160, 1999.
PubMed
8) Oono IP, et al : Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf) 33:496-502, 2011.
PubMed
9) Tan CE, Glantz SA : Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases : a meta-analysis. Circulation l 26:2177-2183, 2012.
 
10) Wolf PA, et al : Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 259:1025-1029, 1988.
PubMed
11) Wannamethee SG, et al : Smoking cessation and the risk of stroke in middle-aged men. JAMA 274:155-160, 1995.
PubMed
12) Nakamura K et al : Influence of smoking combined with another risk factor on the risk of mortality from coronary heart disease and stroke : pooled analysis of 10 Japanese cohort studies. Cerebrovasc Dis 33:480-491, 2012.
PubMed
13) Spence JD : Secondary stroke prevention. Nat Rev Neurol 6:477-486, 2010.
PubMed
14) Aune E, et al : The "smoker's paradox" in patients with acute coronary syndrome : a systematic review. BMC Med 9:97, 2011.
 
15) Ali SF, et al : Paradoxical association of smoking with in-hospital mortality among patients admitted with acute ischemic stroke. J Am Heart Assoc 2 : e000171, 2013.
PubMed
16) 徳永誠ほか : 喫煙脳卒中患者と非喫煙脳卒中患者の回復期リハ病棟における調整FIM利得. 臨床リハ, 22:523-528, 2013.
 
17) Gall SL, et al : Smoking cessation at 5 years after stroke in the North East Melbourne stroke incidence study. Neuroepidemiology 32:196-200, 2009.
 
P.301 掲載の参考文献
1) Iso H, et al : Alcohol consumption and risk of stroke among middle-age men : the JPHC Study Cohort I. Stroke 35:1124-1129, 2004.
PubMed
2) Ikehara S, et al ; JPHC Study Group : Alcohol consumption, social support, and risk of stroke and coronary heart disease among Japanese men : the JPHC Study. Alcohol Clin Exp Res 33:1025-1032, 2009.
 
3) Ikehara S, et al ; JPHC Study Group : Alcohol consumption and risk of stroke and coronary heart disease among Japanese women : the Japan Public Health Center-Based Prospective Study. Prev Med 57:505-510, 2013.
 
4) Ikehara S, et al ; Japan Collaborative Cohort Study Group : Alcohol consumption and mortality from stroke and coronary heart disease among Japanese men and women : the Japan collaborative cohort study. Stroke 39:2936-2942, 2008.
 
5) Reynolds K, et al : Alcohol consumption and risk of stroke. A meta-analysis. JAMA 289:579-588, 2003.
PubMed
6) Brien SE, et al : Effect of alcohol consumption on biological markers associated with risk of coronary heart disease : systematic review and meta-analysis of interventional studies. BMJ 342:d636, 2011.
PubMed
7) Laug WE : Ethyl alcohol enhances plasminogen activator secretion by endothelial cells. JAMA 250:772-776, 1983.
PubMed
8) Rimm EB, et al : Moderate alcohol intake and lower risk of coronary heart disease : meta-analysis of effects on lipids and haemostatic factors. BMJ 319:1523-1528, 1999.
PubMed
P.305 掲載の参考文献
1) Yamada Y : Molecular genetics of stroke. In : Colloquium Series on Genomic and Molecular Medicine (ed by Kumar D), p1-69, Morgan & Claypool Life Sciences, San Rafael, California, 2012.
 
2) CARDIoGRAMplusC4D Consortium : Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45:25-33, 2013.
PubMed
3) Manolio TA, et al : Finding the missing heritability of complex diseases. Nature 461:747-753, 2009.
PubMed
4) Kubo M, et al : A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. Nat Genet 39:212-217, 2007.
PubMed
5) Hata J, et al : Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. Hum Mol Genet 16:630-639, 2007.
 
6) Ikram MA, et al : Genomewide association studies of stroke. N Engl J Med 360:1718-1728, 2009.
PubMed
7) Gretarsdottir S, et al : Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann Neurol 64:402-409, 2008.
PubMed
8) Gudblartsson DF et al : A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet 41:876-878, 2009.
 
9) Debette S, et al : Genome-wide association studies of MRI-defined brain infarcts : meta-analysis from the CHARGE Consortium. Stroke 41:210-217, 2010.
PubMed
10) International Stroke Genetics Consortium (ISGC) ; Wellcome Trust Case Control Consortium 2 (WTCCC2) : Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 44:328-333, 2012.
 
11) Holliday EG, et al : Common variants at 6p21. 1are associated with large artery atherosclerotic stroke. Nat Genet 44:1147-1151, 2012.
 
12) Bilguvar K, et al : Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet 40:1472-1477, 2008.
PubMed
13) Yasuno K et al : Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet 42:420-425, 2010.
PubMed
14) Low SK et al : Genome-wide association study for intracranial aneurysm in Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDNRA. Hum Mol Genet 21:2102-2110, 2012.
 
15) Yamada Y, et al : Identification of CELSR1 as a susceptibility gene for ischemic stroke in Japanese individuals by a genome-wide association study. Atherosclerosis 207:144-149, 2009.
PubMed
P.313 掲載の参考文献
1) World Health Organization : Definition, diagnosis and classhication of diabetes mellitUs and its complications : report of a WHO Consultation. Part 1 : diagnosis and classification of diabetes mellitus. World Health Organization, Geneva, 1999. [http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf]
 
2) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001.
 
3) Alberti KG, et al : Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23:469-480, 2006.
PubMed
4) メタボリックシンドローム診断基準検討委員会 : メタボリックシンドロームの定義と診断基準. 日内会誌 94:188-203, 2004.
 
5) Alberti KG, et al ; International Diabetes Federation Task Force on Epidemiology and Prevention ; National Heart, Lung, and Blood Institute ; American Heart Association ; World Heart Federation : International Atherosclerosis Society ; International Association for the Study of Obesity : Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention ; National Heart, Lung, and Blood Institute ; American Heart Association ; World Heart Federation ; International Atherosclerosis Society ; and International Association for the Study of Obesity. Circulation 120:1640-1645, 2009.
 
6) Iso H, et al : Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 38:1744-1751, 2007.
PubMed
7) Ninomiya T, et al : Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population : the Hisayama study. Stroke 38:2063-2069, 2007.
 
8) Kokubo Y, et al : Impact of Metabolic Syndrome Components on Incidence of Cardiovascular Disease in a General Urban Japanese Population : the Suita Study. Hypertens Res 31:2027-2035, 2008.
 
9) Irie F, et al : Associations between metabolic syndrome and mortality from cardiovascular disease in Japanese general population, findings on overweight and non-overweight individuals : Ibaraki Prefectural Health Study. Circ J 73:1635 -1642, 2009.
 
10) Noda H, et al : The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke : the Japan public health center-based study. Hypertens Res 32:289-298, 2009.
PubMed
11) Okamura T, et al : A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese : the Suita study. Atherosclerosis 217:201-206, 2011.
 
12) Kokubo Y, et al : Impact of high-normal blood pressure on the risk of cardiovascular disease in a Japanese urban cohort : the Suita study. Hypertension 52:652-659, 2008.
 
13) Kokubo Y, et al : The combined impact of blood pressure category and glucose abnormality on the incidence of cardiovascular diseases in a Japanese urban cohort : the Suita Study. Hypertens Res 33:1238-1243, 2010.
 
14) Okamura T, et al : Triglycerides and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort : the Suita study. Atherosclerosis 209:290-294, 2010.
 
15) Okamura T, et al : Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and the incidence of cardiovascular disease in an urban Japanese cohort study : The Suita study. Atherosclerosis 203:587-592, 2009.
 
16) Furukawa Y, et al : The relationship between waist circumference and the risk of stroke and myocardial infarction in a Japanese urban cohort : the Suita study. Stroke 41:550-553, 2010.
 
17) Higashiyama A, et al : Risk of smoking and metabolic syndrome for incidence of cardiovascular disease-comparison of relative contribution in urban Japanese population : the Suita study. Circ J 73:2258-2263, 2009.
PubMed
18) 奈倉淳子ほか : 吹田市基本健診での生活習慣とメタボリックシンドロームに関する研究. 厚生の指標 54:1-6, 2007.
 
P.321 掲載の参考文献
1) Guilleminault C, et al : The sleep apnea syndromes. Ann Rev Med 27:465-487, 1976.
PubMed
2) Ybung T, et al : The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230-1235, 1993.
 
3) Koskenvuo M, et al : Snoring as a risk factor for ischemic heart disease and stroke in men. Br Med J (Clin Res Ed) 294:16-19, 1987.
PubMed
4) Hu FB, et al : Snoring and risk of cardiovascular disease in women. J Am Coll Cardiol 35:308-313, 2000.
PubMed
5) Arzt M, et al : Association of sleep-disordered breathing and occurrence of stroke. Am J Respir Crit Care Med 172:1447-1451, 2005.
PubMed
6) Yaggi HK, et al : Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353:2034-2041, 2005.
PubMed
7) Munoz R, et al : Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke 37:2317-2321, 2006.
PubMed
8) Redline S, et al : Obstructive sleep apnea-hypopnea and incident stroke : the sleep heart health study. Am J Respir Crit Care Med 182:269-277, 2010.
PubMed
9) Dyken ME, et al : Investigating the relationship between stroke and obstructive sleep apnea. Stroke 27:401-407, 1996.
PubMed
10) Sullivan CE, et al : Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1:862-865, 1981.
PubMed
11) Martinez-Garcia MA, et al : Continuous positive airway pressure treatment in sleep apnea prevents new vascular events after ischemic stroke. Chest 128:2123-2129, 2005.
PubMed
12) Lianne M, et al : Continuous positive airway pressure for treatment of obstructive sleep apnea in stroke survivors. What do we really know? Stroke 43:3118-3123, 2012.
 
13) Marin JM, et al : Long-term cardiovascular outcomes in men with obstuctive sleep apnoea-hypopnoea with and without treatment with continuous positive airway pressure : an observation study. Lancet 365 (9464):1046-1053, 2005.
 
P.326 掲載の参考文献
1) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン2013, 東京医学社, 2013.
 
2) Lee M, et al : Low glomerular filtration rate and risk of stroke : Meta-analysis. BMJ 341: c4249, 2010.
PubMed
3) Seliger SL, et al : Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64:603-609, 2003.
PubMed
4) Ninomiya T, et al : Chronic kidney disease and cardiovascular disease in a general Japanese population : The Hisayama study. Kidney Int 68:228-236, 2005.
 
5) Irie F, et al : The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 69:1264-1271, 2006.
PubMed
6) Ninomiya T, et al : Impact of kidney disease and blood pressure on the development of cardiovascular disease : an overview from the Japan Arteriosclerosis Longitudinal Study. Circulation 118:2694-2701, 2008.
PubMed
7) Yahalom G, et al : Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke 40:1296-1303, 2009.
PubMed
8) Kendrick J, Chonchol MB : Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 4:672-681, 2008.
PubMed
9) Kimura G, et al : Salt sensitivity and circadian rhythm of blood pressure : The keys to connect ckd with cardiovascular events. Hypertens Res 33:515-520, 2010.
PubMed
10) Konishi Y, et al : Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension 38:81-85, 2001.
PubMed
11) Imanishi M, et al : Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients. Diabetes Care 24:111-116, 2001.
PubMed
12) Konishi Y, et al : Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with iga nephropathy. Hypertension 58:205-211, 2011.
PubMed
13) Shibata S, et al : Racl GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 121:3233-3243, 2011.
 
14) Palmer SC, et al : Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2 : CD008834, 2013.
 
15) Nakagawa K, et al : Chronic kidney disease and chads (2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol 107:912-916, 2011.
PubMed
16) Limdi NA, et al : Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20:912-921, 2009.
PubMed
P.333 掲載の参考文献
1) Jauch EC, et al ; American Heart Association Stroke Council ; Council on Cardiovascular Nursing ; Council on Peripheral Vascular Disease : Council on Clinical Cardiology : Guidelines for the early management of patients with acute ischemic stroke : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870-947, 2013.
PubMed
2) 日本脳卒中学会脳卒中医療向上・社会保険委員会 ; rt-PA (アルテプラーゼ) 静注療法指針改訂部会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針 第二版, 2012.
 
3) Hand PJ, et al : Distinguishing between stroke and mimic at the bedside : the brain attack study. Stroke 37:769-775, 2006.
PubMed
4) 棚橋紀夫 : 虚血性脳卒中症状を呈した大動脈解離症例の報告について. 脳卒中 30:450-451, 2008.
Medical*Online
5) Wardlaw JM, Mielke O : Early signs of brain infarction at CT : observer reliability and outcome after thrombolytic treatment-systematic review. Radiology 235:444-453, 2005.
PubMed
6) Dippel DW, et al : The validity and reliability of signs of early infarction on CT in acute ischaemic stroke. Neuroradiology 42:629-633, 2000.
 
P.337 掲載の参考文献
1) 奥寺敬ほか : 新しい意識障害評価法ECSの開発-日本神経救急学会ECS検討委員会報告2003-. 日神経救急学会誌 17:66-68, 2004.
 
2) 坂本哲也 : ECS. 救急医学 27:884-886, 2003.
 
3) Takahashi C, et al : The Emergency Coma Scale for patients in emergency department : concept, vaiidity and simplicity. Am J Emerg Med 27:240-243, 2009.
PubMed
4) 奥寺敬, 京島和彦 : 意識障害の鑑別と対策. 外科 56:174-177, 1994.
 
5) 奥寺敬 : 意識障害. 総合臨床 49:2039-2043, 2000.
Medical*Online
6) Ohta T, et al : New grading of disordered consciousness. No Shinkei Geka 2:623-627, 1974.
PubMed
7) Ohta T, et al : Nizofenone administration in the acute stage following subarachnoid hemorrhage. Results of a multi-center controlled double-blind clinical study. J Neurosurg 64:420-426, 1986.
PubMed
8) 後藤修ほか : Japan Coma Scaleによる急性期破裂脳動脈瘤の術前評価とその転帰. 脳神経 47:49-55, 1995.
 
9) 太田富雄 : International Coma Scale-JCSとGCSをひとつにする試み-その利点と問題点-. Neurosurg Emerg 5:1-12, 2000.
 
10) Jennet B, Teasdale G : Aspects of After Severe Head Injury. Lancet 23:878-881, 1977.
 
11) Teasdale G, Jenett B : Assessment of coma and impaired consciousness. A practical scale. Lancet 13:81-82, 1974.
 
12) Teasdale G, Jennet B : Assessment and Prognosis of Coma After Head Injury. Acta Neurochir (Wien) 34: 45-55, 1976.
 
13) Riechers RG 2nd, et al : Physician Knowledge of the Glasgow Coma Scale. J Neurotrauma 22:1327-1334, 2005.
PubMed
14) Teoh LS, et al : Glasgow Coma Scale : variation in mortality among permutations of specific total scores. Intensive Care Med 26:157-161, 2000.
PubMed
15) Wakasugi M, et al : Development of New Coma Scale : Emergency Coma Scale (ECS). In : Minimally Invasive Neurosurgery and Multidisciplinary Neurotraumatology, p400-403, Springer-Verlag, Tokyo, 2006.
 
P.344 掲載の参考文献
1) 寺山靖夫 : 脳血管障害治療の評価-stroke scale. Annual Review神経1995 (後藤文男ほか編), p124-133, 中外医学社, 1995.
 
2) Gotoh F, et al : Development of a Novel Weighted, Quantifiable Stroke Scale : Japan stroke scale. Stroke 32:1800-1807, 2001.
PubMed
3) Feinstein AR : Clinimetrics. Yale University Press, New Haven, Conn, 1987.
 
4) Vanclay F : Functional outcome measures in stroke rehabilitation. Stroke 22:105-108, 1991.
PubMed
5) Cote R et al : Stroke assessment scales : guidelines for development, validation, and reliability assessment. Can J Neurol Sci 15 : 261-265, 1988.
PubMed
6) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中重症度スケール (急性期) Japan Stroke Scale (JSS). 脳卒中 19:2-5, 1997.
 
7) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中運動機能障害重症度スケール Japan Stroke Scale (Motor Function) (JSS-M). 脳卒中 21:352-356, 1999.
 
8) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中高次脳機能 (知的機能) スケール Japan Stroke Scale (Higher Cortical Function) (JSS-H). 脳卒中 24:3, 2002.
 
9) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中感情障害 (うつ・情動障害) スケール Japan Stroke Scale (Emotional Disturbance Scale) (JSS-D・JSS-E). 脳卒中 25:206-214, 2003.
 
P.349 掲載の参考文献
1) Brott T, et al : Measurements of acute cerebral infarction : a clinical examination scale. Stroke 20:864-870, 1989.
PubMed
2) Lyden P, et al : NINDS TPA Stroke Study Group : Improved reliability of the NIH Stroke Scale using video training. Stroke 25:2220-2226, 1994.
 
3) Lyden PD, et al : NINDS rtPA Stroke Study Group : A modified National Institutes of Health Stroke Scale for use in stroke clinical trials : preliminary reliability and validity. Stroke 32:1310-1317, 2001.
 
4) Meyer BC, Lyden PD : The modified National Institutes of Health Stroke Scale : its time has come. Int J Stroke 4:267-273, 2009.
PubMed
5) Cote R et al : The Canadian Neurological Scale : a preliminary study in acute stroke. Stroke 17:731-737, 1986.
PubMed
6) Lyden PD, Lau GT : A clinical appraisal of stroke evaluation and rating scales. Stroke 22:1345-1352, 1991.
PubMed
7) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中重症度スケール (急性期). Japan Stroke Scale (JSS). 脳卒中 19:2-5, 1997.
 
8) 峰松一夫 : 様々な視点からみた脳卒中臨床評価システム-神経脱落機能の立場からの評価システム. Clinical Neuroscience 20:897-900, 2002.
 
9) 日本脳卒中学会Stroke Scale委員会 : 日本脳卒中学会・脳卒中運動機能障害重症度スケール. Japan Stroke Scale (Motor Function) (JSS-M). 脳卒中 21:353-356, 1999.
 
10) 後藤文男 : 現行の脳卒中評価システムの功罪-Japan Stroke Scale. Clinical Neuroscience 20:940-945, 2002.
 
P.358 掲載の参考文献
1) 脳卒中合同ガイドライン委員会 (編) : 脳卒中治療ガイドライン 2004, 協和企画, 2004.
 
2) 脳卒中合同ガイドライン委員会 (編) : 脳卒中治療ガイドライン 2009, 協和企画, 2009.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会 (編) : 高血圧治療ガイドライン 2009, 日本高血圧学会, 2009.
 
4) Dahlof B, et al : Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomised controlled trial. Lancet 366:895-906, 2005.
PubMed
5) Ogihara T, et al : Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks : candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51:393-398, 2008.
PubMed
6) Yusuf S, et al : Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547-1559, 2008.
 
7) Principal Results of the Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS). Hypertens Res 31:2115-2127, 2008,
PubMed
8) Collins R, et al : MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes : a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003.
PubMed
9) Colhoun HM, et al : Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS) : multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004.
PubMed
10) Kearney PM, et al ; Cholesterol Treatment Trialists' (CTT) Collaborators : Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins : a meta-analysis. Lancet 371:117-125, 2008.
PubMed
11) Dormandy JA, et al : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PRO spective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366:1279-1289, 2005.
 
12) 日本動脈硬化学会 (編) : 動脈硬化性疾患予防ガイドライン2007年版, 2007.
 
13) Go AS, et al : Anticoagulation therapy for stroke prevention in atrial fibrillation : how well do randomized trials translate into clinical practice? JAMA 290:2685-2692, 2003.
PubMed
14) Sato H, et al : Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation : Japan Atrial Fibrillation Stroke Trial. Stroke 37:447-451, 2006.
PubMed
15) Sacco RL, et al : Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack : a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke : co-sponsored by the Council on Cardiovascular Radiology and Intervention : the American Academy of Neurology affirms the value of this guideline. Stroke 37(2):577-617, 2006.
 
16) Anavekar NS, et al : Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285-1295, 2004.
PubMed
17) Nakayama M, et al : Kidney dysfUnction as a risk factor for first symptomatic stroke events in a general Japanese population-the Ohasama study. Nephrol Dial Transplant 22:1910-1915, 2007.
 
18) 日本腎臓学会 (編) : CKD診療ガイド, 東京医学社, 2007.
 
19) 日本脳卒中学会 医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針部会 (編) : rt-PA (アルテプラーゼ) 静注療法適正治療指針. 脳卒中 27:327-354, 2005.
 
20) Yamaguchi T, et al : Alteplase at O.6mg/kg for acute ischemic stroke within 3 hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810-1815, 2006
 
21) Vahedi K, et al : Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 38:2506-2517, 2007.
PubMed
22) Juttler E, et al : Decompressive Surgery for the Treatment of Malignant lnfarction of the Middle Cerebral Artery (DESTINY) : a randomized, controlled trial. Stroke 38:2518-2525, 2007.
 
23) Hofmeijer J, et al : Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET). Protocol for a randomised controlled trial of decompressive surgery in space-occupying hemispheric infarction. Trials 7:29, 2006.
PubMed
24) Antithrombotic Trialists' Collaboration : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002.
PubMed
25) Schrader J, et al ; MOSES Study Group : Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention : principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218-1226, 2005.
 
26) Yusuf S, et al : Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225-1237, 2008.
PubMed
27) Amarenco P, et al : Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack : the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38:3198-3204, 2007.
 
28) Tanaka K, et al : Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients : subanalysis of the JELIS trial. Stroke 39:2052 -2058, 2008.
 
29) CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339, 1996.
 
30) Diener HC, et al : Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH) : randomised, double-blind, placebo-controlled trial. Lancet 364:331-337, 2004.
PubMed
31) Bhatt DL, et al : Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717, 2006.
PubMed
32) 日本循環器学会ほか (編) : 循環器疾患における抗凝固・抗血小板療法に関するガイドライン. Circ J 68(Suppl IV):1195-1196, 2004.
 
33) 日本消化器内視鏡学会 (編) : 内視鏡治療時の抗凝固薬・抗血小板薬使用に関する指針. Gastroenterol Endosc 47:2691-2695, 2005.
 
34) Yadav JS, et al : Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351:1493-1501, 2004.
PubMed
35) JET Study Group : Japanese EC-IC Bypass Trial (JET Study) 中間解析結果 (第二報). 脳卒中の外科 30:434-437, 2002.
 
36) Mendelow AD, et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 365:387-397, 2005.
 
37) Hattori N, et al : Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage : a randomized study. J Neurosurg 101:417-420, 2004.
PubMed
38) Hart RG, et al : Aspirin for the primary prevention of stroke and other major vascular events : meta-analysis and hypotheses. Arch Neurol 57:326-332, 2000.
PubMed
P.363 掲載の参考文献
1) 脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン2009 (篠原幸人ほか編), 協和企画, 2009.
 
2) Ronning OM, Guldvog B : Should stroke victims routinely receive supplemental oxygen? A quasi-randomized controlled trial. Stroke 30:2033-2037, 1999.
PubMed
3) Schrader J, et al : The ACCESS Study : evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34:1699-1703, 2003,
PubMed
4) Sandset EC, et al : The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST) : a randomised, placebo-controlled, double-blind trial. Lancet 377:741-750, 2011.
PubMed
5) He J, et al : Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke : the CATIS randomized clinical trial. JAMA 311:479-489, 2014.
PubMed
6) Anderson CS, et al : Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368 :2355-2365, 2013.
 
7) Bonds DE, et al : The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes : retrospective epidemiological analysis of the ACCORD study. BMJ 340:b4909, 2010.
PubMed
8) Goto A, et al : Severe hypoglycaemia and cardiovascular disease : systematic review and meta-analysis with bias analysis. BMJ 347 : f4533, 2013.
PubMed
9) Hajat C, et al : Effects of poststroke pyrexia on stroke outcome : ameta-analysis of studies in patients. Stroke 31:410-414, 2000.
 
10) Davenport RJ, et al : Complications after acute stroke. Stroke 27:415-420, 1996.
PubMed
11) DePippo KL, et al : Validation of the 3-oz water swallow test for aspiration following stroke. Arch Neurol 490:1259-1261, 1992.
 
12) Davenport RJ, et al : Gastrointestinal hemorrhage after acute stroke. Stroke 27:421-424, 1996.
PubMed
13) Bladin CF, et al : Seizures after stroke : a prospective multicenter study. Arch Neurol 57:1617-1622, 2000.
PubMed
14) Berges S, et al : Seizures and epilepsy following strokes : recurrence factors. Eur Neurol 43:3-8, 2000.
PubMed
15) Ferro JM, et al : A multivariate study of headache associated with ischemic stroke. Headache 35:315-319, 1995.
PubMed
P.369 掲載の参考文献
1) 篠原幸人ほか (編) : 脳卒中治療ガイドライン 2009. 協和企画, 2009.
 
2) 篠原幸人ほか (編) : 脳卒中治療ガイドライン 2004. 協和企画, 2004.
 
3) 日本脳卒中学会 医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針部会 (編) : rt-PA (アルテプラーゼ) 静注療法適正治療指針. 脳卒中 27:327-354, 2005.
 
4) 日本脳卒中学会 脳卒中医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針改訂部会 (編) : rt-PA (アルテプラーゼ) 静注療法適正治療指針 第二版. 脳卒中 34:443-480, 2012.
 
P.374 掲載の参考文献
1) 篠原幸人ほか (編) : 脳卒中治療ガイドライン2009, 協和企画, 2009.
 
2) Qureshi AI, et al : Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage : results from antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol 67:570-576, 2010.
PubMed
3) Anderson CS, et al : Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT) : a randomised pilot trial. Lancet Neurol 7:391-399, 2008.
PubMed
4) Morgenstern LB, et al : Guidelines for the management of spontaneous intracerebral hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 41:2108-2129, 2010.
PubMed
5) Mendelow AD, et al ; American Heart Association Stroke Council and Council on Cardiovascular Nursing : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH) : a randomised trial. Lancet 365:387-397, 2005.
 
6) Mendelow AD, et al : Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II) : a randomised trial. Lancet 382:397-408, 2013.
 
7) Hattori N, et al : Impact of stereotactic hematoma evacuation on actiVities of daily living during the chronic period following spontaneous putaminal hemorrhage : a randomized study. J Neurosurg 101 : 417-420, 2004.
PubMed
P.379 掲載の参考文献
1) 篠原幸人ほか (編) : 脳卒中治療ガイドライン2009. 脳卒中合同ガイドライン委員会, 協和企画, 2009.
 
2) 吉峰俊樹 (編) : 科学的根拠に基づくくも膜下出血診療ガイドライン第2版. 日本脳卒中の外科学 36 (増刊号), にゅーろん社, 2008.
 
P.384 掲載の参考文献
1) 篠原幸人ほか (編) : 脳卒中治療ガイドライン2009, 協和企画, 2010.
 
2) Bernick C, et al : Silent MRI infarcts and the risk of future stroke : the cardiovascular health study. Neurology 57:1222-1229, 2001.
PubMed
3) Hart RG, et al : Aspirin for the primary prevention of stroke and other major vascular events : meta-analysis and hypotheses. Arch Neurol 57:326-332, 2000.
PubMed
4) Kobayashi S, et al : Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke 28:1932-1939, 1997.
PubMed
5) 小林祥泰 : 無症候性脳梗塞の臨床的意義. 神経研究の進歩 45:450-460, 2001.
 
6) 篠原幸人 : 脳内出血無症候性脳内出血MRIによる検出例. 日本臨牀 51(増刊号):272-275, 1993.
 
7) 門脇秀和ほか : 脳梗塞患者における微小脳出血の経時的変化の検討. 脳卒中 27:311-316, 2005.
Medical*Online
8) The EC/IC Bypass Study Group : Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 313:1191-1200, 1985.
 
9) Executive Committee for the Asymptomatic Carotid Atherosclerosis Study : Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273:1421-1428, 1995.
PubMed
10) Yamada S, et al : Risk factors for subsequent hemorrhage in patients with cerebral arteriovenous malformations. J Neurosurg 107:965 -972, 2007.
 
11) Reyns N, et al : Role of radiosurgery in the management of cerebral arteriovenous malformations in the pediatric age group : data from a 100-patient series. Neurosurgery 60:268-276, 2007.
PubMed
12) Wiebers DO, et al : Unruptured intracranial aneurysms : natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362:103-110, 2003.
PubMed
13) Wermer MJ, et al : Risk of rupture of unruptured intracranial aneurysms in relation to patient and aneurysm characteristics : an updated meta-analysis. Stroke 38:1404-1410, 2007.
PubMed
14) Morita A : [On-line outcome study of unruptured cerebral aneurysm in Japan (UCAS Japan)] . Rinsho Shinkeigaku 42:1188-1190, 2002.
PubMed
15) UCAS Japan Investigators ; Morita A, et al : The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366:2474-2482, 2012.
 
P.389 掲載の参考文献
1) 成冨博章ほか : VI. その他の脳血管障害. 脳卒中治療ガイドライン2009 (篠原幸人ほか編), p241-270, 協和企画, 2009.
 
2) 塚原徹 : 3. 脳動脈解離の現状, (1) 脳動脈解離の病態, 症状, 診断, 治療のアウトライン. 脳動脈解離診断の手引き (松岡秀樹ほか ; 循環器病研究委託費18公-5研究班編). p1-7, 国立循環器病センター, 2009.
 
3) Yasaka M, et al : Moyamoya disease. In : Stroke ; pathophysiology, diagnosis and management (5th ed) (ed by Mohr JP, et al), p720-733, Elsevier, Philadelphia, 2011.
 
4) Kuriyama S, et al : Prevalence and clinicoepidemiological features of moyamoya disease in Japan : findings from a nationwide epidemiological survey. Stroke 39:42-47, 2008.
PubMed
5) Kamada F et al : A genome-wide association study identified RNF213 as the first Moyamoya disease gene. J Hum Genet 56:34-40, 2011.
 
6) Miyamoto S, et al : JAM (Japan Adult Moyamoya) trial. In : 3rd International Moyamoya Meeting, Sapporo, 2013.
 
7) 高嶋修太郎 : 脳静脈・静脈洞血栓症の脳圧亢進症状に対するグリセロールの適応について (提案). 成冨博章ほか : 提案に対する回答. 臨床神経 52:511-514, 2011.
 
8) Saposnik G, et al : Diagnosis and management of cerebral venous thrombolsis. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158-1192, 2011.
PubMed
9) 石田千穂, 山田正仁 : 脳アミロイド・アンギオパチー. 必携 脳卒中ハンドブック 改訂第2版 (田中耕太郎ほか編), p130-133, 診断と治療社, 2011.
 
10) Piazza F, et al : Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation : Implications for Amyloid-Modifying Therapies. Ann Neurol 73:449-458, 2013.
 
11) Baker-LePain JC, et al : Clinical diagnosis of segmental arterial mediolysis : differentiation from vasculitis and other mimics. Arthritis Care Res 62 : 1655-1660, 2010.
PubMed
12) 佐藤洋 : EPISODE 20 "マカロニサイン" (高安動脈炎でみられる頸動脈超音波所見). バスキュラー・ラボ 5:293-296, 2008.
 
13) 松山晃文 : 大動脈炎症候群の臨床症状と臨床検査. 医学のあゆみ 233:274-278, 2010.
Medical*Online
14) Gorelick PB, et al : Vascular contribution to cognitive impairment and dementia. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:2672-2713, 2011.
PubMed
P.398 掲載の参考文献
1) Shuaib A, et al : Collateral blood vessels in acute ischemia stroke : a potential therapeutic target. Lancet Neurol 10 : 909-921, 2011.
PubMed
2) Ovbiagele B, et al : Statin enhancement of collateralization in acute stroke. Neurology 68:2129-2131, 2007.
PubMed
3) Menon BK, et al : Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol, 2013. [Epub ahead of print]
 
4) Shuaib A, et al : Partial aortic occlusion for cerebral perfusion augmentation. Stroke 42:1680-1690, 2011.
PubMed
5) Liu J, et al : Vascular remodeling after ischemic stroke : Mechanisms and therapeutic potentials. Prog Neurobiol 115C:138-156, 2014.
 
6) Coyle P : Dorsal cerebral collaterals of strole-prone spontaneously hypertensive rats (SHRSP) and Wistar Kyoto rats (WKY). Anat Res 218:40-44, 1987.
 
7) Kitagawa K, et al : Chronic mild reduction of cerebral perfusion pressure induces ischemic tolerance in focal cerebral ischemia. Stroke 36:2270-2274, 2005.
PubMed
8) Todo K, et al : Granulocyte-macrophage colony-stimulating factor enhances leptomeningeal collateral growth induced by common carotid artery occlusion. Stroke 39:1875-1882, 2008.
PubMed
9) Omura-Matsuoka E, et al : Hypertension impairs leptomeningeal collateral growth after common carotid artery occlusion : restoration by antihypertensive treatment. J Neurosci Res 89:108-116, 2011.
PubMed
10) Oyama N, et al : An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. J Neurosci Res 88:2889-2898, 2010.
PubMed
11) Buschmann IR, et al : Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor. Circulation 108:610-615, 2003.
 
12) Sugiyama Y, et al : Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke 42:770-775, 2011.
 
13) Wang J, et al : Bone marrow mononuclear cells exert lomg-term neuroprotection in a rat model of ischemic stroke by promoting arteriogensis and angiogenesis. Brain Behav Immun 34:56-66, 2013.
 
14) Maki T, et al : Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfsuion in mice. Stroke 42:1122-1128, 2011.
PubMed
15) Rink C, et al : Tocotrienol vitamin E protects against preclinical canine ischemic stroke by inducing arteriogenesis. J Cereb Blood Flow Metab 31:2218-2230, 2011.
PubMed
P.402 掲載の参考文献
1) Badaut J, et al : Aquaporins in brain ; distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 22:367-378, 2002.
PubMed
2) Papadopoulos MC, Verkman AS : Potential utility of aquaporin modulators for therapy of brain disorders. Prog Brain Res 170:589-601, 2008.
PubMed
3) Manlay GT, et al : Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med 6:159-163, 2000.
 
4) Yamamoto N, et al : Alterations in the expression of the AQP family in cultured rat astrocytes during hypoxia and reoxygenation. Brain Res Mol Brain Res 90:26-38, 2001.
PubMed
5) Papadopoulos MC, et al : Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18:1291-1293, 2004.
PubMed
6) Friedman B, et al : Acute vascular disruption and aquaporin 4 loss after stroke. Stroke 40:2182-2190, 2009.
PubMed
7) Frydenlund DS, et al : Temporary loss of perivascular aquaporin-4 in neocortex after transient middle cerebral artery occlusion in mice. Proc Natl Acad Sci USA 103:13532-13536, 2006.
PubMed
8) Chiu CD, et al : Hyperglucemia exacerbates intracerebral hemorrhage via the downregulation of aquaporin-4 : temporal assessment with magnetic resonance imaging. Stroke 44:1682-1689, 2013.
 
9) Zeng X, et al : Acute ethanol treatment reduces blood-brain barrier dysfunction following ischemia/reperfusion injury. Brain Res 1437:127-133, 2012.
PubMed
10) Badaut J, et al : Brain water mobidity decreases after astrocytic aquaporin-4 inhibition using RNA interference. J Cereb Blood Flow Metab 31:819-831, 2011.
 
11) Bhattacharya P, et al : Aquaporin-4 inhibition mediates piroxicam-induced neuroprotection against focal cerebral ischemia/reperfUsion injury in rodents. PLoS One 8:e73481, 2013.
PubMed
P.406 掲載の参考文献
1) Ay H, et al : Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 9:131-135, 1999.
PubMed
2) Kawamata T, et al : Intracisternal basic fibroblast growth factor (bFGF) enhances behavioral recovery following focal cerebral infarction in the rat J Cereb Blood Flow Metab 16:542-547, 1996.
 
3) Sogo Y et al : Formation of a FGF-2 and calcium phosphate composite layer on a hydroxyapatite ceramic for promoting bone formation. Biomed Mater 2:S175-180, 2007.
PubMed
4) Oyane A, et al : Novel gene-transferring scaffolds having a cell adhesion molecule-DNA-apatite nanocomposite surface. Gene Ther 4:1750-1753, 2007.
 
5) Oyane A, et al : Highly efficient gene transfer system using a lamnin-DNA-apatitie composite layer. J Gene Med 12:194-206, 2010.
 
6) Ito Y et al : Angiogenesis therapy for brain infarction using a slow-releasing drug delivery system for fibroblast growth factor 2. Biochem Biophys Res Commun 432:182-187, 2013.
PubMed
7) Tsurushima H, et al : Enhanced bone formation using hydroxyapatite ceramic coated with fibroblast growth factor-2. Acta Biomater 6:2751-2759, 2010.
PubMed
P.410 掲載の参考文献
1) Terpolilli NA, et al : Nitric oxide : considerations for the treatment of ischemic stroke. J Cereb Blood Flow Metab 32:1332-1346, 2012.
PubMed
2) Lo EH, et al : Temporal correlation mapping analysis of the hemodynamic penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression. Stroke 27:1381-1385, 1996.
PubMed
3) Fulton D, et al : Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597-601, 1999.
PubMed
4) Dimmeler S, et al : Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601-605, 1999.
PubMed
5) Forstermann U, Munzel T : Endothelial nitric oxide synthase in vascular disease : from marvel to menace. Circulation 113:1708-1714, 2006.
PubMed
6) Elrod JW, et al : eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes : a role for eNOS uncoupling. Circ Res 99:78-85, 2006.
PubMed
7) Oyama N, et al : An angiotensin II type 1 receptor blocker can preserve endothelial function and attenuate brain ischemic damage in spontaneously hypertensive rats. J Neurosci Res 88:2889-2898, 2010.
PubMed
8) Oyama N, et al : Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke 42:2571-2577, 2011.
 
9) Zhang ZG, et al : Cerebral endothelial nitric oxide synthase expression after focal cerebral ischemia in rats. Stroke 24:2016-2022, 1993.
PubMed
10) Veltkamp R, et al : Transient focal ischemia increases endothelial nitric oxide synthase in cerebral blood vessels. Stroke 33:2704-2710, 2002.
PubMed
11) Yagita Y, et al : Functional deterioration of endothelial nitric oxide synthase after focal cerebral ischemia. J Cereb Blood Flow Metab 33:1532-1539, 2013.
PubMed
12) Yagita Y, et al : Rho-kinase activation in endothelial cells contributes to expansion of infarction after focal cerebral ischemia. J Neurosci Res 85:2460-2469, 2007.
PubMed
13) Shin HK, et al : Rho-kinase inhibition acutely augments blood flow in focal cerebral ischemia via endothelial mechanisms. J Cereb Blood Flow Metab 27:998-1009, 2007.
PubMed
14) Rikitake Y, et al : Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36:2251-2257, 2005.
PubMed
15) NiChroinin D, et al : Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke : the North Dublin Population Stroke Study. Stroke 42:1021-1029, 2011,
 
16) ENOS Trial Investigators : Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke : rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 1:245-249, 2006.
PubMed
P.415 掲載の参考文献
1) Lees KR, et al : Time to treatment with intravenous alteplase and outcome in stroke : an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375:1695-1703, 2010.
PubMed
2) Lee SR, et al : Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett 417:1-5, 2007.
PubMed
3) Gursoy-Ozdemir Y, et al : Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447-1455, 2004.
PubMed
4) Rosell A, et al : MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 39:1121-1126, 2008.
PubMed
5) Asahi M, et al : Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain banier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732, 2001.
 
6) Sumii T, Lo EH : Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-836, 2002.
PubMed
7) Pugh CW, Ratcliffe PJ : Regulation of angiogenesis by hypoxia : role of the HIF system. Nat Med 9:677-684, 2003.
PubMed
8) Ferrara N, et al : Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004.
PubMed
9) Hurwitz H, et al : Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
PubMed
10) Zhang ZG, et al : Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22:379-392, 2002.
PubMed
11) Zhang ZG, et al : VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838, 2000.
 
12) van Bruggen N, et al : VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfUsion injury in the mouse brain. J Clin Invest 104:1613-1620, 1999.
 
13) Kanazawa M, et al : Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab 31:1461-1474, 2011.
PubMed
14) Okubo S, et al : FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model. Brain Res 1143:221-227, 2007.
 
15) Lo EH : A new penumbra : transitioning from injury into repair after stroke. Nat Med 14:497-500, 2008,
PubMed
P.422 掲載の参考文献
1) Wang H, et al : HMG-1 as a late mediator of endotoxin lethalityin mice. Science 285:248-251, 1999.
 
2) Andersson U, Tracey KJ : HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139-162, 2011.
PubMed
3) Rauvala H, Pihlaskari R : Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 262:16625-16635, 1987.
PubMed
4) Kim JB, et al : HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 26:6413-6421, 2006.
 
5) Liu K, et al : Anti-high mobility group box-1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904-3916, 2007.
PubMed
6) Zhang J, et al : Anti-high mobility group box-1 monoclonal antibody protects the blood-brain barrier from ischemia-induced disruption in rats. Stroke 42:1420-1428, 2011.
PubMed
7) Hayakawa K et al : Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 55:1280-1286, 2008.
 
8) Hayakawa K, et al : Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39:951-958, 2008.
PubMed
9) Kikuchi K et al : The free radical scavenger edaravone rescues rats from cerebral infarction by attenuating the release of high-mobility group box-1 in neuronal cells. J Pharmacol Exp Ther 329:865-874, 2009.
 
10) Kim ID, et al : Neuroprotection by bidegradable PAMAM ester (e-PAM-R) -mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release 142:422-430, 2010.
 
11) Wang L et al : Atrovasttin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NK-kB expression. Neurosci Lett 471:152-156, 2010.
 
12) Kim SW, et al : Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 46:147-156, 2012.
 
13) Yue, et al : Cynandione A mitigates ischemic injuries in rats with cerebral ischemia. J Neurochem 121:451-464, 2012.
PubMed
14) Kim ID, et al : Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci Lett 525:179-183, 2012.
PubMed
P.427 掲載の参考文献
1) Jay DG, Keshishian H : Laser inactivation of fasciclin I disrupts axon adhesion of grasshopper pioneer neurons. Nature 348:548-550, 1990.
PubMed
2) Hoersch S, Andrade-Navarro MA : Periostin shows increased evolutionary plasticity in its alternatively spliced region. BMC Evol Biol 10:30, 2010.
 
3) Katsuragi N, et al : Periostin as a novel factor responsible for ventricular dilation. Circulation 110:1806-1813, 2004.
PubMed
4) Orecchia P, et al : Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer 47:2221-2229, 2011.
PubMed
5) Kuhn B, et al : Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med 13:962-969, 2007,
PubMed
6) Zimmermann DR, Dours-Zimmermann MT : Extracellular matrix of the central nervous system : from neglect to challenge. Histochem Cell Biol 130:635-653, 2008.
PubMed
7) Zhao LR, et al : Synthetic fibronectin peptide exerts neuroprotective effects on transient focal brain ischemia in rats. Brain Res 1054:1-8, 2005.
PubMed
8) Meiners S, Mercado ML T : Functional peptide sequences derived from extracellular matrix glycoproteins and their receptors : strategies to improve neuronal regeneration. Mol Neurobiol 27:177-196, 2003.
PubMed
9) Shimamura M, et al : Role of central nervous system periostin in cerebral ischemia. Stroke 43:1108-1114, 2012.
PubMed
10) Shimamura M, et al : Long-term expression of periostin during the chronic stage of ischemic stroke in mice. Hypertens Res. (in press)
 
11) Iadecola C, Anrather J : The immunology of stroke : from mechanisms to translation. Nat Med 17:796-808, 2011.
PubMed
12) Shimamura M, et al : Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 38:3251-3258, 2007.
PubMed
13) Gordon ED, et al : A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness. Clin Exp Allergy 42:144-155, 2012.
PubMed
14) Zhao B-Q, et al : Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 12:441-445, 2006.
PubMed
15) Belvindrah R, et al : Betal integrins control the formation of cell chains in the adult rostral migratory stream. J Neurosci 27:2704-2717, 2007.
 
P.432 掲載の参考文献
1) Luo T, et al : Protein misfolding, aggregation, and autophagy after brain ischemia. Transl Stroke Res 4:581-588, 2013.
PubMed
2) Roussel BD, et al : Endoplasmic reticulum dysfunction in neurological disease. Lancet Neurol 12:105-118, 2012.
 
3) Kinouchi H, et al : Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 13:105-115, 1993.
 
4) Sharp FR, et al : Heat-shock protein protection. Trends Neurosci 22:97-99, 1999.
PubMed
5) Joly AL, et al : Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun 2:238-247, 2010.
PubMed
6) Hayashi T, et al : Oxidative damage to the endoplasmic reticulum is implicated in ischemic neuronal cell death. J Cereb Blood Flow Metab 23:1117-1128, 2003.
 
7) Kudo T, et al : A molecular chaperone inducer protects neurons from ER stress. Cell Death Differ 15:364-375, 2008.
 
8) Lu A, et al : Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J Neurochem 81:355-364, 2002.
PubMed
9) Truettner JS, et al : Subcellular stress response and induction of molecular chaperones and folding proteins after transient global ischemia in rats. Brain Res 1249:9-18, 2009.
PubMed
10) Stetler RA, et al : Phosphorylation of HSP27 by protein kinase D is essential for mediating neuroprotection against ischemic neuronal injury. J Neurosci 32:2667-2682, 2012.
PubMed
11) Shah ZA, et al : Heme oxygenase 1, beneficial role in permanent ischemic stroke and in gingko biloba (EGB 761) neuroprotection. Neuroscience 180:248-255, 2011.
PubMed
12) Latchman DS : Protective effect of heat shock proteins in the nervous system. Curr Neurovasc Res 1:21-27, 2004.
PubMed
13) Sharp FR, et al : Heat shock proteins in the brain : role of Hsp70, Hsp27, and HO-1 (Hsp32) and their therapeutic potential. Transl Stroke Res 4:685-692, 2013.
PubMed
14) Hayashi T, et al : Induction of GRP78 by ischemic preconditioning reduces endoplasmic reticulum stress and prevents delayed neuronal cell death. J Cereb Blood Flow Metab 23 : 949-961, 2003.
PubMed
15) Kirino T : Ischemic tolerance. J Cereb Blood Flow Metab 22:1283-1296, 2002.
PubMed
P.437 掲載の参考文献
1) 吉川雄一郎ほか : くも膜下出血後の脳血管平滑筋収縮性亢進の分子機構. 福岡医学誌 102:325-332, 2011.
 
2) Hirano K, Hirano M : Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J Pharmacol Sci 114:127-133, 2010.
PubMed
3) Hirano K : The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 27:27-36, 2007.
PubMed
4) Maeda Y, et al : Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid hemorrhage. Br J Pharmacol 152:1131-1139, 2007.
PubMed
5) Kai Y, et al : Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 38:3259-3265, 2007.
PubMed
6) Kikkawa Y, et al : Impaired feedback regulation of the receptor activity and the myofilament Ca2+ sensitivity contributes to increased vascular reactiveness after subarachnoid hemorrhage. J Cereb Blood Flow Metab 30:1637-1650, 2010.
PubMed
7) Kameda K, et al : Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid haemorrhage. Br J Pharmacol 165:106-119, 2012.
PubMed
8) Maeda Y, et al : Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarachnoid hemorrhage. Stroke 40:591-596, 2009.
PubMed
9) Kikkawa Y, et al : Mechanisms underlying potentiation of endothelin-1-induced myofilament Ca2+ sensitization after subarachnoid hemorrhage. J Cereb Blood Flow Metab 32:341-352, 2012.
PubMed
10) Hirano K, et al : Physiology and pathophysiology of Proteinase-activated receptors (PARs) : regulation of the expression of PARs. J Pharmacol Sci 97:31-37, 2005.
PubMed
11) Trejo J : Protease-activated receptors : new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 307:437-442, 2003.
PubMed
12) Hirano K : Current topics in the regulatory mechanism underlying the Ca2+ sensitization of the contractile apparatus in vascular smooth muscle. J Pharmacol Sci 104:109-115, 2007.
PubMed
13) 平野勝也 : トロンビン受容体拮抗薬. 日薬理学誌 138:258-259, 2011.
 
14) Morrow DA. et al : Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 44:691-698, 2013.
PubMed
P.442 掲載の参考文献
1) 金田伸一ほか : カプセル型人工酸素運搬体-リポソーム化ヘモグロビンの開発. 人工血液 21:49-59, 2013.
Medical*Online
2) 富樫広子ほか : 虚血-再開通モデルラットにおける脳機能不全の多角的評価と人工酸素運搬体の有効性について. 人工血液 12:121-126, 2004.
Medical*Online
3) Kakehata J, et al : Therapeutic potentials of an artificial oxygen-carrier, liposome-encapsulated hemoglobin, for ischemia/reperfusion-induced cerebral dysfunction in rats. J Pharmacol Sci 114:189-197, 2010.
PubMed
4) Hamadate N, et al : Liposome-encapsulated hemoglobin ameliorates impairment of fear memory and hippocampal dysfUnction after cerebral ischemia in rats. J Pharmacol Sci 114:409-419, 2010,
PubMed
5) Kawaguchi AT, et al : Liposome-encapsulated hemoglobin alleviates brain edema after permanent occlusion of the middle cerebral artery in rats. Artif Organs 33:153-158, 2009.
PubMed
6) Kawaguchi AT, et al : Liposome-encapsulated hemoglobin reduces the size of cerebral infarction in the rat : evaluation with photochemically induced thrombosis of the middle cerebral artery. Stroke 38:1626-1632, 2007.
PubMed
7) Urakami T, et al : In vivo distribution of liposome-encapsulated hemoglobin determined by positron emission tomography. Artif Organs 33:164-168, 2009.
PubMed
8) Kawaguchi AT, et al : Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates : an acute study. J Pharmacol Exp Ther 332:429-436, 2010.
PubMed
9) Kawaguchi AT, et al : Liposome-encapsulated hemoglobin ameliorates ischemic stroke in nonhuman primates : longitudinal observation. Artif Organs 37:904-912, 2013.
PubMed
P.446 掲載の参考文献
1) Abe K, et al : Stem cell therapy for cerebral ischemia : From basic science to clinical applications. J Cereb Blood Flow Metab 32:1317-1331, 2012.
PubMed
2) Takahashi K Yamanaka S : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676, 2006.
PubMed
3) Azizi SA, et al : Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci USA 95:3908-3913, 1998.
PubMed
4) Kondziolka D, et al : Neurotransplantation for patients with subcortical motor stroke : aphase 2 randomized trial. J Neurosurg 103:38-45, 2005.
 
5) Savitz SI, et al : Neurotransplantation of fetal porcine cells in patients with basal ganglia infarcts : A preliminary safety and feasibility study. Cerebrovasc Dis 20:101-107, 2005.
PubMed
6) Bang OY, et al : Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 57:874-882, 2005.
PubMed
7) Lee JS, et al ; STARTING collaborators : A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 28 : 1099-1106, 2010.
PubMed
8) Savitz SI, et al : Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol 70:59-69, 2011.
PubMed
9) Honmou O, et al : Intravenous administration of auto serum-expanded autologous mesenchymal strum cells in stroke. Brain 134:1790-1807, 2011.
 
10) 田口明彦 : 脳梗塞患者に対する再生医療の現状とその未来. (第54回日本老年医学会学術集会記録). 日老年医会誌 50:359-361, 2013.
 
11) Moriya Y, et al : Phase i study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke. J Stroke Cerebrovasc Dis 22:1088-1097, 2013.
PubMed
12) Stroke Therapy Academic Industry Roundtable (STAIR) : Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752-2758, 1999.
PubMed
13) Saver JL, et al ; STAIR VIII Consortium : Stroke treatment academic industry roundtable : research priorities in the assessment of neurothrombectomy devices. Stroke 44:3596-3601, 2013.
PubMed
14) Stem Cell Therapies as an Emerging Paradigm in Stroke Participants : Stem cell therapies as an emerging paradigm in stroke (steps) : Bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke 40:510-515, 2009.
PubMed
15) Savitz SI, et al ; STEPS Participants : Stem cell therapy as an emerging paradigm for stroke (steps) II. Stroke 42:825-829, 2011.
PubMed
16) Svensson J, et al : Societal value of stem cell therapy in stroke-a modeling study. Cerebrovasc Dis 33:532-539, 2012.
PubMed
17) Editorials : Unknown territory. Nature 494:5, 2013.
PubMed
P.451 掲載の参考文献
1) 澤本和延 : 成体におけるニューロン新生. 脳の発生学 : ニューロンの誕生・分化・回路形成 (宮田卓樹, 山本亘彦編), p205-220, 化学同人, 2013.
 
2) Seld T, et al (ed) : Neurogenesis in the adult brain II : Clinical implications. Springer, Berlin, 2011.
 
3) Tavazoie M, et al : A specialized vascular niche for adult neural stem cells. Cell Stem Cell 3(3):279-288, 2008.
PubMed
4) Kokovay E, et al : Adult SVZ lineage cells home to and leave the vascular niche via differential responses to SDF1/CXCR4 signaling. Cell Stem Cell 7(2):163-173, 2010.
PubMed
5) Sawamoto K, et al : New neurons follow the flow of cerebrospinal fluid in the adult brain. Science 311:629-632, 2006.
PubMed
6) Kaneko N, et al : New neurons clear the path of astrocytic processes for their rapid migration in the adult brain. Neuron 67:213-223, 2010.
PubMed
7) Snapyan M, et al : Vasculature guides migrating neuronal precursors in the adult mammalian forebrain via brain-derived neurotrophic factor signaling. J Neurosci 29:4172-4188, 2009.
 
8) Arvidsson A, et al : Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 8:963-970, 2002.
PubMed
9) Yamashita T, et al : Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 26:6627-6636, 2006.
PubMed
10) Imitola J, et al : Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1 alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci USA 101:18117-18122, 2004.
 
11) Kojima T, et al : Subventricular zone-derived neural progenitor cells migrate along a blood vessel scaffold toward the post-stroke striatum. Stem Cells 28:545-554, 2010.
PubMed
12) Nakaguchi K, et al : Growth factors released from gelatin hydrogel microspheres increase new neurons in the adult mouse brain. Stem Cells Int 2012:915160, 2012.
PubMed
13) Liu F, et al : Brain injury does not alter the intrinsic differentiation potential of adult neuroblasts. J Neurosci 29:5075-5087, 2009.
 
14) Sanai N, et al : Corridors of migrating neurons in the human brain and their decline during infancy. Nature 478:382-386, 2011.
PubMed
15) Jin K, et al : Evidence for stroke-induced neurogenesis in the human brain. Proc Natl Acad Sci USA 103:13198-13202, 2006.
PubMed
P.457 掲載の参考文献
1) Honmou O, et al : Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134:1790-1807, 2011.
PubMed
2) Taguchi A, et al : Administration of CD34+cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114:330-338, 2004.
 
3) Lindvall O, Kokaia Z : Stem cell research in stroke : how far from the clinic? Stroke 42:2369-2375, 2011.
PubMed
4) Reynolds BA, Weiss S : Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255:1707-1710, 1992.
PubMed
5) Eriksson PS, et al : Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317, 1998.
PubMed
6) Gomi M, et al : Functional recovery of the murine brain ischemia model using human induced pluripotent stem cell-derived telencephalic progenitors. Brain Res 1459:52-60, 2012.
PubMed
7) Jensen MB, et al : Survival and differentiation of transplanted neural stem cells derived from human induced pluripotent stem cells in a rat stroke model. J Stroke Cerebrovasc Dis 22:304-308, 2013.
 
8) Mohamad O, et al : Vector-free and transgene-free human iPS cells differentiate into functional neurons and enhance functional recovery after ischemic stroke in mice. PLoS One 8:e64160, 2013.
PubMed
9) Oki K, et al : Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells 30:1120-1133, 2012.
PubMed
10) Fujimoto Y, et al : Treatment of a mouse model of spinal cord injury by transplantation of human induced pluripotent stem cell-derived long-term self-renewing neuroepithelial-like stem cells. Stem Cells 30:1163-1173, 2012.
PubMed
11) Miura K, et al : Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27:743-745, 2009.
PubMed
12) Tsuji O, et al : Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci USA 107:12704-12709, 2010.
PubMed
13) Nakagawa M, et al : Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26:101-106, 2008.
PubMed
14) Tornero D, et al : Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain 136(Pt 12):3561-3577, 2013.
 
15) Ishizaka S, et al : Intra-arterial cell transplantation provides timing-dependent cell distribution and functional recovery after stroke. Stroke 44:720-726, 2013.
PubMed
16) Okano H : Stem cell biology of the central nervous system. J Neurosci Res 69:698-707, 2002.
PubMed
P.462 掲載の参考文献
1) Bliss T, et al : Cell transplantation therapy for stroke. Stroke 38:817-826, 2007.
PubMed
2) Kondziolka D, et al : Neurotransplantation for patients with subcortical motor stroke : a phase 2 randomized trial. J Neurosurg 103:38-45, 2005.
 
3) Kondziolka D, et al : Transplantation of cultured human neuronal cells for patients with stroke. Neurology 55:565-569, 2000.
PubMed
4) Bacigaluppi M, et al : Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms. Brain 132 (Pt 8) : 2239-2251, 2009.
 
5) Kokaia Z, Lindvall O : Neurogenesis after ischaemic brain insults. Curr Opin Neurobiol 13(1):127-132, 2003.
PubMed
6) Ohira K, et al : Ischemia-induced neurogenesis of neocortical layer l progenitor cells. Nat Neurosci 13:173-179, 2010.
 
7) Bliss TM, et al : Transplantation of hNT neurons into the ischemic cortex : cell survival and effect on sensorimotor behavior. J Neurosci Res 83:1004-1014, 2006.
PubMed
8) Kelly, et al : Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci USA 101:11839-11844, 2004.
PubMed
9) Imitola, et al : Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1 alpha/CXC chemoldne receptor 4 pathway. Proc Natl Acad Sci USA 101:18117-18122, 2004.
 
10) del Zoppo GJ : Relationship of neurovascular elements to neuron injury during ischemia. Cerebrovasc Dis 27(Suppl 1):65-76, 2009.
 
11) Lo EH : A new penumbra : transitioning from injury into repair after stroke. Nat Med 14:497-500, 2008.
PubMed
12) Ishizaka S, et al : Intra-arterial cell transplantation provides timing-dependent cell distribution and functional recovery after stroke. Stroke 44(3):720-726, 2013.
PubMed
13) Andres RH, et al : Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain 134(Pt 6):1777-1789, 2011.
 
14) Horie N, et al : Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells 9(2):274-285, 2011.
 
15) Chopp M, et al : Who's in favor of translational cell therapy for stroke : STEPS forward please? Cell Transplant 18 :691-693, 2009.
PubMed
16) Stem Cell Therapies as an Emerging Paradigm in Stroke Participants : Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS) : bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke, Stroke 40:510-515, 2009.
PubMed
P.467 掲載の参考文献
1) Akiyama Y, et al : Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 39:229-236, 2002.
PubMed
2) Honma T, et al : Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol 199:56-66, 2006.
 
3) Horita, et al : Intravenous administration of GDNF gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. J Neurosci Res 84:1495-1504, 2006.
 
4) Iihoshi S, et al : Atherapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res 1007(1-2):1-9, 2004.
 
5) Inoue M, et al : Comparative analysis of remyelinating potential of focal and intravenous administration of autologous bone marrow cells into the rat demyelinated spinal cord. Glia 44(2):111-118, 2003.
PubMed
6) Kim S, et al : Neural differentiation potential of peripheral blood-and bone marrow-derived precursor cells. Brain Res 1123:27-33, 2006.
PubMed
7) Komatsu K, et al : Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. Brain Res 1334:84-92, 2010.
PubMed
8) Liu H, et al : Neuroprotection by PIGF gene-modified human mesenchymal stem cells after cerebral ischemia. Brain 129:2734-2745, 2006.
 
9) Nakamura K, et al : Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 11(14):1155-1164, 2004.
 
10) Nomura T, et al : I. V. infusion of BDNF gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 136:161-169, 2005.
 
11) Omori Y, et al : Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Brain Res 1236:30-38, 2008.
PubMed
12) Onda T, et al : Therapeutic benefits by Ang-1 gene-modified human mesenchymal stem cells after cerebral ischemia. J Cereb Blood Flow Metab 28:329-340, 2008.
PubMed
13) Toyama K, et al : Therapeutic benefits of angiogenetic gene-modified human mesenchymal stem cells after cerebral ischemia. Exp Neurol 216:47-55, 2009.
PubMed
14) Ukai R, et al : Mesenchymal stem cells derived from peripheral blood protects against ischemia. J Neurotrauma 24(3):508-520, 2007.
PubMed
15) Zheng W, et al : Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res 1310:8-16, 2009.
PubMed
16) Honmou O, et al : Intravenous administration of auto-serum expanded autologous mesenchymal stem cells derived from bone marrow into stroke patients. Brain 134:1790-1807, 2011.
 
17) Song CH, et al : The effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prion. J Virol 83(11):5918-5927, 2009.
PubMed
18) Honmou O, Houkin K : Stem cell therapy for cerebral ischemia. No Shinkei Geka 38(6):515-520, 2010.
PubMed
19) Sasaki M, et al : Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 35:26-34, 2001.
PubMed
20) Suzuki J, et al : Bilateral conical hyperactiVity detected by fMRI associates With improved motor function following intravenous infusion of mesenchymal stem cells in a rat stroke model. Brain Res 1497:15-22, 2013.
 
21) Sasaki M, et al : BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury. J Neurosci 29(47):14932-14941, 2009.
PubMed
P.472 掲載の参考文献
1) Louissaint A Jr, et al : Coordinated interaction of neurogenesis and angiogenesis in the adult songbird brain. Neuron 34: 945-960, 2002.
PubMed
2) Taguchi A, et al : Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114:330-338, 2004.
 
3) Taguchi A, et al : Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. Eur J Vasc Endovasc Surg 25:276-278, 2003.
 
4) Taguchi A, et al : A Reproducible and Simple Model of Permanent Cerebral Ischemia in CB-17 and SCID Mice. J Exp Stroke Transl Med 3:28-33, 2010.
 
5) Nakano-Doi A, et al : Bone marrow mononuclear cells promote proliferation of endogenous neural cells through vascular niches after cerebral infarction. Stem Cells 28:1292-1302, 2010.
PubMed
6) Taguchi A, et al : Granulocyte colony-stimulating factor has a negative effect on stroke outcome in amurine model. Eur J Neurosci 26:126-133, 2007.
 
7) Taguchi A, et al : Letter by Taguchi et al Regarding Article, "Granulocyte Colony-Stimulating Factor in Patients With Acute Ischemic Stroke : Results of the AX200 for Ischemic Stroke Trial". Stroke 45(1):e8, 2014.
PubMed
8) Uemura M, et al : Cell-based therapy to promote angiogenesis in the brain following ischemic damage. Curr Vasc Pharmacol 10:285-288, 2012.
PubMed
9) Nakayama D, et al : Injury-induced neural stem/progenitor cells in post-stroke human cerebral cortex. Eur J Neurosci 31:90-98, 2010.
PubMed
10) Terai S, et al : Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 24:2292-2298, 2006.
PubMed
P.476 掲載の参考文献
1) Nakagomi T, et al : Isolation and characterization of neural stem/progenitor cells from post-stroke cerebral cortex in mice. Eur J Neurosci 29:1842-1852, 2009.
PubMed
2) Nakayama D, et al : Injury-induced neural stem/progenitor cells in post-stroke human cerebral cortex. Eur J Neurosci 31:90-98, 2010.
PubMed
3) Nakagomi T, et al : Leptomeningeal-derived doublecortin-expressing cells in poststroke brain. Stem Cells Dev 21:2350-2354, 2012.
PubMed
4) Nakagomi T, et al : Ischemia-induced neural stem/progenitor cells in the pia mater following cortical infarction. Stem Cells Dev 20:2037-2051, 2011.
PubMed
5) Siegenthaler JA, et al : Retinoic acid from the meninges regulates cortical neuron generation. Cell 1390:597-609, 2009.
 
6) Halfter W, et al : A critical function of the pial basement membrane in cortical histogenesis. J Neurosci 22:6029-6040, 2002.
PubMed
7) Bifari F, et al : Novel stem/progenitor cells with neuronal dififerentiation potential reside in the leptomeningeal niche. J Cell Mol Med 13:3195-3208, 2009.
PubMed
8) Mignone JL, et al : Neural stem and progenitor cells in nestin-GFP transgenic mice. J Comp Neurol 469:311-324, 2004.
PubMed
9) Etchevers HC, et al : The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 128:1059-1068, 2001.
PubMed
10) Nagoshi N, et al : Neural crest-derived stem cells display a wide variety of characteristics. J Cell Biochem 107:1046-1052, 2009.
PubMed
11) Dore-Duffy P, et al : CNS microvascular pericytes exhibit multipotential stem cell activity. J Cereb Blood Flow Metab 26:613-624, 2006.
PubMed
12) Mohyeldin A et al : Oxygen in stem cell biology : a critical component of the stem cell niche. Cell Stem Cell 7:150-161, 2010.
PubMed
13) Thier M, et al : Direct conversion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 10:473-479, 2012.
PubMed
14) Decimo I, et al : Nestin-and doublecortin-positive cells reside in adult spinal cord meninges and participate in injury-induced parenchymal reaction. Stem Cells 29:2062-2076, 2011.
PubMed
15) Zhou B, et al : Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454:109-113, 2008.
 
P.480 掲載の参考文献
1) Jiang Y, et al : Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49, 2002.
PubMed
2) Mezey E, et al : Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci USA 100:1364-1369, 2003.
PubMed
3) Corti S, et al : Modulated generation of neuronal cells from bone marrow by expansion and mobilization of circulating stem cells with in vivo cytokine treatment. Exp Neurol 177:443-452, 2002.
PubMed
4) Kawada H, et al : Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating Proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 113:701-710, 2006.
PubMed
5) Morita Y, et al : Administration of hematopoietic cytokines provide a favorable microenvironment for neurogenesis after stroke. Neurosci Res 58:356-360, 2007.
PubMed
6) Abe K, et al : Stem cell therapy for cerebral ischemia : from basic science to clinical applications. J Cereb Blood Flow Metab 32(7):1317-1331, 2012.
PubMed
7) Shyu WC, et al : Granulocyte colony-stimulating factor for acute ischemic stroke : a randomized controlled trial. CMAJ 174:927-933, 2006.
PubMed
8) Sprigg N, et al : Granulocyte-colony-stimulating factor mobilizes bone marrow stem cells in patients with subacute ischemic stroke : the Stem cell Trial of recovery EnhanceMent after Stroke (STEMS) pilot randomized, controlled trial. Stroke 37:2979-2983, 2006.
PubMed
9) Prasad K, et al : Mobilization of Stem Cells Using G-CSF for Acute Ischemic Stroke : A Randomized Controlled, Pilot Study. Stroke Res Treat 2011:283473, 2011.
PubMed
10) England TJ, et al : Granulocyte-colony stimulating factor for mobilizing bone marrow stem cells in subacute stroke : the stem cell trial of recovery enhancement after stroke 2 randomized controlled trial. Stroke 43:405-411, 2012.
PubMed
11) Schabitz WR, et al : AXIS : a trial of intravenous granulocyte colony-stimulating factor in acute ischemic stroke. Stroke 41:2545-2551, 2010.
 
12) Ringelstein EB, et al : Granulocyte colony-stimulating factor in patients with acute ischemic stroke : results of the AX200 for Ischemic Stroke trial. Stroke 44:2681-2687, 2013.
PubMed
13) Moriya Y, et al : Phase I study of intravenous low-dose granulocyte colony-stimulating factor in acute and subacute ischemic stroke. J Stroke Cerebrovasc Dis 22:1088-1097, 2013.
PubMed
14) Duelsner A, et al : Granulocyte colony-stimulating factor improves cerebrovascular reserve capacity by enhancing collateral growth in the circle of Willis. Cerebrovasc Dis 33:419-429, 2012.
PubMed
P.489 掲載の参考文献
1) Murayama K, et al : Whole-brain perfusion CT performed with a prototype 256-detector row CT system : initial experience. Radiology 250:202-211, 2009.
PubMed
2) Siebert E, et al : 320-slice CT neuroimaging : initial clinical experience and image quality evaluation. Br J Radiol 82:561-570, 2009.
 
3) Siebert E, et al : Neuroimaging by 320-row CT : is there a diagnostic benefit or is it just another scanner? A retrospective evaluation of 60 consecutive acute neurological patients. Neurol Sci 31:585-593, 2010.
PubMed
4) Gervaise A, et al : CT image quality improvement using adaptive iterative dose reduction with wide-volume acquisition on 320-detector CT. Eur Radiol 22:295-301, 2012.
PubMed
5) Gibbs JM, et al : Evaluation of cerebral perfusion reserve in patients with carotid-artery occlusion. Lancet 1:310-314, 1984.
PubMed
6) Nabavi DG, et al : CT assessment of cerebral perfusion : experimental validation and initial clinical experience. Radiology 213:141-149, 1999.
PubMed
7) Wintermark M, et al : Comparison of admission perfusion computed tomography and qualitative diffusion-and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke 33:2025-2031, 2002.
PubMed
8) Bisdas S, et al : Comparison of perfusion computed tomography with diffusion-weighted magnetic resonance imaging in hyperacute ischemic stroke. J Comput Assist Tomogr 28:747-755, 2004.
PubMed
9) Parsons MW, et al : Perfusion computed tomography : prediction of final infarct extent and stroke outcome. Ann Neurol 58:672-679, 2005.
PubMed
10) Silvennoinen HM, et al : CT perfusion identifies increased salvage of tissue in patients receiving intravenous recombinant tissue plasminogen activator within 3 hours of stroke onset. AJNR Am J Neuroradio 29:1118-1123, 2008.
 
11) Hayakawa M, et al : Detection of Pulsation in Unruptured Cerebral Aneurysms by ECG-Gated 3D-CT Angiography (4D-CTA) with 320-Row Area Detector CT (AD CT) and Follow-up Evaluation Results : Assessment Based on Heart Rate at the Time of Scanning. Chn Neuroradiol, 2013. [Epub ahead of print]
 
12) Hayakawa M, et al : Detection of pulsation in ruptured and unruptured cerebral aneurysms by electrocardiographically gated 3-dimensional computed tomographic angiography with a 320-row area detector computed tomography and evaluation of its chnical usefulness. Neurosurgery 69:843-851; discussion 851, 2011.
 
P.493 掲載の参考文献
1) Dzialowski I, et al : Computed tomography-based evaluation of cerebrovascular disease. In : Stroke, 5th ed ; pathophysiology, diagnosis and management (ed by Mohr JP, et al), p870-881, Elsevier Saunders, Philadelphia, 2011.
 
2) ASIST-Japan実践ガイドライン策定委員会 : CTA (CT血管造影). 急性期脳梗塞画像診断実践ガイドライン2007 (興梠征典編), p47-51, 南江堂, 2007.
 
3) 佐々木真理 : 3D CT angiography (CTA). 日本臨牀 64:323-326, 2006.
Medical*Online
4) Rad Fan編集委員会 : 64列・128列・256列・320列マルチスライスCT造影プロトコール. Rad Fan 9:91-113, 2011.
 
5) 脳卒中合同ガイドライン委員会 : 無症候性脳血管障害. 未破裂脳動脈瘤の診断とスクリーニング. 脳卒中治療ガイドライン2009 (篠原幸人編), p233, 協和企画, 2009.
 
6) 日本医学放射線学会ガイドライン委員会 : 脳神経領域の標準的撮像法. 未破裂動脈瘤のスクリーニングにはどの検査法を推奨するか? 画像診断ガイドライン2013年版 (山下康行編). p60-61, 金原出版, 2013.
 
7) Kumar A, et al : Recent advances in diagnostic approaches for sub-arachnoid hemorrhage. Asian J Neurosurg 6:94-98, 2011.
PubMed
8) Connolly ES Jr, et al : Guidelines for the management of aneurismal subarachnoid hemorrhage : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 43:1711-1737, 2012.
 
9) Sameshima T, et al : Clinical usefulness of and problems with three-dimensional CT angiography for the evaluation of arteriosclerotic stenosis of the carotid artery : Comparison with conventional angiography, MRA, and ultrasound sonography. Surg Neurol 51:301-308, 1999.
PubMed
10) Brouwer PA, et al : Dynamic 320-section CT angiography in cranial arteriovenous shunting lesions. AJNR Am J Neuroradiol 31:767-770, 2010.
PubMed
11) Willems PW, et al : The use of 4D-CTA in the diagnostic work-up of brain arteriovenous malformatioins. Neuroradiology 54:123-131, 2012.
PubMed
12) 小阪崇幸ほか : 狭窄部位および発症機序の同定に頸部血管エコーと4D-CT angiographyが有用であったbow hunter症候群の1例. Neurosonology 26:98-101, 2014.
Medical*Online
13) Hayakawa M, et al : Detection of Pulsation in Unruptured Cerebral Aneurysms by ECG-Gated 3D-CT Angiography (4D-CTA) with 320-Row Area Detector CT (AD CT) and Follow-up Evaluation Results : Assessment Based on Heart Rate at the Time of Scanning. Clin Neuroradiol. 2013 Aug 3. [Epub ahead of print]
 
14) Bendszus M, et al : Silent embolism in diagnostic cerebral angiography and neurointerventional procedures ; a prospective study. Lancet 354:1594-1597, 1999.
PubMed
15) U-King-Im JM, et al : Carotid-artery imaging in the diagnosis and management of patients at risk of stroke. Lancet Neurol 8:569-580, 2009.
PubMed
P.499 掲載の参考文献
1) レイ H. ハシェミほか : エコープラナーイメージング (EPI). MRIの基本パワーテキスト第3版 (荒木力監訳), p264-274, メディカル・サイエンス・インターナショナル, 2013.
 
2) 荒木力ほか : 拡散入門. これでわかる拡散MRI第3版 (青木茂樹編), p16-61, 秀潤社, 2013.
 
3) 井田正博ほか : 脳梗塞. これでわかる拡散MRI第3版 (青木茂樹編), p208-229, 秀潤社, 2013.
 
4) 山田直明 : 診断・検査法MRI, 9 閉塞性脳血管障害. 脳神経外科学大系 (山浦昌編), p54-65, 中山書店, 2004.
 
5) 山田恵 : 微小脳梗塞の画像診断update. 脳と神経 65:783-788, 2013.
 
6) Kuker W, et al : MRI characteristics of acute and subacute brainstem and thalamic infarction : Value of T2-and diffusion-weighted sequences. J Neurol 249:33-42, 2002.
PubMed
7) 三澤園子ほか : 脳梗塞急性期におけるMRI拡散強調画像の感度. 第22回The Mt. Fuji Workshop on CVD講演集 22:112-114, 2004.
 
8) Easton JD, et al : Deffinition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals from the American Heart Associatio/American Stroke Association Stroke Council ; Council on Cardiovascular Surgery and Anesthesia ; Council on Caridiovascular Radiology and Intervention ; Council on Cardiavascular Nursing ; and the Inter disciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 40:2276-2293, 2009.
 
9) Brazzelli M, et al : Diffusion-weighted imaging and diagnosis of transient ischemic attack. Ann Neurol 75:67-76, 2014
PubMed
10) 安井敬三ほか : 一過性脳虚血発作における急性期拡散強調画像陽性例の頻度と臨床特徴. 脳卒中 35:328-336, 2013.
Medical*Online
11) Uchiyama S : The concept of acute cerebrovascular syndrome. Front Neuro Neurosci 33:11-18, 2014.
PubMed
P.502 掲載の参考文献
1) 日本医学放射線学会/日本放射線科専門医会・医会 (編) : 脳神経領域の標準的撮像法. 画像診断ガイドライン2013年版. p50-52, 金原出版株式会社, 2013.
 
2) Kuhl CK et al : Sensitivity encoding for diffusion-weighted MR imaging at 3.0 T : Intraindividual comparative study. Radiology 234:517-526, 2005.
 
3) Lettau M, Laible M : 3-T high-b-value diffusion-weighted MR imaging in hyperacute ischemic stroke. J Neuroradiol 40:149-157, 2013.
 
4) Kakeda S, et al : MRA of intracranial aneurysms embolized with platinum coils : a vascular phantom study at 1.5T and 3T. J Magn Reson Imaging 28:13-20, 2008.
PubMed
5) Choi CG, et al : Detection of Intracranial atherosclerotic steno-occlusive disease with 3D time-offlight magnetic resonance angiography with sensitivity encoding at 3T. AJNR Am J Neuroradiol 28:439-446, 2007.
 
6) Lohan DG, et al : MR angiography at 3 T for assessment of the external carotid artery system. AJR Am J Roentgenol 189:1088-1094, 2007.
PubMed
7) Thomalla G, et al : DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4.5 h of symptom onset (PRE-FLAIR) : a multicentre observational study. Lancet Neurol 10:978-986, 2011.
 
8) Sohn CH, et al : MR imaging of hyperacute subarachnoid and intraventricular hemorrhage at 3T : a preliminary report of gradient echo T2*-weighted sequences. AJNR Am J Neuroradiol 26(3):662-665, 2005.
PubMed
9) Nishimura S, et al : Evaluation of dural arteriovenous fistulas with 4D contrast-enhanced MR angiography at 3T. AJNR Am J Neuroradiol 31:80-85, 2010.
PubMed
10) Iryo Y, et al : Intracranial dural arteriovenous fistulas : Evaluation with 3-T four-dimensional MR angiography using arterial spin labeling. Radiology 271:193-199, 2014.
PubMed
11) Akter M, et al : Detection of hemorrhagic hypointense foci in the brain on susceptibility-weighted imaging : clinical and phantom studies. Acad Radiol 14:1011-1019, 2007.
PubMed
12) Nandigam RN, et al : MR imaging detection of cerebral microbleeds : effect of susceptibilityweighted imaging, section thickness, and field strength. AJNR Am J Neuroradiol 30:338-343, 2009.
PubMed
P.507 掲載の参考文献
1) Akashi T, et al : Branching pattern of lenticulostriate arteries observed by MR angiography at 3.0 T. Jpn J Radiol 30:331-335, 2012.
 
2) Takada H, et al : Diagnosis of vertebral artery dissection by basi-parallel anatomical scanning (BPAS) MRI. Interv Neuroradiol 12:129-132, 2006.
PubMed
3) Aoki S, et al : Two-dimensional thick-slice MR digital subtraction angiography for assessment of cerebrovascular occlusive diseases, Eur Radiol 10:1858-1864, 2000.
PubMed
4) Parmar H, et al : Dynamic MRA with four-dimensional time-resolved angiography using keyhole at 3tesla in head and neck vascular lesions. J Neuroophthalmol 29:119-127, 2009.
 
5) Hori M, et al : Time-resolved three-dimensional magnetic resonance digital subtraction angiography without contrast material in the brain : Initial investigation. J Magn Reson Imaging 30:214-218, 2009.
PubMed
6) Haacke EM, et al : Susceptibility-weighted imaging : Technical aspects and clinical applications, part 1. AINR Am J Neuroradiol 30:19-30, 2009.
 
7) Santhosh K, et al : Susceptibility weighted imaging : A new tool in magnetic resonance imaging of stroke. Clin Radiol 64:74-83, 2009.
PubMed
P.511 掲載の参考文献
1) Mori S, et al : Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol 45(2):265-269, 1999.
PubMed
2) Melhem ER, et al : Diffusion tensor MR imaging of the brain and white matter tractography. AJR Am J Roentgenol 178(1):3-16, 2002.
PubMed
3) Kunimatsu A, et al : Three-dimensional white matter tractography by diffusion tensor imaging in ischaemic stroke involving the corticospinal tract. Neuroradiology 45(8):532-535, 2003,
PubMed
4) Radlinska B, et al : Diffusion tensor imaging, permanent pyramidal tract damage, and outcome in subcortical stroke. Neurology 75(12):1048-1054, 2010.
PubMed
5) Budde MD, Frank JA : Neurite beading is sufficient to decrease the apparent diffusion coefficient after ischemic stroke. Proc Natl Acad Sci USA 107(32):14472-14477, 2010.
PubMed
6) Hui ES, et al : Stroke assessment with diffusional kurtosis imaging. Stroke 43(11):2968-2973, 2012.
PubMed
7) Rifber T, et al : Compensatory role of the cortico-rubro-spinal tract in motor recovery after stroke. Neurology 79(6):515-522, 2012.
 
8) Wang X, et al : White matter microstructure changes induced by motor skill learning utilizing a body machine interface. Neuroimage 88:32-40, 2014.
PubMed
P.515 掲載の参考文献
1) Calautti C, Baron JC : Functional neuroimaging studies of motor recovery after stroke in adults. A review. Stroke 34: 1553-1566, 2003.
PubMed
2) Kato H, et al : Near-infrared spectroscopic topography as a tool to monitor motor reorganization after hemiparetic stroke. A comparison with functional MRI. Stroke 33:2032-2036, 2002.
PubMed
3) Kato H, Izumiyama M : Activation of brain sensorimotor network by somatosensory input in patients with hemiparetic stroke : A functional MRI study. In : Novel Frontiers of Advanced Neuroimaging (ed by Fountas KN), p67-80, InTech, Croatia, 2013. [http://www.intechopen.com/books/novel-frontiers-of-advanced-neuroimaging/activation-of-brain-sensorimotor-network-by-soma-tosensory-input-in-patients-with-hemiparetic-stroke-]
 
4) Cao Y, et al : Cortical language activation in stroke patients recovering from aphasia with functional MRI. Stroke 30:2331-2340, 1999.
PubMed
5) Ogawa S, et al : Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 87:9868-9872, 1990.
PubMed
6) SPM8脳画像解析マニュアル (菊池吉晃ほか編), 医歯薬出版, 2012.
 
7) Murata Y, et al : Effects of cerebral ischemia on evoked cerebral blood oxygenation responses and bold contrast functional MRI in stroke patients. Stroke 37:2514-2520, 2006.
PubMed
8) Masutani Y, et al : MR diffusion tensor imaging : recent advance and new techniques for diffusion tensor visualization. Eur J Radiol 46:53-66, 2003.
PubMed
9) 加藤宏之ほか : 脳梗塞後の片麻痺の回復と大脳皮質運動機能の再構築-機能的MRI, 光トポグラフィー. 経頭蓋磁気刺激による検討-. 脳神経 53:869-874, 2001.
 
10) Kato H, Izumiyama M : Restorative and compensatory changes in the brain during early motor recovery from hemiparetic stroke : a functional MRI study. In : Neuroimaging (ed by Del-Ben CM), p125-135, Sciyo, Croatia, 2010. [http://sciyo.com/articles/show/title/restorative-and-compensatory-changes-in-the-brain-during-early-motor-recovery-from-hemiparetic-strok]
 
11) 加藤宏之 : 随意運動の機能回復-機能的MRIの知見-. Jpn J Rehabil Med 46:17-40, 2009.
Medical*Online
12) Fox MD, Raichle ME : Spontaneous fluctuations in brain activity observed with fUnctional magnetic resonance imaging. Nat Rev Neurosci 8:700-711, 2007.
PubMed
13) Biswal R, et al : Functional connectivity in the motor cortex of resting human brain using echo-planar imaging. Magn Reson Med 34:537-541, 1995.
 
14) Park C, et al : Longitudinal changes of resting-state functional connectivity during motor recovery after stroke. Stroke 42:1357-1362, 2011.
PubMed
P.521 掲載の参考文献
1) Dai W, et al : Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 60(6):1488-1497, 2008,
PubMed
2) Garcia DM, et al : Efficiency of inversion pulses for background suppressed arterial spin labeling. Magn Reson Med 54(2):366-372, 2005.
PubMed
3) Wang DJ, et al : The value of arterial spin-labeled perfusioll inlaging in acute ischemic stroke : comparison with dynamic susceptibility contrast-enhanced MRI. Stroke 43(4):1018-1024, 2012.
PubMed
4) Kambiz NA, et al : Quantitative Evaluation of Mislnatch in Recanalized Acute Stroke Patients : Comparison Between Arterial Spin Labeling and Dynamic Susceptibility Contrast Perfusion. p3003, Proceedings of ISMRM, 2013.
 
5) Ay H, et al : A score to predict early risk of recurrence after ischemic stroke. Neurology 74(2):128-135, 2010.
PubMed
6) Kimura Ht, et al : Pulsed Continuous 3DASL Cerebral Perfusion Imaging Using Multiple Post Label Delay (PDL) Acq. in the Clinical Utility of Arterial Transit Tilne (ATT) Mapping : Comparative Study with PET-OEF in Patients with Chronic Occlusive Vascular Disease. p3043, Proceedings of ISMRM, 2013.
 
7) Ye FQ, et al : H (2) (15) O PET validation of steady-state arterial spin tagging cerebral blood flow measurements in humans. Magn Reson Med 44(3):450-456, 2000.
PubMed
8) Kimura H, et al : Multislice continuous arteria1spin-labeled perfusion MRI in patients with chronic occlusive cerebrovascular disease : A correlative study with CO2 PET validation. J Magn Reson Imaging 22(2): 189-198, 2005.
PubMed
9) Kimura H, et al : Cerebral Blood Flow and Arterial Transit Time Measurements in Patients with Chronic Occlusive Cerebrovascular Disease Using 3D Spiral SE Arterial Spin Labeling on 3T-MR : Correlative Study with O15 Labeled H2O PET Examination. p3646, Proceedings of ISMRM, 2009.
 
10) Dai W, et al : Reduced resolution transit delay prescan for quantitative continuous arterial spin labeling perfusion imaging. Magn Reson Med 67(5):1252-1265, 2012.
PubMed
11) Dai WA et al : Volumetric measurement of perfusion and arterial transit delay using hadamard encoded continuous arterial spin labeling. Magn Reson Med 69(4):1014-1022, 2012.
 
P.526 掲載の参考文献
1) Ward KM, et al : A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson 143:79-87, 2000.
PubMed
2) Zhou J, et al : Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 9:1085-1090, 2003.
PubMed
3) Van Zijl PCM, et al : MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc Natl Acad Sci USA 104:4359-4364, 2007.
PubMed
4) Haris M, et al : In vivo mapping of brain myo-inositol. Neuroimage 54:2079-2085, 2011.
PubMed
5) Jones CK et al : Amide proton transfer imaging of human brain tumors at 3T. Magn Reson Med 56:585-592, 2006.
PubMed
6) Togao O, et al : Amide proton transfer imaging of adult diffuse gliomas : correlation with histopathological grades. Neuro Oncol 16(3):441-448, 2014.
PubMed
7) Sun PZ, et al : Detection of the ischemic penumbra using pH-weighted MRI. J Cereb Blood Flow Metab 27:1129-1136, 2007.
PubMed
8) Zhao X, et al : Saturation power dependence of amide proton transfer imaging contrast in human brain tumors and strokes at 3T. Magn Reson Med 66:1033-1041, 2011.
PubMed
9) Tietze A, et al : Assessment of ischemic penumbra in patients with hyperacute stroke using amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI. NMR Biomed 27(2):163-174, 2014.
PubMed
P.531 掲載の参考文献
1) Pexman JH, et al : Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 22:1534-1542, 2001.
PubMed
2) Demchuk AM, et al : Importance of early ischemic computed tomography changes using ASPECTS in NIHDS rtPA Stroke Study. Stroke 36:2110-2115, 2005.
 
3) Dzialowski I, et al : Extent of early ischemic changes on computed tomography (CT) before thrombolysis : prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke 37:973-978, 2006.
PubMed
4) Hirano T, et al : Low Alberta Stroke Program Early Computed Tomography Score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6mg/kg alteplase. J Stroke Cerebrovasc Dis 21:898-902, 2012.
 
5) Sasaki M, et al : Standardizing display conditions of diffusion-weighted images using concurrent b0 images : a multi-vendor multi-institutional study. Magn Reson Med Sci 6:133-137, 2007.
PubMed
6) Barber PA, et al : Imaging of the brain in acute ischaemic stroke : comparison of computed tomography and magnetic resonance diffUsion-weighted imaging. J Neurol Neurosurg Psychiatry 76:1528-1533, 2005.
PubMed
7) Nezu T, et al : Early ischemic change on CT versus diffusion-weighted imaging for patients with stroke receiving intravenous recombinant tissue-type plasminogen activator therapy : stroke acute management with urgent risk-factor assessment and improvement (SAMURAI) rt-PA registry. Stroke 42:2196-2200, 2011.
 
8) Fiebach JB, et al : CT and diffusion-weighted MR imaging in randomized order : diffusion-weighted imaging results in higher accuracy and lower interrater variability in the diagnosis of hyperacute stroke. Stroke 33:2206-2210, 2002.
PubMed
9) Singer OC, et al : Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging. Ann Neurol 63:52-60, 2008.
PubMed
10) Nezu T, et al : Pretreatment ASPECTS on DWI predicts 3-months outcome following rt-PA : SAMURAI rt-PA registry. Neurology 75:555-561, 2010.
PubMed
11) Kawano H, et al : Presence of deep white matter lesions on diffusion-weighted imaging is a negative predictor of early dramatic improvement after intravenous tissue plasminogen activator thrombolysis. Cerebrovasc Dis 30:230-236, 2010.
PubMed
12) Kim EY, et al : Reversed discrepancy between CT and diffusion-weighted MR imaging in acute ischemic stroke. AJNR Am J Neuroradiol 27:1990-1995, 2006.
PubMed
13) Kawano H, et al : Diffusion-weighted magnetic resonance imaging may underestimate acute ischemic lesions : cautions on neglecting a computed tomography-diffusion-weighted imaging discrepancy. Stroke 44:1056-1061, 2013.
PubMed
14) Kawano H, et al : Hyperacute-phase computed tomography-diffusion-weighted imaging discrepancy and response to thrombolysis. J Stroke Cerebrovasc Dis 22:290-296, 2013.
PubMed
15) Kawano H, et al : Modified ASPECTS for DWI including deep white matter lesions predicts subsequent intracranial hemorrhage. J Neurol 259:2045-2052, 2012.
PubMed
P.537 掲載の参考文献
1) Meier P, Zierler KL : On the theory of the indicator-dilution method for measurement of blood flow and volume. J Appl Physiol 6:731-744, 1954.
PubMed
2) Zierler KL : Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. Handbook of Physiology 1:585-615, 1962.
 
3) Wintermark M, et al : Perfusion-CT assessment of infarct core and penumbra : receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 37:979-985, 2006.
PubMed
4) Powers WJ : Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 29:231-240, 1991.
PubMed
5) Wintermark M, et al : Using 80 kVp versus 120 kVp in perfusion CT measurement of regional cerebral blood fiow. AJNR Am J Neuroradiol 21:1881-1884, 2000.
 
6) Wintermark M, et al : Quantitative assessment of regional cerebral blood flows by perfUsion CT studies at low injection rates : a critical review of the underlying theoretical models. Eur Radiol 11:1220-1230, 2001.
 
7) Wintermark M, et al : Dynamic perfUsion CT : optimizing the temporal resolution and contrast volume for calculation of perfusion CT parameters in stroke patients. AJNR Am J Neuroradiol 25:720-729, 2004.
PubMed
8) Lin CJ, et al : Can iterative reconstruction improve imaging quality for lower radiation CT perfusion? Initial experience. AJNR Am J Neuroradiol 34:1516-1521, 2013.
PubMed
9) Juluru K, et al : Effects of increased image noise on image quality and quantitative interpretation in brain CT perfUsion. AJNR Am J Neuroradiol 34:1506-1512, 2013.
 
10) Kudo K et al : Differences in CT perfusion maps generated by different commercial software : quantitative analysis by using identical source data of acute stroke patients. Radiology 254:200-209, 2010.
PubMed
11) Suzuki K, et al : Utility of CT perfusion with 64-row multi-detector CT for acute ischemic brain stroke. Emerg Radiol 18:95-101, 2010.
PubMed
12) Murayama K, et al : Whole-brain perfusion CT performed with a prototype 256-detector row CT system : initial experience. Radiology 250 : 202-211, 2009.
PubMed
13) Suzuki K, et al : Active bleeding in acute subarachnoid hemorrhage observed by multiphase dynamic-enhanced CT. AJNR Am J Neuroradiol 33:1374-1379, 2012.
PubMed
P.542 掲載の参考文献
1) Calamante F, et al : Delay and dispersion effects in dynamic susceptibility contrast MRI : simulations using singular value decomposition. Magn Reson Med 44:466-473, 2000.
PubMed
2) Carroll TJ, et al : Automatic calculation of the arterial input function for cerebral perfusion imaging with MR imaging. Radiology 227: 593-600, 2003.
PubMed
3) Ostergaard L : Principles of cerebral perfusion imaging by bolus tracking. J Magn Reson Imaging 22:710-717, 2005.
PubMed
4) Ostergaard L, et al : High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I : Mathematical approach and statistical analysis. Magn Reson Med 36:715-725, 1996.
 
5) Ostergaard L, et al : High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II : Experimental comparison and preliminary results. Magn Reson Med 36:726-736, 1996.
PubMed
6) Smith AM, et al : Whole brain quantitative CBF and CBV measurements using MRI bolus tracking : comparison of methodologies. Magn Reson Med 43:559-564, 2000.
PubMed
7) Smith AM, et al : Whole brain quantitative CBF, CBV, and MTT measurements using MRI bolus tracking : implementation and application to data acquired from hyperacute stroke patients. J Magn Reson Imaging 12:400-410, 2000.
PubMed
8) Wittsack HJ, et al : MR imaging in acute stroke : diffusion-weighted and perfusion imaging parameters for predicting infarct size. Radiology 222:397-403, 2002.
PubMed
9) Wu O, et al : Predicting tissue outcome in acute human cerebral ischemia using combined diffusion-and perfusion-weighted MR imaging. Stroke 32:933-942, 2001.
PubMed
10) Wu O, et al : Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med 50:164-174, 2003.
PubMed
11) Kudo K, et al : Difference in tracer delay-induced effect among deconvolution algorithms in CT perfusion analysis : quantitative evaluation with digital phantoms. Radiology 251(1):241-249, 2009.
PubMed
12) Kudo K, et al : Differences in CT perfusion maps generated by different commercial software : quantitative analysis by using identical source data of acute stroke patients. Radiology 254(1):200-209, 2010.
PubMed
13) Kudo K, et al : Accuracy and reliability assessment of CT and MR perfUsion analysis software using a digital phantom. Radiology 267(1):201-211, 2013.
 
P.547 掲載の参考文献
1) 伊藤靖 : Biplane Flat panel時代における血管撮影装置の基本操作. 脳血管内治療の進歩2014 もう一段上の治療を目指して-血管撮影装置を使いこなす (坂井信幸ほか編), p54-56, 診断と治療社, 2013.
 
2) ACR-ASNR-SIR-SNIS practice guideline for the perforlnance of diagnostic cervicocerebral catheter angiography in adults. Revised 2011 (Resolution 41). [http://www.acr.org/-/media/261A171F55D744439FAACDgC61BOD462.pdf]
 
3) Saitoh H, et al : Rerupture of cerebral aneurysms during angiography. AJNR Am J Neuroradiol 16:539-542, 1995.
PubMed
4) Kaufmann TJ, et al : Complications of diagnostic cerebral angiography : evaluation of 19826 consecutive patients. Radiology 243:812-819, 2007.
 
5) Fifi JT, et al : Complications of modern diagnostic cerebral angiography in an academic medical center. J Vasc Interv Radiol 20:442-447. 2009.
 
6) Sato M, et al : Risk factors of ischelnic lesions related to cerebral angiography and neuro-interventional procedures. Neurol Med Chir (Tokyo) 53:381-387, 2013.
PubMed
7) Marder CP, et al : Multimodal imaging of reversible cerebral vasoconstriction syndrome : a series of 6 cases. AJNR Am J Neuroradiol 33:1403-1410, 2012.
PubMed
8) Choi KD, et al : Rotational vertebral artery occlusion. Mechanisms and long-term outcome. Stroke 44:1817-1824, 2013.
PubMed
9) Engelhorn T, et al : Flat panel detector angiographic CT in the management of aneurismal rupture during coil embolization. AJNR Am J Neuroradiol 29:1581-1584, 2008.
 
10) Richter G, et al : Flat panel detector angiographic CT for stent-assisted coil embolization of broad-based cerebral aneurysms. AJNR Am J Neuroradiol 28:1902-1908, 2007.
PubMed
11) Mordasini P, et al : Applicability of tableside flat panel detector CT parenchymal cerebral blood volume measurement in neurovascular interventions : preliminary clinical experience. AJNR Am J Neuroradiol 33:154-158, 2012.
PubMed
12) 吉村良, 寺田友昭 : 脳循環評価へのチャレンジ. 脳血管内治療の進歩2014 もう一段上の治療を目指して-血管撮影装置を使いこなす (坂井信幸ほか編), p128-131, 診断と治療社, 2013.
 
13) 石橋敏寛, 高尾洋之 : 脳動脈瘤血行動態の評価へのチャレンジ. 脳血管内治療の進歩2014 もう一段上の治療を目指して-血管撮影装置を使いこなす (坂井信幸ほか編), p122-127, 診断と治療社, 2013.
 
P.552 掲載の参考文献
1) Biasi GM, et al : Carotid plaque echolucency increases the risk of stroke in carotid stenting : The imaging in carotid angioplasty and risk of stroke (ICAROS) study. Circulation 110(6):756-762, 2004.
PubMed
2) Kawasaki M, et al : Noninvasive quantitative tissue characterization and two-dimensional color-coded map of human atherosclerotic lesions using ultrasound integrated backscatter : Comparison between histology and integrated backscatter images. J Am Coll Cardiol 38(2):486-492, 2001.
PubMed
3) Faggioli GL et al : Identification of carotid 'vulnerable plaque' by contrast-enhanced ultrasonography : Correlation with plaque histology, symptoms and cerebral computed tomography. Eur J Vasc Endovasc Surg 41(2):238-248, 2011.
PubMed
4) Moody AR, et al : Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation 107:3047-3052, 2003.
PubMed
5) Narumi S, et al : Predicting carotid plaque characteristics using quantitative color-coded T1-weighted MR plaque imaging : Correlation with carotid endarterectomy specimens. AJNR Am J Neuroradiol, 2013. [Epub ahead of print]
 
6) Yoshimura S, et al : High-intensity signal on time-of-flight magnetic resonance angiography indicates carotid plaques at high risk for cerebral embolism during stenting. Stroke 42(11):3132-3137, 2011.
PubMed
7) 佐々木真理 : 頸動脈プラークイメージング. 脳神経外科 40(7):579-584, 2012.
 
8) 菱川朋人 : 頸動脈プラークイメージングの現状と展望. 脳神経外科ジャーナル 19(11):836-844, 2010.
 
9) de Weert TT, et al : In Vivo characterization and quantification of atherosclerotic carotid plaque components with multidetector computed tomography and histopathological correlation. Arterioscler Thromb Vasc Biol 26(10):2366-2372, 2006.
PubMed
10) Kom A, et al : Grading of carotid artery stenosis in the presence of extensive calcifications : Dual-energy CT angiography in comparison with contrast-enhanced MR angiography. Clin Neuroradiol, 2013. [Epub ahead of print]
 
11) Ohota M, et al : A histological and clinical comparison of new and conventional integrated backscatter intravascular ultrasound (IB-IVUS). Circ J 76(7):1678-1686, 2012.
PubMed
12) Nasu K, et al : Accuracy of in vivo coronary plaque morphology assessment : a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 47(12):2405-2412, 2006.
PubMed
13) Hishikawa T, et al : Virtual histology-intravascular ultrasound in assessment of carotid plaques : ex vivo study. Neurosurgery 65(1):146-152, 2009.
PubMed
14) Yoshimura S, et al : OCT of human carotid arterial plaques. JACC Cardiovasc Imaging 4(4):432-436, 2011.
PubMed
15) Tawakol A, et al : In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 48(9):1818-1824, 2006.
PubMed
P.560 掲載の参考文献
1) Chida K, et al : Postoperative cortical neural loss associated with cerebral hyperperfusion and cognitive impairment after carotid endarterectomy : 123I-iomazenil SPECT study. Stroke 40:448-453, 2009.
PubMed
2) Kobayashi M, et al : I-123 iomazenil SPECT imaging in a patient with hemispheric brain damage due to cerebral ischemia during carotid endarterectomy. Clin Nucl Med 35:51-52, 2010.
 
3) Chida K, et al : Central benzodiazepine receptor binding potential and CBF images on SPECT correlate with oxygen extraction fraction images on PET in the cerebral cortex with unilateral major cerebral artery occlusive disease. J Nucl Med 52:511-518, 2011.
 
4) Kuroda H, et al : Accuracy of central benzodiazepine receptor binding potential/cerebral blood flow SPECT imaging for detecting misery perfusion in patients with unilateral major cerebral artery occlusive diseases : comparison with cerebrovascular reactivity to acetazolamide and cerebral blood flow SPECT imaging. Clin Nucl Med 37:235-240, 2012.
PubMed
5) Suzuki T, et al : Comparison of early and late images on 123I-iomazenil SPECT with cerebral blood flow and oxygen extraction fraction images on PET in the cerebral cortex of patients with chronic unilateral major cerebral artery occlusive disease. Nucl Med Commun 33:171-178, 2012.
PubMed
6) Sato Y, et al : Preoperative central benzodiazepine receptor binding potential and cerebral blood flow images on SPECT predict development of new cerebral ischemic events and cerebral hyperperfusion after carotid endarterectomy. J Nucl Med 52:1400-1407, 2011.
PubMed
7) Ogasawara Y, et al : Preoperative 123I-iomazenil SPECT imaging predicts cerebral hyperperfusion following endarterectomy for unilateral cervical internal carotid artery stenosis. Am J Nucl Med Mol Imaging 2:77-87, 2012.
PubMed
8) Kuroda H, et al : Spontaneous recovery of reduced cortical central benzodiazepine receptor binding potential on I-123 Iomazenil SPECT in a patient with status epilepticus. Clin Nucl Med 35:126-127, 2010.
 
9) Chida K, et al : Postcarotid endarterectomy improvement in cognition is associated with resolution of crossed cerebellar hypoperfusion and increase in 123I-iomazenil uptake in the cerebral cortex : a SPECT study. Cerebrovasc Dis 29:343-351, 2010.
PubMed
10) Yamashita T, et al : Combination of preoperative cerebral blood flow and 123I-iomazenil SPECT imaging predicts postoperative cognitive improvement in patients undergoing uncomplicated endarterectomy for unilateral carotid stenosis. Clin Nucl Med 37:128-133, 2012.
PubMed
P.566 掲載の参考文献
1) Ito H, et al : Human cerebral circulation : positron emission tomography studies. Ann Nucl Med 19:65-74, 2005.
 
2) Ibaraki M, et al : Interindividual variations of cerebral blood flow, oxygen delivery, and metabolism in relation to hemoglobin concentration measured by positron emission tomography in humans. J Cereb Blood Flow Metab 30:1296-1305, 2010.
PubMed
3) Ibaraki M, et al : Quantification of cerebral blood flow and oxygen metabolism with 3-dimensional PET and 150 : validation by comparison with 2-dimensional PET. J Nucl Med 49:50-59, 2008.
 
4) Derdeyn CP, et al : Increased oxygen extraction fraction is associated with prior ischemic events in patients with carotid occlusion. Stroke 29:754-758, 1998.
PubMed
5) 山内浩ほか : PETにより評価した症候性内頸動脈閉塞症の脳循環動態と脳梗塞再発の関係. 臨床神経 39:513-519, 1999.
 
6) Kuroda S, et al : Cerebral oxygen metabolism and neuronal integrity in patients with impaired vasoreactivity attributable to occlusive carotid artery disease. Stroke 37:393-398, 2006.
PubMed
7) Powers WJ, et al : The effect of hemodynamically significant carotid artery disease on the hemodynamic status of the cerebral circulation. Ann Intern Med 106:27-34, 1987.
PubMed
8) Powers WJ, et al : Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia ; the Carotid Occlusion Surgery Study randomized trial. JAMA 306:1983-1992, 2011.
PubMed
9) Carlson AP, et al : Failure of cerebral hemodynamic selection in general or of specific positron emission tomography methodology? Carotid Occlusion Surgery Study (COSS). Stroke 42:3637-3639, 2011.
PubMed
10) Marchal G, et al : Voxel-based mapping of irreversible ischaemic damage with PET in acute stroke. Brain 122:2387-2400, 1999.
PubMed
11) Shimosegawa E, et al : Metabolic penumbra of acute brain infarction : a correlation with infarct growth. Ann Neurol 57:495-504, 2005.
PubMed
12) Sobesky J, et al : Crossed cerebellar diaschisis in acute human stroke ; a PET study of serial changes and response to supratentorial reperfusion. J Cereb Blood Flow Metab 25:1685-1691, 2005.
PubMed
13) Takasawa M, et al : Prognostic value of subacute crossed cerebellar diaschisis : single-photon emission CT study in patients with middle cerebral artery territory infarct. AJNR Am J Neuroradiol 23:189-193, 2002.
PubMed
14) Heiss WD, et al : Probability of cortical infarction predicted by flumazenil binding and diffusionweighted imaging signal intensity : a comparative positron emission tomography/magnetic resonance imaging study in early ischemic stroke. Stroke 35:1892-1898, 2004.
PubMed
15) Read SJ, et al : The fate of hypoxic tissue on 18F-fluoromisonidazole positron emission tomography after ischemic stroke. Ann Neurol 48:228-235, 2000.
PubMed
P.571 掲載の参考文献
1) 松本昌泰ほか : 頸部血管超音波検査ガイドライン. Neurosonology 19:50-69, 2006.
 
2) Koga M. et al : Diagnosis of internal carotid artery stenosis greater than 70% with power Doppler duplex sonography. AJNR Am J Neuroradiol 22:413-417, 2001.
PubMed
3) Kimura K, et al : Oscillating thromboemboli within the extracranial internal carotid artery demonstrated by ultrasonography in patients with acute cardioembolic stroke. Ultrasound Mcd Biol 24:1121-1124, 1998.
 
4) Kimura K, et al : Duplex carotid sonography in distinguishing acute unilateral atherothrombotic from cardioembolic carotid artery occlusion. AJNR Am J Neuroradiol 18:1447-1452, 1997.
PubMed
5) Iguchi Y, et al : Hyper-acute stroke patients associated with aortic dissection. Intern Med 49:543-547, 2010.
PubMed
6) 峰松一夫ほか : rt-PA (アルテプラーゼ) 静注療法 適正治療指針 (第2版). 脳卒中 34:443-480, 2012.
 
7) 木村和美ほか : Subclavian steal syndrome (SSS) とsubclavian steal phenomenon (SSP) における椎骨動脈血流動態の検討 Duplex頸部超音波による検討. 臨床神経学 31:970-973, 1991.
 
P.577 掲載の参考文献
1) Yasaka M, et al : Transoral carotid ultrasonography. Stroke 29:1383-1388, 1998.
PubMed
2) Hayashi N, et al : Surgical anatomy of the cervical carotid artery for carotid endarterectomy. Neurol Med Chir (Tokyo)45:25-30, 2005.
PubMed
3) Suzuki R, et al : Identification of internal carotid artery dissection by transoral carotid ultrasonography. Cerebrovasc Dis 33 : 369-377, 2012,
PubMed
4) 松岡秀樹 : 脳動脈解離の現状「本邦の実態 (アンケート調査, 後ろ向き登録研究から)」. 脳動脈解離診療の手引き (松岡秀樹ほか編), p8-14, 国立循環器病センター, 2009.
 
5) Schievink WI, et al : Spontaneous dissection of cervicocephalic arteries in childhood and adolescence. Neurology 44:1607-1612, 1994.
PubMed
6) Koga M, et al : Transoral carotid ultrasonographic findings in internal carotid artery dissection-a case report. Angiography 51:699-703, 2000.
 
7) Yakushiji Y, et al : Serial transoral carotid ultrasonographic findings in extracranial internal carotid artery dissection. J Ultrasound Med 24:877-880, 2005.
PubMed
8) Yakushiji Y, et al : Transoral carotid ultrasonography is useful for detection and follow-up of extracranial internal carotid artery dissecting aneurysm. Cerebrovasc Dis 24:114-146, 2007.
 
9) Isa K et al : Transoral carotid ultrasonography for evaluating internal carotid artery occlusion. Intern Med 44: 567-571, 2005.
PubMed
10) Kishikawa K, et al : Evaluation of distal extracranial internal carotid artery by transoral carotid ultrasonography in patients with severe carotid stenosis. AJNR Am J Neuroradiol 23:924-928, 2002.
PubMed
11) Kamouchi M, et al : Poststenotic flow and intracranial hemodynamics in patients with carotid stenosis : transoral carotid ultrasonography study. AJNR Am J Neuroradiol 26:76-81, 2005.
PubMed
12) Kamouchi M, et al : Transoral ultrasonographic evaluation of carotid fiow in predicting cerebral hemodynamics after carotid endarterectomy. AJNR Am J Neuroradiol 27:1295-1299, 2006.
 
13) Fujimoto S, et al : Accuracy of conventional plus transoral carotid ultrasonography in distinguishing pseudo-occlusion from total occlusion of the internal carotid artery. Cerebrovasc Dis 22:170-176, 2006.
PubMed
14) Yasaka M, et al : Bottle neck sign of the proximal portion of the intemal carotid artery in moyamoya disease. J Ultrasound Med 25:1547-1552, 2006.
 
15) 姉川敬裕ほか : マイクロコンベックス型探触子を用いた経口腔頸部血管超音波検査法 (modified TOCU). 脳卒中 35:1-4, 2013.
Medical*Online
P.583 掲載の参考文献
1) Aaslid R, et al : Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 57:769-774, 1982.
PubMed
2) Bogdahn U, et al : Transcranial color-coded real-time sonography in adults. Stroke 21:1680-1688, 1990.
PubMed
3) Ringelstein EB, et al : Transcranial Doppler sonography : anatomical landmark and normal velocity values, Ultrasound Med Biol 16:745-761, 1990.
PubMed
4) Tegeler CH, et al : Transcranial Doppler velocities in a large, healthy population. J Neuroimaging 23:466-472, 2013.
 
5) Sorond FA, et al : Brain blood flow and velocity : correlations between magnetic resonance imaging and transcranial Doppler sonography. J Ultrasound Med 29:1017-1022, 2010.
PubMed
6) Sugimori H, et al : Cerebral hemodynamics in hypertensive patients compared with normotensive volunteers. A transcranial Doppler study. Stroke 25:1384-1389, 1994.
PubMed
7) Aaslid R, et al : Cerebral autoregulation dynamics in humans. Stroke 20:45-52, 1989.
PubMed
8) Tzeng YC, et al : Cerebrovascular regulation during transient hypotension and hypertension in humans. Hypertension 56:268-273, 2010.
PubMed
9) Sugimori H, et al : Can transcranial Doppler really detect reduced cerebral perfusion states? Stroke 26:2053-2060, 1995.
PubMed
10) Baumgartner RW, et al : Assessment of >= 50% and < 50% intracranial stenoses by transcranial color-coded duplex sonography. Stroke 30:87-92, 1999.
PubMed
11) Almekhlafi MA, et al : Malignant emboli on transcranial Doppler during carotid stenting predict postprocedure diffusion weighted imaging lesions. Stroke 44:1317-1322, 2013.
PubMed
12) Silbert BS, et al : Review of transcranial Doppler ultrasound to detect microemboli during orthopedic surgery. AJNR Am J Neuroradiol, 2013. [Epub ahead of print]
 
13) Gerriets T, et al : Sonographic monitoring of midline shift in hemispheric infarctions. Neurology 52:45-49, 1999.
PubMed
14) Lazaridis C, et al : Cerebral blood flow changes and the values of pulsatility index post decompressive craniectomy. J Clin Neurosci 19:1052-1054, 2011.
 
15) Brouwer MJ, et al : New reference values for the neonatal cerebral ventricles. Radiology 262:224-233, 2012.
PubMed
16) Grosset DG, et al : Prediction of symptomatic vasospasm after subarachnoid hemorrhage by rapidly increasing transcranial Doppler velocity and cerebral blood flow changes. Stroke 23:674-679, 1992.
PubMed
17) Lindegaard KF, et al : Cerebral vasospasm diagnosis by means of angiography and blood velocity measurements. Acta Neurochir (Wien) 100:12-24, 1989.
PubMed
18) Kirsch JD, et al : Advances in transcranial Doppler US : imaging ahead. Radiographics 33:E1-E14, 2013.
PubMed
19) Zhang Y, Rabinstein AA : Lower head of the bed position does not change blood flow velocity in subarachnoid hemorrhage. Neurocrit Care 14:73-76, 2011.
 
20) Maurer M, et al : Differentiation between intracranial hemorrhage and ischemic stroke by transcranial color-coded duplex-sonography. Stroke 29:2563-2567, 1998.
PubMed
21) Baumgartner RW, et al : Transoccipital power-based color-coded duplex sonography of cerebral sinuses and veins. Stroke 28:1319-1323, 1997.
PubMed
22) Bos MJ, et al : Transcranial Doppler hemodynamic parameter and risk of stroke : the Rotterdam study. Stroke 38:2453-2458, 2007.
PubMed
23) Lopez-Cancio E, et al : The Barcelona-Asymptomatic Intracranial Atherosclerosis (AsIA) study : prevalence and risk factors. Atherosclerosis 221:221-225, 2012.
PubMed
24) Hajjar I, et al : Renin angiotensin system gene polymorphisms and cerebral blood flow regulation : the MOBILIZE Boston study. Stroke 41:635-640, 2010.
PubMed
25) Keage HA, et al : Cerebrovascular function in aging and dementia : a systemic review of transcranial Doppler studies. Dement Geriatr Cogn Dis Extra 2:258-270, 2012.
 
26) Rosengarten B, et al : Methodological aspects of functional transcranial Doppler sonography and recommendations for simultaneous EEG recording. Ultrasound Med Biol 38:989-996, 2012.
PubMed
P.588 掲載の参考文献
1) Habara S, et al : Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 28:2217-2222, 2007.
PubMed
2) Asinger RW, et al : Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation : II. Dense spontaneous echocardiographic contrast. J Am Soc Echocardiogr 12:1088-1096, 1999.
PubMed
3) Fatkin D, et al : Relations between left atrial appendage blood velocity, spontaneous echocardio-graphic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 23:961-969, 1994.
 
4) Mugge A et al : Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation : identification of a subgroup of patients at increased embolic risk. J Am Coll Cardiol 23:599-607, 1994.
 
5) Zabalgoitia M, et al : Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31:1622-1666, 1998.
PubMed
6) Ueno Y, et al : Paradoxical brain embolism may not be uncommon-prospective study in acute ischemic stroke. J Neurol 254:763-766, 2007.
 
7) Hoen B, et al : Changing profile of infective endocarditis : result of a 1-year survey in France. JAMA 288:75-81, 2002.
PubMed
8) Di Salvo G, et al : Echocardiography predicts embolism events in infective endocarditis. J Am Coll Cardiol 37:1069-1076, 2001.
PubMed
9) Tice JP, et al : Mitral valve strands in patients with forcal cerebral ischemia. Stroke 27:1183-1186, 1996.
 
10) Molina JE, et al : Primary cardiac tumors : experience at the University Minnesota. Thorac Cardiovasc Surg 38:183-191, 1990.
PubMed
11) Ha JW, et al : Echocardiographic and morphologic characteristics of atrial myxoma and their relation to systemic embolism. Am J Cardiol 83:1579-1582, 1999.
PubMed
12) Kronzon I, Tunick PA : Aorta atherosclerotic disease and stroke. Circulation 114:63-75, 2006.
 
13) Cohen A, et al : Aortic plaque morphology and vascular events : a follow-up study in patients with ischemic stroke. FAPS Investigators. French Study of Aortic Plaque in Stroke. Circulation 96:3838-3841, 1997.
PubMed
14) Harloff A, et al : Complex plaques in proximal descending aorta : an underestimated embolic source of stroke. Stroke 41:1145-1150, 2010.
PubMed
P.599 掲載の参考文献
1) 日本脳卒中学会 (編) : rt-PA (アルテプラーゼ) 静注療法適正治療指針 第二版. p1-36, 2012.
 
2) Takano K, et al : Activation of coagulation in acute cardioembolic stroke. Stroke 22:12-16, 1991.
PubMed
3) Isenegger J, et al : D-dimers predict stroke subtype when assessed early. Cerebrovasc Dis 29:82-86, 2010.
PubMed
4) Shibazaki K, et al : Plasma brain natriuretic peptide can be a biological marker to distinguish cardi-oembolic stroke from other stroke types in acute ischemic stroke. Intern Med 48:259-264, 2009.
 
5) 雨宮志門ほか : 高齢非弁膜症性心房細動合併脳塞栓症急性期における低用量ヘパリン療法. 脳卒中 20:678-682, 1998.
 
6) Stone GW, et al ; MAPT-DES Investigators : Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (MAPT-DES) : a prospective multicentre registry study. Lancet 17:614-623, 2013.
 
7) 篠原幸人ほか : 脳卒中治療ガイドライン2009, p111-115, 協和企画, 2010.
 
8) Stangier J, et al : The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303, 2007.
PubMed
9) Lippi G, et al : Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation : a tentative approach based on routine laboratory tests. J Thromb Thrombolysis, 2014. [Epub ahead of print]
 
10) Becker RC, et al : Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 104:976-983, 2010.
PubMed
11) Berendes E, et al : Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 349:245-249, 1997.
PubMed
12) Kurokawa Y, et al : Pathogenesis of hyponatremia following subarachnoid hemorrhage due to rup tured cerebral aneurysm. Surg Neurol 46:500-508, 1996.
 
P.605 掲載の参考文献
1) Landi G, et al : Hypercoagulability in acute stroke : prognostic sign近cance. Neurology 37:1667-1671, 1987.
 
2) Feinberg WM, et al : Hemostatic markers in acute stroke. Stroke 20:592-597, 1989.
PubMed
3) Takano K, et al : Hypercoagulability in acute ischemic stroke : analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method. Thromb Res 58:481-491, 1990.
PubMed
4) Takano K, et al : Activation of coagulation in acute cardioembolic stroke. Stroke 22:12-16, 1991.
PubMed
5) Takano K, et al : Markers of a hypercoagulable state following acute ischemic stroke. Stroke 23:194-198, 1992.
PubMed
6) Yamazaki M, et al : Alterations of haemostatic markers in various subtypes and phases of stroke. Blood Coagul Fibrinolysis 4:707-712, 1993.
PubMed
7) Nagao T, et al : Platelet activation is not involved in accerelation of the coagulation system in acute cardioembolic stroke with nonvalvular atrial fibrillation. Stroke 26:1365-1368, 1995.
 
8) Takano K, et al : Hemostatic differences in atrial fibrillation with and without prior thromboembolism using low-intensity warfarin anticoagulation. Stroke 26:162, 1995.
 
9) Abumiya T, et al : Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 74:1050-1054, 1995.
PubMed
10) Yasaka M, et al : Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 40:1183-1188, 2001.
PubMed
11) 高野健太郎 : 心房細動と凝固亢進状態-分子マーカーによる解析-. 綜合臨牀 54:2213-2219, 2005.
Medical*Online
12) Takano K, et al : Hypercoagulable state under low-intensity warfarin anticoagulation assessed with hemostatic markers in cardiac disorders. Am J Cardiol 74:935-939, 1994.
PubMed
13) Nozawa T, et al : Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 68:29-34, 2004.
PubMed
14) Nozawa T, et al : D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 109:59-65, 2006.
PubMed
P.610 掲載の参考文献
1) Saenger M, Christenson RH : Stroke biomarkers : progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem 56:21-33, 2010.
 
2) Kernagis DN, Laskowitz DT : Evolving role of biomarkers in acute cerebrovascular disease. Ann Neurol 71:289-303, 2012.
PubMed
3) Jickling GC, Sharp FR : Blood biomarkers of ischemic stroke. Neurotherapeutics 8:349-360, 2011.
PubMed
4) Laborde CM, et al : Potential blood biomarkers for stroke, Expert Rev Proteomics 9:437-449, 2012.
PubMed
5) Hasan N, et al : Towards the identification of blood biomarkers for acute stroke in humans : a comprehensive systematic review. Br J Clin Pharmacol 74:230-240, 2012.
PubMed
6) Whiteley W, et al : Blood biomarkers in the diagnosis of ischemic stroke : a systematic review. Stroke 39:2902-2909, 2008.
PubMed
7) El Husseini N, Laskowitz DT : Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev Neurother 10:189-203, 2010.
PubMed
8) Laskowitz DT, et al : Clinical usefulness of a biomarker-based diagnostic test for acute stroke : the Biomarker Rapid Assessment in Ischemic Injury (BRAIN) study. Stroke 40:77-85, 2009.
PubMed
9) Montaner J : Blood biomarkers to guide stroke thrombolysis. Front Biosci 1:200-208, 2009.
PubMed
10) Foerch C, et al : Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 35:2160-2164, 2004.
PubMed
11) Whiteley W, et al : The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke. Stroke 43:86-91, 2012.
 
12) Castellanos M, et al : Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34:40-46, 2003.
PubMed
13) Cucchiara BL, et al : Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke 40:2332-2336, 2009.
 
14) Matsuo R, et al : Clinical significance of plasma VEGF value in ischemic stroke-research for biomarkers in ischemic stroke (REBIOS) study. BMC Neurol 13:32, 2013.
PubMed
15) Tokami H, et al : RANTES has a potential to play a neuroprotective role in an autocrine/paracrine manner after ischemic stroke. Brain Res 1517:122-132, 2013.
 
P.616 掲載の参考文献
1) Plum F, Posner JB : Diagnosis of Stupor and Coma, 2nd ed, Davis, Philadelphia, 1972.
 
2) Fisher CM : Brain hemiation : a revision of classical concepts. Can J Neurol Sci 22(2):83-91, 1995.
 
3) Ropper AH : Herniation. Handb Clin Neurol 90:79-98, 2008.
PubMed
P.619 掲載の参考文献
1) Schurks M, et al : Migraine and cerebrovascular disease : systemic review and meta-analysis. BMJ 339 : b3914, 2009.
 
2) Kurth T, et al : Migraine frequency and risk of cardiovascular disease in women. Neurology 73:581-588, 2009.
PubMed
3) Ophoff RA, et al : Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-552, 1996.
PubMed
4) De Fusco, et al : Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha-2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 33:192-196, 2003.
 
5) Joutel A, et al : Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383:707-710, 1996.
PubMed
6) Goto Y, et al : A mutation in the tRNA-leu (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348:651-653, 1990.
PubMed
7) Vestergaard K, et al : Headache in stroke. Stroke 24:1621-1624, 1993.
PubMed
8) Verdelho A, et al : Headache in acute stroke. A prospective study in the first 8 days. Cephalalgia 28:346-354, 2008.
PubMed
9) Hansen AP, et al : Pain following stroke : a prospective study. Eur J Pain 16:1128-1136, 2012.
PubMed
10) Perry JJ, et al : Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA. 310:1248-1255, 2013.
PubMed
11) Mizutani T : Natural course of intracranial arterial dissections. J Neurosurg 114:1037-1044, 2011.
PubMed
12) Ducros A : Reversible cerebral vasoconstriction syndrome. Lancet Neurol 11:906-917, 2012.
PubMed
13) Saposnik G, et al : American Heart Association Stroke Council and the Council on Epidemiology and Prevention : Diagnosis and management of cerebral venous thrombosis : a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:1158-1192, 2011.
PubMed
14) Klit H, et al : Pain following stroke : a population-based follow-up study. PloS One 6:e27607, 2011.
PubMed
15) Widar M, et al : Coping with long-term pain after a stroke. J Pain Symptom Manage 27:215-225, 2004.
PubMed
P.623 掲載の参考文献
1) 北川泰久, 大熊壮尚 : めまいへのアプローチ. 日医師会誌 140:2066-2070, 2012.
 
2) Karatas M : Vascular vertigo : epidemiology and clinical syndromes. Neurologist 17:1-10, 2011.
PubMed
3) Kerber KA, et al : Stroke among patients with dizziness, vertigo, and imbalance in the emergency department : a population-based study. Stroke 37:2484-2487, 2006.
PubMed
4) Navi BB, et al : Application of the ABCD2 score to identify cerebrovascular causes of dizziness in the emergency department. Stroke 43:1484-1489, 2012.
PubMed
5) Oppenheim C, et al : False-negative diffusion-weighted MR findings in acute ischemic stroke. AJNR Am J Neuroradiol 21:1434-1440, 2000.
PubMed
6) Nakase T, et al : Clinical evaluation of lacunar and branch atheromatous disease. J Stroke Cerebrovasc Dis 22:406-412, 2013.
 
7) 篠原幸人ほか (編) : 脳卒中治療ガイドライン2009. 協和企画, 2009.
 
8) 城倉健 : めまい. BRAIN and NERVE 65:1057-1069, 2013.
 
9) Shinohara Y ; OASIS Study Group : Factors affecting health-related quality of life assessed with the SF-36v2 health survey in outpatients with chronic-stage ischemic stroke in Japan-cross-sectional analysis of the OASIS study. Cerebrovasc Dis 29:361-371, 2010.
 
10) Johkura K, et al : Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. Clin Neurol Neurosurg 114:876-880, 2012.
PubMed
P.629 掲載の参考文献
1) 鈴木一夫 : 地域脳卒中発症登録を利用した脳卒中医療の質の評価に関する研究, 厚生労働省科学研究費補助金 (健康科学総合研究事業) 総括研究報告書, 2005.
 
2) Gainotti G : Emotional behavior and hemispheric side of the lesion. Cortex 8:41-55, 1972.
PubMed
3) Folstein MF, et al : Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry 40:1018-1020, 1977.
PubMed
4) Robinson RG : The Clinical Neuropsychiatry of Stroke, 2nd ed, Cambridge University Press, 2006. (木村真人監訳 : 脳卒中における臨床神経精神医学, 第2版, 星和書店, 2013.)
 
5) American Psychiatric Association : Diagnostic and statistical manual of mental disorders Fourth Edition Text Revision, 2000. (高橋三郎ほか訳 : DSM-IV-TR精神疾患の分類と診断の手引, 医学書院, 2003,)
 
6) 村松公美子, 上島国利 : プライマリ・ケア診療とうつ病スクリーニング評価ツール ; Patient Health Questionnaire-9 日本語版「こころとからだの質問票」. 診断と治療 97:1465-1473, 2009.
 
7) 福田一彦 : 自己評価式抑うつ性尺度の研究. 精神神経学雑誌 75:673-679, 1973.
 
8) 日本脳卒中学会 : 脳卒中感情障害 (うつ・情動障害) スケール. 脳卒中 25:206-214, 2003.
Medical*Online
9) Marin RS : Apathy : a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 3:243-254, 1991.
 
10) Morris PL et al : Association of depression with 10-year poststroke mortality. Am J Psychiatry 150:124-129, 1993,
PubMed
11) Jorge RE, et al : Mortality and poststroke depression : a placebo-controlled trial of antidepressants. Am J Psychiatry 160:1823-1829, 2003.
PubMed
12) Camus V, et al : Geriatric depression and vascular diseases : what are the links? J Affect Disord 81:1-16, 2004.
 
13) 木村真人ほか : 脳卒中地域医療連携パスにおけるうつ病の評価と治療. 日社精医会誌 22:147-154, 2013.
Medical*Online
P.635 掲載の参考文献
1) French JA, Pedley TA : Clinical practice. Initial management of epilepsy. N Engl J Med 359:166-176, 2008.
PubMed
2) Schuele SU, Luders HO : Intractable epilepsy : management and therapeutic alternatives. Lancet Neurol 7:514-524, 2008.
PubMed
P.641 掲載の参考文献
1) 山鳥重 : 神経心理学入門. 医学書院, 1985.
 
2) Hodges JR : 臨床家のための高次脳機能のみかた (森悦朗 (監修, 翻訳)). 新興医学出版社, 2011.
 
3) 飯塚統, 森悦朗 : 脳卒中でみられる高次脳機能障害. よくわかる脳卒中のすべて (山口武典, 岡田靖編), p227-252, 永井書店, 2006.
 
4) 森悦朗 : 失語の概念と分類. Clinical Neuroscience 7:762-766, 2013.
 
5) 森悦朗 : 血管性認知症. 認知症 : 臨床の最前線 (池田学編), p34-46, 医歯薬出版, 2014.
 
6) 森悦朗 : 高次脳機能障害の症候. 精神医学 52:951-956, 2010.
 
P.646 掲載の参考文献
1) Klit H, et al : Central post-stroke pain : clinical characteristics, pathophysiology, and management. Lancet Neurol 8 : 857-868, 2009.
PubMed
2) Jonsson AC, et al : Prevalence and intensity of pain after stroke : a population based study focusing on patients' perspectives. J Neurol Neurosurg Psychiatry 77:590-595, 2006.
PubMed
3) Sackley C, et al : The prevalence of joint contractures, pressure sores, painful shoulder, other pain, falls, and depression in the year after a severely disabling stroke. Stroke 39:3329-3334, 2008.
PubMed
4) Lundstrom E, et al : Risk factors for stroke-related pain 1 year after first-ever stroke. Eur J Neurol 16:188-193, 2009.
PubMed
5) Indredavik B, et al : Medical comprecations in a comprehensive stroke unit and an elderly supported discharge service. Stroke 39:414-420, 2008.
 
6) O'Donnell MJ, et al : Chronic pain syndromes after ischemic stroke : PRoFESS trial. Stroke 44:1238-1243, 2013.
PubMed
7) Anderson G, et al : Incidence of central post-stroke pain. Pain 61:187-193, 1995.
 
8) Bowsher D : Stroke and central poststroke pain in an elderly population, J Pain 2:258-261, 2001.
 
9) Nasreddine ZS, Saver JL : Pain after thalamic stroke ; Right diencephalic predominance and clinical features in 180 patients. Neurology 48:1196-1199, 1997.
PubMed
10) Leijon G, et al : Central post-stroke pain-neurological symptoms and pain characteristics. Pain 36:13-25, 1989.
PubMed
11) 脳卒中合同ガイドライン委員会 (編) : 脳卒中治療ガイドライン2009, 協和企画, 2009.
 
12) 平林秀裕, 榊寿右 : 脳卒中と難治性疼痛. 日本臨牀 64(増刊号3):458-462, 2006.
 
P.653 掲載の参考文献
1) Ramsey DJC, et al : Early assessments of dysphagia and aspiration risk in acute stroke patients. Stroke 34:1252-1257, 2003.
PubMed
2) Marik PE : Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 344:665-671, 2001.
PubMed
3) Aslanyan S, et al : Pneumonia and urinary tract infection after acute ischemic stroke : a tertiary analysis of the GAIN international trial. Eur J Neurol 11:49-53, 2004.
 
4) Teramoto S, et al : High incidence of aspiration pneumonia in community-and hospital-aqured pneumonia in hospitalized patients. J Am Geriatr Soc 56:577-579, 2008.
PubMed
5) Yamawaki M (ed) : Risk Management in swallowing movement. In : Risk Managemnet for Dysphagia : Application of Hazard & Operability Study (HAZOP), p6-22, University Education Press, Okayama, 2010.
 
6) 山脇正永, 野村徹 : HAZOP 誤嚥・嚥下障害のリスクマネージメント. 医歯薬出版, 2009.
 
7) McGee S (ed) : Evidence Based Physical Diagnosis, 2nd ed, Saunders Elsevier, St Louis, 2007.
 
8) van der Maarel-Wierink CD, et al : Risk factors for aspiration pneumonia in frail older people : a systematic literature review. J Am Med Dir Assoc 12:344-354, 2011.
PubMed
9) El Solh AA, Saliba R : Pharmacologic prevention of aspiration pneumonia : a systematic review. Am JGeriatr Pharmacother 5:352-362, 2007.
PubMed
10) Shinohara Y, Origasa H : Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors : results of a meta-analysis of five studies in Asians. Adv Ther 29:900-912, 2012.
PubMed
11) Iwasaki K et al : A pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementia. J Am Geriatr Soc 55:2035-2040, 2007.
 
12) Takatori K, et al : Therapeutic effects of mosapride citrate and lansoprazole for prevention of aspiration pneumonia in patients receiving gastrostomy feeding. J Gastroenterol 48:1105-1110, 2013.
PubMed
13) Amberson JB : Aspiratin bronchopneumonia. Int Clin 3:126-138, 1937.
 
14) Smith CH, et al : Incidence and patient characteristics associated with silent aspiration in the acute care setting. Dysphagia 14:1-7, 1999.
PubMed
15) Silver KH, Van Nostrand D : The use of scintigraphy in the management of patients with pulmonary aspiration. Dysphagia 9:107-115, 1994.
PubMed
16) Holas MA, et al : Aspiration and relative risk of medical complications following stroke. Arch Neurol 51:1051-1053, 1994.
PubMed
17) Nakagawa T, et al : High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 157:321-324, 1997.
PubMed
P.660 掲載の参考文献
1) Kraepelin E : Psychiatrie : Ein Lehrbuch fur Studierende und Arzte, p593-632, Barth, Leipzig, 1910.
 
2) Tomlinson BE, et al : Observations on the brains of demented old people. J Neurol Sci 11:205-242, 1970.
 
3) Fisher CM : Lacunar strokes and infarcts : a review. Neurology 32:871-876, 1982.
PubMed
4) Stern K : Severe dementia associated with bilateral symmetrical degeneration of the thalamus. Brain 62:157-171, 1939.
 
5) Alvarez WC : Cerebral arteriosclerosis with small, commonly unrecognized apoplexies. Geriatrics 1:189-216, 1946.
PubMed
6) Alvarez WC : Little Strokes, JB Lippincott, New York, 1966.
 
7) Hachinski VC, et al : Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 2(7874):207-210, 1974.
PubMed
8) Roman GC, et al : Vascular dementia : diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43:250-260, 1993.
 
9) Gorelick PB, et al ; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia : Vascular contributions to cognitive impairment and dementia : a statement for healthcare professionals from the American heart association/American stroke association. Stroke 42:2672-2713, 2011.
PubMed
10) World Health Organization : The ICD-10 classification of mental and behavioral disorders. Diagnostic criteria for research, World Health Organization, Geneva, 1993.
 
P.666 掲載の参考文献
1) Heller A, et al : Arm function after stroke : measurement and recovery over the first three months. Neurol Neurosurg Psychiatry 50:714-719, 1987.
PubMed
2) Sunderland A, et al : Arm function after stroke : an evaluation of grip strength as a measure of recovery and prognostic indicator. J Neurol Neurosurg Psychiatry 52(11):1267-1272, 1989.
PubMed
3) Wade DT, et al : The hemiplegic arm after stroke : measurement and recovery. J Neurol Neurosurg Psychiatry 46(6):521-524, 1983.
 
4) Nakayama H, et al : Recovery of upper extremity function in stroke patients : the Copenhagen Stroke Study. Arch Phys Med Rehabil 75(4):394-398, 1994.
 
5) 藤原俊之 : Hybrid Assistive Neuromuscular Dynamic Stimulation (HANDS) therapyとBrain Machine Interface (BMI). Jpn J Rehabil Med 50(9):718-722, 2013.
Medical*Online
6) Wolf SL et al : Forced use of hemiplegic upper extremities to reverse the effect of learned nonuse among chronic stroke and head-injured patients. Exp Neurol 104:125-132, 1989.
PubMed
7) Wolf SL, et al : Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke : the EXCITE randomized clinical trial. JAMA 296:2095-2104, 2006.
 
8) Peurala SH, et al : Effectiveness of constraint-induced movement therapy on activity and participation after stroke : a systematic review and meta-analysis of randomized controlled trials. Clin Rehabil 26(3):209-223, 2012.
 
9) de Kroon JR et al : Relation between stimulation characteristics and clinical outcome in studies using electrical stimulation to improve motor control of the upper extremity in stroke. J Rehabil Med 37:65-74, 2005.
PubMed
10) Gabr U, et al : Home-based electromyography-triggered stimulation in chronic stroke. Clin Rehabil 19:737-745, 2005.
 
11) 村岡慶裕ほか : 運動介助型電気刺激装置の開発と脳卒中片麻痺患者への使用経験. 理学療法学 31:29-35, 2004.
Medical*Online
12) Hara Y, et al : Hybrid power assisted functional electrical stimulation to improve hemiparetic upperextremity function. Am J Phys Med Rehabil 85:977-985, 2006.
PubMed
13) Fujiwara T, et al : Motor improvement and corticospinal modulation induced by hybrid assistive neuromuscular dynamic stimulation (HANDS) therapy in patients with chronic stroke. Neurorehabil Neural Repair 23:125-132, 2009.
PubMed
14) Shindo K, et al : Effectiveness of hybrid assistive neuromuscular dynamic stimulation therapy in patients with subacute stroke : a randomized controlled pilot trial. Neurorehabil Neural Repair 25:830-837, 2011.
PubMed
15) Buch E, et al : Think to move : a neuromagnetic brain computer interface (BCI) system for chronic stroke. Stroke 39 :910-917, 2008.
PubMed
16) Shindo K, et al : Effects of neurofeedback training with an electroencephalogram-based brain-computer interface for hand paralysis in patients with chronic stroke : a preliminary case series study. J Rehabil Med 43:951-957, 2011.
PubMed
17) Hummel FC, Cohen LG : Non-invasive brain stimulation : a new strategy to improve neurorehabilitation after stroke? Lancet Neurol 5:708-712, 2006.
PubMed
18) Elsner B, et al : Transcranial direct current stimulation (tDCS) for improving function and activities of daily living in patients after stroke. Cochrane Database Syst Rev (11) : CD009645, 2013.
PubMed
19) Hao Z, et al : Repetitive transcranial magnetic stimulation for improVing function after stroke. Cochrane Database Syst Rev (5) : CD008862, 2013.
PubMed
20) Bastani A Jaberzadeh S : Does anodal transcranial direct current stimulation enhance excitability of the motor cortex and motor function in healthy individuals and subjects with stroke : a systematic review and meta-analysis. Clin Neurophysiol 123:644-657, 2012.
PubMed
21) Kakuda W, et al : Six-day course of repetitive transcranial magnetic stimulation plus occupational therapy for post-stroke patients with upper limb hemiparesis : a case series study. Disabil Rehabil 32:801-807, 2010.
PubMed
22) Takeuchi N, et al : Inhibition of the unaffected motor cortex by 1 Hz repetitive transcranical magnetic stimulation enhances motor performance and training effect of the paretic hand in patients with chronic stroke. J Rehabil Med 40:298-303, 2008.
PubMed
23) Takeuchi N, et al : Repetitive transcranial magnetic stimulation over bilateral hemispheres enhances motor fUnction and training effect of paretic hand in patients after stroke. J Rehabn Med 41:1049-1054, 2009.
PubMed
24) Honaga H, et al : State of intracortical inhibitory interneuron activity in patients with chronic stroke. Clin Neurophysiol 124:364-379, 2013.
 
P.671 掲載の参考文献
1) 脳卒中ガイドライン委員会 (編) : 脳卒中ガイドライン, 協和企画, 2009.
 
2) Bernhardt J, et al : A very early rehabilitation trial for stroke (AVERT) : phase II safety and feasibility. Stroke 39:390-396, 2008.
 
3) 原寛美 : 急性期リハビリテーション. 救急・集中治療 15(12):1339-1347, 2003.
 
4) 原寛美 : 急性期リハビリテーション. Progress in Medicine 27:299-304, 2007.
Medical*Online
5) 栗原正紀 : Stroke unitと急性期リハビリテーション. MEDICAL REHABILITATION 90:1-8, 2008.
 
6) 伊藤秀樹ほか : 脳血管障害急性期リハビリテーションの開始時期. Journal of Clinical Rehabilitation 34:564-572, 1997.
 
7) 前島伸一郎ほか : 急性期リハビリテーションの実際. MEDICAL REHABILITATION 90:9-16, 2008.
 
8) 高橋博達 : 合併症発症時の急性期リハビリテーション. MEDICAL REHABILITATION 90:73-83, 2008.
 
9) 原寛美 : 脳卒中片麻痺にみられるDVT. Journal of Clinical Rehabilitation 10(9):781-784, 2001.
Medical*Online
P.677 掲載の参考文献
1) 全国回復期リハビリテーション病棟協会 : 回復期リハビリテーション病棟の現状と課題に関する調査報告書 (2002年-2013年版).
 
P.681 掲載の参考文献
1) 安保雅博, 角田亘 : 上肢痙縮に対するボツリヌス治療とリハビリテーション, 金原出版, 2012.
 
2) Rosales RL, Chua-Yap AS : Evidence-based systematic review on the efficacy and safety of botulinum toxin-A therapy in post-stroke spasticity. J Neural Transm 115:617-623, 2008.
PubMed
3) Foley N, et al : Treatment with botulinum toxin improves upper-extremity function post stroke : a systematic review and meta-analysis. Arch Phys Med Rehabil 94:977-989, 2013.
PubMed
4) Foley N, et al : Does the treatment of spastic equinovarus deformity following stroke with botulinum toxin increase gait velocity? A systematic review and meta-analysis. Eur J Neurol 17:1419-1427, 2010.
PubMed
5) 篠原幸人ほか : 脳卒中治療ガイドライン2009, 協和企画, 2009.
 
6) Simpson DM, et al : Assessment : Botulinum neurotoXin for the treatment of spasticity (an evidence-based review) : report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 70:1691-1698, 2008.
 
7) Sheean G, et al : Botulinum toxin assessment, intervention and after-care for upper limb heypertonicity in adults : international consensus statement. Eur J Neurol 17(Suppl 2):74-93, 2010.
 
8) Olver J, et al : Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults : international consensus statement. Eur J Neurol 17(Suppl 2):57-73, 2010.
 
9) 安保雅博ほか : BoNT-Aを用いて脳卒中後の上肢痙縮に対するリハビリテーション医療を進める. 日医師会誌 141:100-101, 2012.
 
10) Takekawa T, et al : Botulinum toxin type A injection, followed by home-based functional training for upper limb hemiparesis after stroke. Int J Rehabil Res 35:146-152, 2012.
PubMed
11) Takekawa T, et al : Long-term effects of injection of botulinum toxin type A combined with home-based functional training for post-stroke patients with spastic upper limb hemiparesis. Acta Neurol Belg 113:469-475, 2013.
PubMed
12) 佐瀬洋輔ほか : 脳卒中後の重度痙性上肢麻痺に対するボツリヌス毒素投与と低周波治療, 作業療法士による自主トレーニング指導との併用療法 : パイロット研究. 作業療法 32:233-243, 2013.
Medical*Online
13) Kakuda W, et al : Combined therapeutic application of botulinum toxin type A, low-frequency rTMS, and intensive occupational therapy for post-stroke spastic upper limb hemiparesis. Eur J Phys Rehabil Med 48:47-55, 2012.
PubMed
14) 山田尚基ほか : 各種疾患に対するボツリヌス治療 脳卒中 (上肢痙縮). Monthly Book Medical Rehabilitation 144:48-54, 2012.
Medical*Online
P.685 掲載の参考文献
1) 平野哲ほか : 動く支援機器-電動義肢からロボットまで リハビリテーションロボットの開発現況. 日本義肢装具学会誌 29(2):90-97, 2013.
 
2) Volpe BT, et al : A novel approach to stroke rehabilitation : robot-aided sensorimotor stimulation. Neurology 54(10) :1938-1944, 2000.
PubMed
3) Bovolenta F et al : Robot therapy for functional recovery of the upper limbs : apilot study on patients after stroke. J Rehabil Med 41(12):971-975, 2009.
 
4) 蜂須賀研二 : リハビリテーション医療におけるロボット訓練の臨床的意義 上肢訓練支援ロボットの無作為化比較試験. Jpn J Rehabil Med 50(7):489-494, 2013.
 
5) Colombo G, et al : Driven gait orthosis for improvement of locomotor training in paraplegic patients. Spinal Cord 39(5):252-255, 2001.
PubMed
6) 中島孝 : 今後の難病対策のあり方について 神経・筋難病患者が装着するロボットスーツHALの医学応用に向けた進捗, 期待される臨床効果. 保健医療科学 60(2):130-137, 2011.
 
7) 平野哲ほか : リハビリテーションロボット. 現代医学 60(2):449-454, 2012.
Medical*Online
8) 平野哲ほか : リハビリテーション医療におけるロボット訓練の臨床的意義 バランス練習アシストロボットの効果. Jpn J Rehabil Med 50(7):500-504, 2013.
 
9) Mehrholz J, et al : Electromechanical and robot-assisted arm training for improving generic activities of daily living, arm fUnction, and arm muscle strength after stroke. Cochrane Database Syst Rev 6 : CD006876, 2012.
PubMed
10) VA/DOD Clinical practice guideline for the management of stroke rehabilitation. J Rehabil Res Dev 47(9):1-43, 2010.
PubMed
11) Miller EL et al : Comprehensive overview of nursing and interdisciplinary rehabilitation care of the stroke patient : a scientific statement from the American Heart Association. Stroke 41(10):2402-2448, 2010.
 
12) Mehrholz J, et al : Electromechanical-assisted training for walking after stroke. Cochrane Database Syst Rev 7 : CD006185, 2013.
PubMed
13) Ozaki K et al : Preliminary trial of postural strategy training using a personal transport assistance robot for patients with central nervous system disorder. Arch Phys Med Rehabil 94(1):59-66, 2013.
PubMed
14) Tanabe S, et al : Wearable Power-Assist Locomotor (WPAL) for supporting upright walking in persons with paraplegia. NeuroRehabilitation 33(1):99-106, 2013.
PubMed
P.689 掲載の参考文献
1) Leopold NA, Kagel MC : Swallowing, ingestion and dysphagia : a reappraisal. Arch Phys Med Rehabil 64(8):371-373, 1983.
PubMed
2) Hamdy S, et al : Organization and reorganization of human swallowing motor cortex : implications for recovery after stroke. Clin Sci (Lond) 99(2):151-157, 2000.
PubMed
3) 大熊るりほか : 摂食・嚥下障害スクリーニングのための質問紙の開発. 日摂食嚥下リハ会誌 6(1):3-8, 2002.
Medical*Online
4) 小口和代ほか : 機能的嚥下障害スクリーニングテスト「反復唾液嚥下テスト」 (the Repetitive Saliva Swallowing Test : RSST) の検討 (2) 妥当性の検討. リハビリテーション医学 37(6):383-388, 2000.
 
5) Mann G : The Mann Assessment of Swallowing Ability, Delmar Cengage Learning, New York, 2002.
 
6) 兵頭政光, 弘瀬かほり : 嚥下機能の評価法の検証 嚥下内視鏡検査 嚥下器官の運動と器質的異常の評価. 嚥下医学 2(2):208-211, 2013.
 
7) Pandolfino JE, et al : Transient lower esophageal sphincter relaxations and reflux : mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology 131(6):1725-1733, 2006.
PubMed
8) Fujii N, et al : Evaluation of swallowing using 320-detector-row multislice CT. Part I : single-and multiphase volume scanning for three-dimensional morphological and kinematic analysis. Dysphagia 26(2): 99-107, 2011.
PubMed
9) 藤島一郎 : 脳卒中の摂食・嚥下障害, p72, 医歯薬出版, 1993.
 
10) Kunieda K, et al : Reliability and validity of a tool to measure the severity of dysphagia : the Food Intake LEVEL Scale. J Pain Symptom Manage 46(2):201-206, 2013.
PubMed
11) 藤島一郎ほか : 訓練法のまとめ (改訂2010). 日摂食嚥下リハ会誌 14(3):644-663, 2010.
Medical*Online
12) Nakamura T, Fujishima I : Usefulness of ice massage in triggering the swallow reflex. J Stroke Cerebrovasc Dis 22(4):378-382, 2013.
PubMed
13) Khedr EM, et al : Treatment of post-stroke dysphagia with repetitive transcranial magnetic stimulation. Acta Neurol Scand 119(3):155-161, 2009.
PubMed
14) Shigematsu T, et al : Transcranial direct current stimulation improves swallowing function in stroke patients. Neurorehabil Neural Repair 27(4):363-369, 2013.
PubMed
P.693 掲載の参考文献
1) 高次脳機能障害支援モデル事業地方支援拠点機関等連絡協議会 : 平成17年度高次脳機能障害支援モデル事業実施報告, 2006年9月30日.
 
2) 渡邊修ほか : 東京都における高次脳機能障害者数の推計. Jpn J Rehabil Med 46:118-125, 2009.
 
3) 東京都高次脳機能障害者実態調査研究会 : 平成11年度高次脳機能障害者実態調査報告書, 東京都衛生局医療計画部医療計画課, 2000.
 
4) 高次脳機能障害全国実態調査委員会 : 高次脳機能障害全国実態調査報告. 高次脳機能研究 26(2):209-218, 2006.
 
5) 並木幸司 : 高次脳機能障害の評価. 高次脳機能障害ポケットマニュアル (原寛美監), p37-64, 医歯薬出版, 2005.
 
6) 先崎章 : 高次脳機能障害者への対応-薬物療法, 診断書作成を中心に. 第46回日本リハビリテーション医学会学術集会抄録集, p137, 2009.
 
7) 先崎章 : 高次脳機能障害に対する薬物療法-脳外傷を中心に-. 注意・遂行機能障害のリハビリテーション (渡邊修編). p53-57, 全日本病院出版会, 2013.
 
8) Cicerone KD, et al : Evidence-based cognitive rehabilitation : recommendations for clinical practice. Arch Phys Med Rehabil 81:1596-1615, 2000.
PubMed
9) 武本暁生ほか : 社会参加・職業復帰の実際 高次脳機能障害 (佐伯覚編), p69-73, 全日本病院出版会, 2012.
 
10) 倉持昇ほか : 脳血管障害による高次脳機能障害者に対する就労支援とその効果-医療機関での外来訓練結果より-. 認知リハビリテーション, p19-25, 認知リハビリテーション研究会, 2008.
 
P.701 掲載の参考文献
1) Sato S, et al : Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan : the Stroke Unit Multicenter Observational (SUMO) Study. Stroke 40:30-34, 2009.
 
2) Wardlaw JM, et al : Recombinant tissue plasminogen activator for acute ischaemic stroke : an updated systematic review and meta-analysis. Lancet 379:2364-2372, 2012.
PubMed
3) Parsons M, et al : A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366:1099-1107, 2012.
 
4) von Kummer R, et al : The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program. Int J Stroke 7:589-596, 2012.
PubMed
5) Barreto AD, et al : The argatroban and tissue-type plasminogen activator stroke study : final results of a pilot safety study. Stroke 43:770-775, 2012.
PubMed
6) Pancioli AM, et al : Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial. Stroke 44:2381-2387, 2013.
PubMed
7) Barreto AD, et al : CLOTBUST-Hands Free : Pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke. Stroke 44:3376-3381, 2013.
PubMed
8) Chimowitz MI : Endovascular treatment for acute ischemic stroke-still unproven. N Engl J Med 368:952-955, 2013.
PubMed
9) Wang Y, et al : Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 369:11-19, 2013.
 
10) Toyoda K, et al ; Bleeding with Antithrombotic Therapy (BAr) Study Group : Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease : a prospective, multicenter, observational study. Stroke 39:1740-1745, 2008.
 
11) Koga M, et al : Systolic blood pressure lowering to 160mmHg or less using nicardipine in acute intracerebral hemorrhage : a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). J Hypertens 30:2357-2364, 2012.
PubMed
12) Anderson CS, et al : Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 368:2355-2365, 2013.
PubMed
13) 佐藤祥一郎ほか : わが国におけるAntihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) -II試験の開始 : デザインと国内研究体制の構築. 臨床神経学 52:642-650, 2012.
 
14) Dennis M, et al ; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration : Effectiveness of intemiittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3) : a multicentre randomised controlled trial. Lancet 382:516-524, 2013.
PubMed
15) Chollet F, et al : Fluoxetine for motor recovery after acute ischaemic stroke (FLAME) : a randomised placebo-controlled trial. Lancet Neurol 10:123-130, 2011.
PubMed
P.707 掲載の参考文献
1) PROGRESS Collaborative Group : Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001.
PubMed
2) Toyoda K et al : Blood pressure levels and bleeding events during antithrombotic therapy : the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 41:1440-1444, 2010.
PubMed
3) Dahlof B, et al : Cardiovascular morbidity and mortality in the Losartan lntervention For Endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet 359:995-1003, 2002.
 
4) Dahlof B, et al : Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) : a multicentre randomized controlled trial. Lancet 366:895-906, 2005.
PubMed
5) UK Prospective Diabetes Study (UKPDS) Group : Etifect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998.
PubMed
6) Kushiro T, et al : Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 53:135-141, 2009.
PubMed
7) Amarenco P, et al : High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355(6):549-559, 2006.
 
8) Antithrombotic Trialists' Collaboration : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86, 2002.
PubMed
9) CAPRIE Steering Committee : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329-1339, 1996.
 
10) Shinohara Y, et al : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959 -968, 2010.
 
11) Connolly SJ, et al : RE-LY Steering Committee and Investigators : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151, 2009.
Medical*Online
12) Patel MR, et al ; ROCKET AF Investigators : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891, 2011.
PubMed
13) Granger CB, et al ; ARISTOTLE Committees and Investigators : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992, 2011.
PubMed
14) Giugliano RP, et al ; ENGAGE AF-TIMI 48 Investigators : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093-2104, 2013.
PubMed
15) Camm AJ, et al ; ESC Committee for Practice Guidelines (CPG) : 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-2747, 2012.
 
P.713 掲載の参考文献
1) 篠原幸人ほか (編) : 脳卒中合同ガイドライン委員会 : 脳卒中治療ガイドライン2009, 協和企画, 2009.
 
2) Hunt WE, Kosnik EJ : Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 21:79-89, 1974.
PubMed
3) Hadeishi H, et al : Hyperdynamic therapy for cerebral vasospasm. Neurol Med Chir (Tokyo) 30:317-323, 1990.
PubMed
4) 吉峰俊樹 (編) ; 脳卒中の外科学会 くも膜下出血診療ガイドライン改訂委員会 : 脳卒中の外科 第36巻増刊号 科学的根拠に基づくくも膜下出血診療ガイドライン, 第2版, にゅーろん社, 2008.
 
5) Juttler E, et al : Decompressive Surgery for the Treatment of Malignant lnfarction of the Middle Cerebral Artery (DESTINY) : a randomized, controlled trial. Stroke 38:2518-2525, 2007.
 
6) Vahedi K, et al : Early decompressive surgery in malignant infarction of the middle cerebral artery : a pooled analysis of three randomised controlled trials. Lancet Neurol 6:215-222, 2007.
PubMed
7) Vahedi K et al : Sequential-design, multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial). Stroke 38:2506-2517, 2007.
PubMed
8) Hoimeijer J, et al : Hemicraniectomy after middle cerebral artery infarction with life-threatening Edema trial (HAMLET). Protocol for a randomised controlled trial of decompressive surgery in space-occupying hemispheric infarction. Trials 7:29, 2006.
PubMed
9) Yamaguchi T, et al : Alteplase at 0.6mg/kg for acute ischemic stroke within 3hours of onset : Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810-1815, 2006.
 
10) Ogawa A, et al : Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke : the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 38:2633-2639, 2007,
PubMed
11) 一ツ松勤ほか : 超急性期脳梗塞に対する再灌流療法 : 当施設の治療戦略 ; rt-PA静注・UK動注・急性期バイパス. Neurosurg Emerg 14:157-165, 2009.
Medical*Online
12) Blaisdell WF et al : Joint study of extracranial arterial occlusion. IV. A review of surgical considerations. JAMA 209 : 1889-1895, 1969.
 
13) Gay JL, et al : Urgent carotid artery repair : retrospective study of 21 cases. Ann Vasc Surg 16:401-406, 2002.
PubMed
P.719 掲載の参考文献
1) Barnett HJ, et al : Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 339:1415-1425, 1998.
 
2) North American Symptomatic Carotid Endarterectomy Trial Collaborators : Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325:445-453, 1991.
PubMed
3) MRC European Carotid Surgery Trial : interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 337:1235-1243, 1991.
 
4) Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 273:1421-1428, 1995.
PubMed
5) Halliday A, et al ; MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group : Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms : randomised controlled trial. Lancet 363:1491-1502, 2004.
 
6) Yadav JS, et al ; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators : Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351:1493-1501, 2004.
PubMed
7) Mas JL, et al ; EVA-3S investigators : Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial : results up to 4 years from a randomised, multicentre trial. Lancet Neurol 7:885-892, 2008.
PubMed
8) SPACE Collaborative Group ; Ringleb PA et al : 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients : a randomised non-inferiority trial. Lancet 368:1239-1247, 2006.
 
9) International Carotid Stenting Study investigators ; Ederle J, et al : Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study) : an interim analysis of a randomised controlled trial. Lancet 375:985-997, 2010.
 
10) Brott TG, et al ; CREST lnvestigators : Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 363:11-23, 2010.
PubMed
11) 脳卒中合同ガイドライン委員会 : 脳梗塞慢性期. 脳卒中治療ガイドライン2009 (篠原幸人ほか編), p85-126, 協和企画, 2009.
 
12) 脳卒中合同ガイドライン委員会 : 無症候性頸部頸動脈狭窄・閉塞. 脳卒中治療ガイドライン2009 (篠原幸人ほか編), p227-229, 協和企画, 2009.
 
13) Brott TG, et al : 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 42:e420-463, 2011.
PubMed
14) Yasargil MG : Microsurgery Applied to Neuro-surgery, p105-115, Georg Thieme, Stuttgart, 1969.
 
15) The EC/IC Bypass Study Group : Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 313:1191-1200, 1985.
 
16) JET study group : Japanese EC-IC trial (JET study) -study designと中間解析結果-. 脳卒中の外科 30:97-100, 2002.
 
17) Powers WJ, et al ; COSS Investigators : Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia : the Carotid Occlusion Surgery Study randomized trial. JAMA 306:1983-1992, 2011.
PubMed
P.726 掲載の参考文献
1) Ogawa A, et al ; MELT Japan Study Group : Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke : the middle cerebral artery embolism local fibrinolytic intervention trial (MEIT) Japan. Stroke 38:2633-2639, 2007.
 
2) The Penumbra Pivotal Stroke Trial Investigators : The penumbra pivotal stroke trial : safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke 40:2761-2768, 2009.
PubMed
3) Saver JL, et al ; SWIFT Trialists : Solitaire now restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFr) : a randomised, parallel-group, non-inferiority trial. Lancet 380:1241-1249, 2012.
 
4) Broderick JP, et al ; Interventional Management of Stroke (IMS) III Investigators : Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368(10):893-903, 2013.
PubMed
5) Kidwell CS, et al ; MR RESCUE Investigators : A trial of imaging selection and endovascular therment for ischemic stroke. N Engl J Med 368:914-923, 2013.
 
6) Ciccone A, et al ; SYNTHESIS Expantion Investigators : Endovascular treatment for acute ischemic stroke. N Engl J Med 368:904-913, 2013.
 
7) Brott TG, et al ; CREST Investigators : Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 363:11-23, 2010.
PubMed
8) Chimowitz MI, et al ; SAMMPRIS Trial Investigators : Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 365:993-1003, 2011.
PubMed
9) Becske T, et al : Pipeline for uncoilable or failed aneurysms : results from a multicenter clinical trial. Radiology 267:858-868, 2013.
 
10) Chalouhi N, et al : Treatment of recurrent intracranial aneurysms with the Pipeline Embolization Device. J Neurointerv Surg 6(1):19-23, 2014.
 
P.734 掲載の参考文献
1) Connolly SJ, et al ; RE-LY Steering Committee and Investigators : Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151, 2009 and Erratum in : N Engl J Med 363:1877, 2010.
 
2) Patel MR, et al ; the ROCKET AF Investigators : Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891, 2011.
PubMed
3) Granger CB, et al ; ARISTOTLE Committees and Investigators : Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992, 2011.
PubMed
4) Giugliano RP, et al : Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369:2093-2104, 2013.
PubMed
5) Ogawa S, Hori M : Urgent statement on antithrombotic therapy of atrial fibrillation. Circ J 75:2719-2721, 2011.
PubMed
6) Hart RG, et al : Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran : the RE-LY trial. Stroke 43:1511-1517, 2012.
 
7) Oldgren J, et al : Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score : a subgroup analysis of the RE-LY trial. Ann Intern Med 155:660-667, 2011.
 
8) Ogawa S, et al : Antithrombotic therapy in atrial fibrillation : evaluation and positioning of new oral anticoagulant agents. Circ J 75:1539-1547, 2011.
PubMed
9) 矢坂正弘 : 心房細動に対する抗凝固療法. 新規経口抗凝固薬の特徴と注意点. 直接トロンビン阻害薬 (ダビガトラン). 日本臨牀 71:113-118, 2012.
 
10) Yasaka M : Current strategy for anticoagulation therapy for patients with non-valvular atrial fibrillation. Journal of Arrhythmia 28:324-332, 2012.
 
11) Hori M, et al : Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J 76:2104-2111, 2012.
PubMed
12) Sacco RL, et al : Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359:1238-1251, 2008.
PubMed
13) The SPS3 Investigators : Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 367:817-825, 2012.
PubMed
14) Shinohara Y, Nishimaru K : Sarpogrelate versus aspirin in secondary prevention of cerebral infarction : differential efficacy in diabetes? Subgroup analysis from S-ACCESS. Stroke 40:2862-2865, 2009.
 
15) Shinohara Y, et al : Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:959-968, 2010.
PubMed
16) Uchiyama S, et al : The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study : a randomized, double-blind, controlled trial. Cerebrovasc Dis 31:601-613, 2011.
PubMed
17) Wiviott SD, et al : Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015, 2007.
PubMed
18) Wallentin L, et al : Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057, 2009.
PubMed
19) Shinohara Y, et al : Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26:63-70, 2008.
PubMed
20) Tricoci P, et al : Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J 20-33, 2012.
 
21) Morrow DA, et al : Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 44:2013.
PubMed

書評

最近チェックした商品履歴

Loading...